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ABSTRACT 
Feline immunodeficiency virus (FIV) and feline leukaemia virus (FeLV) remain important 
infections of domestic cats in Australia and overseas. This thesis begins by providing up-
to-date Australian prevalence data in three cohorts of cats, comprising approximately 4,300 
cats. Interestingly, the prevalence of both retroviral infections is higher in Perth, Western 
Australia compared to the rest of the country (Chapter 2). The diagnosis of FIV infection in 
FIV-vaccinated cats using fast, readily accessible, cheap point-of-care antibody kits, 
previously thought impossible, is reported in Chapter 3, which includes also the results of 
FIV testing using PCR methodology. This finding will expedite the diagnosis of FIV by 
veterinarians in most clinical scenarios encountered in the field, and has already 
contributed to changed recommendations concerning the use of the FIV vaccine (WSAVA 
Vaccination Guidelines, changed from ‘Not Recommended’ in 2010 to ‘Non-Core’ in 
2015). Using the same cohort of cats and same antibody test kits, it was discovered that 
FIV infection can also be reliably diagnosed in FIV-vaccinated and FIV-unvaccinated cats 
using saliva by two of the kits tested (Chapter 4). The duration of antibody response in 
FIV-vaccinated cats using four commercially available FIV antibody test kits and a 
prospective study of client-owned kittens and cats, and the effect on point-of-care testing 
for FIV infection, is reported in Chapter 5. The first ever study into the effectiveness of the 
only currently commercially available FIV vaccine in the field is reported in Chapter 6. 
The effectiveness (protective rate) of the vaccine was determined to be 56%, and five 
confirmed vaccine ‘breakthroughs’ are discussed, these being the first vaccine 
breakthroughs observed in the field. This finding has stimulated renewed discussion about 
the effectiveness of the FIV vaccine (e.g. meeting of Key Opinion Leaders organised by 
Boehringer Ingelheim, The Shangri-La Hotel, Sydney, 24
th
 June, 2016) and will likely lead 
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to further studies in other countries using similar methodology. Diagnosis of FeLV 
infection was investigated using both blood and saliva as diagnostic specimens with the 
same three commercially available kits tested in Chapters 3 and 4 (kits were FIV/FeLV 
combination kits) and also an in-house real-time PCR assay, with one kit found to produce 
substantially more false-positive results using blood than the other two kits (Chapter 7). 
The combined outcomes of Chapters 3, 4 and 7 will provide guidance for Australian 
veterinarians on the most accurate FIV/FeLV test kits to use in practice, as well as 
introduce the concept to shelters and rescue organisations who currently routinely screen 
for FIV/FeLV that testing using saliva is a viable and less stressful alternative to testing 
using blood. Finally, an in-depth study of possible outcomes following FeLV exposure for 
the client-owned cats recruited for Chapter 6 and two cohorts of group-housed cats 
sampled from two different rescue facilities experiencing recent FeLV outbreaks is 
reported, leading to recommendations regarding FeLV testing and vaccination (Chapter 8). 
Dr. Mark Edward Westman Faculty of Veterinary Science  
Thesis 2016 The University of Sydney  
1 
 
CHAPTER 1.  INTRODUCTION AND LITERATURE REVIEW 
The domestic cat (Felis silvestris catus) is host to three known exogenous retroviruses, all 
with worldwide distribution: feline immunodeficiency virus (FIV; subfamily 
Orthoretrovirinae, Genus Lentivirus), feline leukaemia virus (FeLV; subfamily 
Orthoretrovirinae, Genus Gammaretrovirus) and feline foamy virus (FFV; subfamily 
Spumaretrovirinae, Genus Spumavirus). While FFV is thought to be of minimal clinical 
significance, both FIV and FeLV result in a variety of immunologic perturbations that 
impact on morbidity and mortality. 
1.1. Discovery and prevalence of FIV 
FIV was first isolated in Petaluma, California, USA in 1986 following the investigation of 
an immunodeficiency syndrome in a cat colony. FIV was isolated by Pedersen and 
colleagues after inoculating two SPF kittens with whole blood and plasma obtained from 
three affected colony cats (Pedersen et al., 1987). IFA testing, using infected feline 
lymphocytes as the substrate, led to the diagnosis of 11/43 cats with FIV infection (then 
called feline T-lymphotropic lentivirus [FTLV]), of which one cat was clinically healthy 
and ten were sick. Signs of illness observed (to a varying extent in different individual 
cats) included gingivitis, dermatitis, otitis externa, rhinitis, conjunctivitis, cystitis, anaemia, 
thin body condition and diarrhoea. Over a period of four years, all ten ‘sick’ FIV-infected 
cats died. A short time later, an epidemiological survey found FIV to be endemic in the 
North American cat pet population (14% among ‘high risk’ cats) (Yamamoto et al., 1989). 
FIV was subsequently shown to have worldwide distribution. An estimated 14.5 million 
pet cats are infected with FIV worldwide, and 33.5 million if feral cats are included 
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(Yamamoto et al., 2007). Healthy client-owned (pet) cat populations have been reported 
with infection rates of approximately 3% in Germany (Gleich et al., 2009b) and the USA 
(Levy et al., 2006), 6% in Canada (Ravi et al., 2010) and the United Kingdom (Hosie et al., 
1989), 8% in Australia (Norris et al., 2007), 10% in New Zealand (Jenkins et al., 2013), 
20% in Thailand (Sukhumavasi et al., 2012), 23% in Japan (Nakamura et al., 2010) and 
31% in Malaysia (Bande et al., 2012). Serological surveys investigating the prevalence of 
FIV in stray and feral cat populations have found variable prevalence rates compared to the 
pet cat population. Feral and stray cats with full-time outdoor access and subjected to the 
dangers of fights with other potentially infected cats goes a long way to explaining the 
higher prevalence in these cats compared with pet cats, given the mode of transmission for 
FIV. For example, a small Australian survey of two feral cat colonies reported FIV 
prevalence of 20-25%, contrasting the 8% prevalence found in the pet cat sample 
population (Norris et al., 2007). Other studies have reported comparable FIV prevalence 
between shelter cats and pet cats, with differences likely relating to recruitment criteria (for 
example more sick cats are likely to be tested in veterinary clinics as part of an illness 
investigation, whereas shelters are more likely to test healthy cats as part of a standard 
screening process). For example, a North American study that recruited from 145 animal 
shelters located in the USA, Canada and Puerto Rico reported FIV prevalence of 2% in 
shelter cats (versus 3% in pet cats) (Levy et al., 2006), and a Canadian survey that 
recruited from 13 animal shelters representing 10 Canadian provinces reported FIV 
prevalence of 6% in shelter cats (versus 4% in pet cats) (Little et al., 2009). 
An updated serosurvey of FIV prevalence rates in both client-owned and shelter cats in 
Australia forms the basis of the work presented in Chapter 2. 
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1.2. FIV transmission and disease associations 
FIV has broad cellular tropism in vivo, targeting B lymphocytes, CD4+ T lymphocytes, 
CD8+ T lymphocytes, macrophages and dendritic cells (Lecollinet and Richardson, 2008; 
Hosie et al., 2009). Cell entry is achieved by the FIV surface glycoprotein gp120 binding 
to a primary receptor on the cell surface, the CD134 molecule (Shimojima et al., 2004), 
with assistance from the ubiquitous chemokine receptor CXCR4 as co-receptor following 
conformational changes to gp120 (Willett et al., 1997; Lecollinet and Richardson, 2008). 
Within one week of experimental infection, FIV can be isolated from PBMCs and tissues 
including the thymus, spleen, lymph nodes, salivary glands and bone marrow of infected 
cats, and within two weeks it can be isolated from plasma and saliva (Yamamoto et al., 
1989; Matteucci et al., 1993; Hosie et al., 2009). FIV transmission is usually via the 
inoculation of virus-laden saliva subcutaneously during a cat fight, thus entire male cats, 
castrated male cats and feral cats (all more likely to engage in displays of territorial 
aggression) are considered most at risk for infection (Yamamoto et al., 1989; Levy et al., 
2006; Norris et al., 2007; Ravi et al., 2010). Vertical transmission of FIV has been 
demonstrated experimentally, although in the field this mechanism appears uncommon 
(Callanan et al., 1991; O'Neil et al., 1995; Allison and Hoover, 2003a, b). 
Three main phases are recognised in cats experimentally infected with FIV. After initial 
infection, rapid viral replication leaks to peak viraemia 8-12 weeks later, which manifests 
clinically as generalised lymphadenomegaly, anorexia, depression and fever; this is called 
the acute phase of infection. Once viraemia declines, the infected cat enters a long period 
where few or no clinical signs are usually seen; this is called the asymptomatic phase of 
infection, and can last months but typically many years. By the time the infected cat 
reaches the final phase of infection, the secondary phase, the CD4:CD8 T lymphocyte ratio 
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has decreased due to a progressive CD4+ T lymphocytopenia and CD8+ T lymphocyte 
expansion, viral replication increases and a range of diseases classified as feline acquired 
immunodeficiency syndrome (FAIDS) may be observed (Torten et al., 1991; Willett et al., 
1993; Hosie et al., 2009). Figure 1.1 illustrates schematically the three phases of infection 
described (Hosie and Beatty, 2007). Interestingly, although FIV causes progressive 
immune dysfunction due to a gradual depletion of CD4+ T lymphocytes, paradoxically a 
concurrent hyperimmunoactive state occurs which manifests as increased serum IgG levels 
reflective of FIV-induced virus-specific B-cell lymphocyte hyperactivity (Uhl et al., 2002). 
It is this B-cell hyperactivity that results in FIV-infected cats being at increased risk of 
developing high grade B-cell lymphomas compared with FIV-uninfected cats (Torten et 
al., 1991; Matsumura et al., 1993; Callanan et al., 1996). 
Figure 1.1 Stages of FIV infection. (Reproduced from Hosie and Beatty, 2007). 
 
In the field, many studies have reported some of the disease manifestations classified 
collectively as FAIDS. Often these disease manifestations are the result of opportunistic 
infections secondary to the animal’s immunosuppressed state, rather than being a direct 
result of the virus; consequently, clinical signs associated with FIV-infection are widely 
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varied and generally non-specific (Hosie et al., 2009). The seminal FIV publication 
reporting the deaths of 10 FIV-infected cats listed a range of clinical signs including 
sudden death, enteritis, rhinitis, conjunctivitis, oral cavity disease, weight loss, 
neurological disease, anaemia, dermatitis, and ‘terminal hysteria and rage’ (Pedersen et al., 
1987). A short time later, the same group studied 2,765 client-owned cats in USA and 
Canada and reported the most common clinical findings as oral cavity disease (56% of 
infected cats), anaemia (42%), upper respiratory tract infections (33%), leukopenia (30%), 
gastrointestinal disease (20%), neoplasia (3%) and central nervous system disease (< 1%) 
(Yamamoto et al., 1989). Around the same time, Ishida and colleagues reported a similar 
pattern of disease in 3,323 client-owned cats in Japan including oral cavity disease (52%), 
upper respiratory tract infections (29%), anaemia (18%), weight loss (15%), opportunistic 
bacterial infections (14%), skin disease (13%), enteritis (12%), renal disease (9%), 
lymphadenopathy (8%) and leukopenia (5%) (Ishida et al., 1989). Evidence for FIV-
induced lymphomagenesis in pet cats, like experimentally infected cats, is strong yet 
largely circumstantial; Shelton and colleagues in America found FIV-infected cats were 
5.6 times more likely to develop high-grade B-cell lymphoma than control cats negative 
for both FIV and FeLV (Shelton et al., 1990), while a study of client-owned cats in 
Australia diagnosed with lymphoma found 50% were FIV-positive using Western blot 
analysis, suggesting a causal relationship (Gabor et al., 2001b). Haematological and 
biochemical changes reported in FIV-infected cats include neutropenia, increased serum 
total protein concentration and increased ɣ–globulin concentration, compared to similarly 
aged control cats (Gleich and Hartmann, 2009a). In an Australian study of 911 cats, the 
prevalence of FIV among ‘sick’ cats was approximately three times that of ‘healthy’ cats 
(21% versus 8%) (Malik et al., 1997). An association between FIV infection and chronic 
Dr. Mark Edward Westman Faculty of Veterinary Science  
Thesis 2016 The University of Sydney  
6 
 
kidney disease (CKD) has been suggested from Australian and Italian field studies. 
Thomas and collaborators, investigating pet cats that had blood submitted to a Western 
Australian (WA) veterinary pathology laboratory, found FIV-infected cats were 3.1 times 
more likely to be azotaemic than FIV-uninfected cats (Thomas et al., 1993a). A case-
control study using pet cats recruited from two veterinary hospitals in Sydney, NSW, 
found an increased incidence of CKD in FIV-infected cats < 11 years of age (compared to 
FIV-uninfected cats) (White et al., 2010). Researchers in Italy investigated and compared 
the renal tissue of naturally and experimentally infected cats and reported the presence of 
renal disease in both groups, consequently proposing a lentivirus-associated nephropathy 
(Poli et al., 2012). Recently, immunohistochemistry performed on the myocardium of five 
cats diagnosed with myocarditis or hypertrophic cardiomyopathy found an intense 
infiltration of FIV in lymphocytes and macrophages, leading to speculation about a 
possible disease association (Machado Rolim et al., 2016). 
Other studies have not shown a clear relationship between FIV infection and the 
development of associated disease. Norris and colleagues did not demonstrate an 
unequivocal or immediate impact of FIV infection on feline health, finding equal FIV 
prevalence amongst ‘sick’ and ‘healthy’ Australian cats (8% versus 8%) (Norris et al., 
2007). An Australian retrospective case-control study, recruiting client-owned cats from a 
university teaching hospital that were tested for FIV infection as part of a general work up 
for a variety of clinical signs, did not find a significant difference in survival age or 
survival time between FIV-infected and FIV-uninfected cats (Liem et al., 2013). A 
Canadian case-control study, which compared 58 FIV-infected and 58 FIV-uninfected cats, 
identified lethargy and oral cavity disease as being significantly associated with FIV-
positivity, but did not find a significant difference in survival time between the two groups 
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(Ravi et al., 2010). A long-term study of a closed household in the UK consisting of 26 
cats infected with a variety of viruses (FIV, FeLV and FCoV) actually found the survival 
time for FIV-infected cats was longer than the survival time for FIV-uninfected cats 
(median 51 versus 18 months), although this was not statistically significant (Addie et al., 
2000). A recent study of naturally FIV-infected cats in America found a dramatic 
difference in outcomes between two cohorts, suggesting that management and housing 
conditions have a major impact on disease progression and survival times of FIV-infected 
cats. In this study, only 1/17 cats in the first group (FIV-infected cats kept in households 
with one or two cats) died during the 22-month observation period (from hypertrophic 
cardiomyopathy), while 17/27 cats in the second group (FIV-infected cats kept in a multi-
cat household with more than 60 cats) died during the same period, including at least 11 
cats diagnosed with lymphoma (Bęczkowski et al., 2015a). 
An investigation of the impact of FIV-infection on the general health of Australian cats 
formed part of the epidemiological survey of retroviral infections presented in Chapter 2. 
1.3. Structure of FIV 
The FIV genome is composed of approximately 9,500 nucleotides, comprising three main 
open reading frames (orfs; gag, pol and env) encoding major capsid proteins (MA, matrix, 
p15; CA, capsid, p24; NC, nucleocapsid, p7), viral enzymes (PR, protease; RT, reverse 
transcriptase; IN, integrase) and envelope glycoproteins (TM, transmembrane, gp40; SU, 
surface, gp120), respectively (Olmsted et al., 1989). 
FIV is subdivided into seven clades (subtypes) based on genetic diversity in the variable 
V3-5 region of the env gene (A, B, C, D, E, F and U-NZenv) (Duarte and Tavares, 2006; 
Hayward et al., 2007; Yamamoto et al., 2007; Hayward and Rodrigo, 2010). Subtypes A, B 
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and C are most commonly encountered worldwide (Yamamoto et al., 2007), with subtype 
A predominant in Australia (Kann et al., 2006; Iwata and Holloway, 2008). Nucleotide 
sequence may vary up to 15% within a subtype and up to 38% between subtypes (Sodora 
et al., 1994; Duarte et al., 2002). Subtyping of FIV infections in each geographic area is 
important as the only commercially available FIV vaccine
1
 contains only subtypes A and D 
and heterologous challenge may lower vaccine effectiveness (Kusuhara et al., 2005; Huang 
et al., 2010), although subtyping alone appears insufficient to predict vaccine performance 
(Hosie and Beatty, 2007). 
1.4. Antibody production following FIV infection 
FIV infection is life-long and results in persistently high antibody titres that are useful 
diagnostically for identifying infected patients (Jarrett et al., 1991; Tonelli, 1991; 
Hartmann et al., 2001; Hartmann et al., 2007), except in the terminal (FAIDS) stage of 
infection when antibody levels, particularly to p15 and p24, may wane (Figure 1.2; 
Lecollinet and Richardson, 2008). Areas of the FIV genome capable of evoking host 
antibody response (B-cell epitopes) have been identified in the p7, p15, p24, gp40 and 
gp120 domains, with immunodominant epitopes located in the highly variable V3 region 
of gp120 (Lecollinet and Richardson, 2008; Yamamoto et al., 2010). Antibodies to p24 and 
gp40 are usually detectable within three weeks of infection, while antibodies to p15 
become detectable within four weeks of infection using Western blot (Yamamoto et al., 
1988; O'Connor et al., 1989), although occasionally antibodies may take up to a year to 
develop following infection (Yamamoto et al., 1988). Antibodies to gp120 are usually not 
measurable by Western blot owing to shearing of the viral envelope during purification, 
unless cell lysate is used for antigen preparation, rather than concentrated virus 
(Yamamoto et al., 1988; Pedersen et al., 1989; Hosie and Jarrett, 1990). Variable 
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definitions of FIV positivity based on results from Western blotting have been proposed, 
including (i) presence of antibodies to gp120, (ii) antibodies to gp120 and at least one core 
protein (p7, p15, or p24); (iii) antibodies to at least two core proteins; or (iv) antibodies to 
three core proteins (O'Connor et al., 1989; Hosie and Jarrett, 1990). 
Figure 1.2 Disease course of FIV and HIV infections, included to illustrate the variable 
antibody response to FIV infection depending on the B epitope studied. Using Western blot 
analysis, antibodies to p24 and gp40 appear slightly earlier than antibodies to p15. 
Antibodies to the envelope proteins (gp40 and gp120) persist throughout the course of FIV 
infection, while antibodies to matrix protein (p15) and capsid protein (p24) may wane in 
the terminal stages of FIV infection. (Reproduced from Lecollinet and Richardson, 2008). 
 
 
1.5. Serological testing for FIV infection 
Serologic testing for FIV infection is commonly undertaken by veterinarians when 
confronted with feline patients with severe stomatitis, sequential or persistent opportunistic 
infections, lymphoma and other malignancies, or signs of non-specific illness when a cause 
is not apparent after preliminary investigations. Veterinarians in shelters also typically 
perform serological testing for FIV infection prior to admission into a shelter, or prior to 
re-homing (Levy et al., 2008a; Hosie et al., 2009). 
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Point-of-care test kits to detect antibodies directed against FIV are inexpensive, easy to use 
and reliably diagnose FIV infection in FIV-unvaccinated cats (Hartmann et al., 2007). 
There is variation between commercially available antibody test kits in the methodology 
and target viral antigen for antibody detection. SNAP FIV/FeLV Combo
2
 is a lateral flow 
ELISA kit that detects antibodies to p15 (matrix protein) and p24 (capsid protein) in kits 
sold in North America, Australia and New Zealand, with gp 40 (transmembrane 
glycoprotein) added to kits sold in Europe. Witness FeLV/FIV
3
 is a lateral flow 
immunochromatography (IC) kit that detects antibodies to gp40, while Anigen Rapid 
FIV/FeLV
4
 is a lateral flow IC kit that detects antibodies to p24 and gp40 (Figure 3.1 and 
Table 3.1). SNAP FIV/FeLV Combo Plus, available only in Europe, is a lateral flow 
ELISA kit that detects antibodies to p15, p24 and gp40. Published sensitivity and 
specificity of each test kit in FIV-unvaccinated cats are 94% and 100% for SNAP 
FIV/FeLV Combo (www.idexx.com/files/small-animal-health/products-and-services/snap-
products/snap-fiv-felv-combo/snap-combo-test-accuracy.pdf), 100% and 100% for SNAP 
FIV/FeLV Combo Plus, 95% and 99% for Witness FeLV/FIV
 
(Hartmann et al., 2007), and 
89% and 100% for Anigen Rapid FIV/FeLV
 
(Sand et al., 2010). 
1.6. Antibody production following FIV vaccination 
The only commercial FIV vaccine (Fel-O-Vax FIV)
1
 currently available consists of 
formalin-inactivated whole cells (IWC) and whole virus (IWV) suspended together in an 
adjuvant (Yamamoto et al., 2007). It was presumed, on the basis of this composition, that 
the antibody response of FIV-vaccinated cats would be indistinguishable from those of 
FIV-infected cats (Uhl et al., 2002). Using laboratory-based ELISA testing, Huang and 
collaborators showed antibody against p24 and gp40 peaked 1–3 weeks after the third 
primary FIV vaccination (vaccines given three weeks apart) in kittens and decreased over 
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the following three months, with antibody levels maintained for 12 months in most cats 
(Huang et al., 2004; Huang et al., 2010). The same result was found by another group 
using ELISA testing for antibodies to whole FIV antigen and recombinant p24 (r-gag) in 
cats aged 7–12 months (Kusuhara et al., 2005), as well as from p24 ELISA determinations 
in experimental kittens vaccinated three times 2-3 weeks apart (unpublished data, 
Boehringer Ingelheim). Western blot analysis of four FIV-vaccinated cats confirmed 
antibody production to p15, p24 and gp40 three weeks after the second primary FIV 
vaccination, which persisted for at least 12 months following the third primary FIV 
vaccination (Uhl et al., 2002). Work by Levy and colleagues shortly after the release of the 
FIV vaccine reported that all FIV-vaccinated cats tested FIV-positive by three weeks after 
the first vaccine dose using a lateral flow ELISA kit (SNAP FIV/FeLV Combo),
2
 and by 
14 weeks used a microwell plate ELISA (PetChek FIV)
2 
(Levy et al., 2004). Consequently, 
in FIV-vaccinated cats and cats of unknown FIV vaccination status, diagnosis of FIV 
shifted to more expensive molecular methods such as nucleic acid amplification, with 
variable results in terms of accuracy and reliability (Bienzle et al., 2004; Crawford et al., 
2005; Crawford and Levy, 2007; Litster et al., 2012; Morton et al., 2012; Ammersbach et 
al., 2013). 
Chapter 3 revisits the assertion that point-of-care antibody kits are unable to differentiate 
FIV-infected and FIV-vaccinated cats by testing FIV-vaccinated cats, with variable FIV 
infection status, using three different antibody kits available in Australia. 
Chapter 5 expands on these results by prospectively recruiting a group of cats to administer 
the primary vaccination course against FIV and systematically and regularly test them over 
time to monitor their antibody response, as measured by four point-of-care antibody kits.  
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1.7. Diagnosis of FIV infection using saliva 
Antibody testing using saliva accurately detects HIV infection in people; a meta-analysis 
of the OraQuick Advance Rapid HIV-1/2 In-Home HIV Test
5
 identified similar specificity, 
and only a 2% reduction in sensitivity, when saliva was used instead of whole blood (Pai et 
al., 2012). As a result, this test kit has been approved by the USA Food and Drug 
Administration (FDA) for self-testing using saliva
6
 (Delaney et al., 2006). Surprisingly, 
despite similarities between serological testing for HIV-1 and FIV infection, and the 
potential welfare benefits of collecting saliva instead of blood from a cat, few studies have 
been performed to investigate the potential for diagnosing FIV infection by detecting FIV 
antibodies in saliva. The first study to investigate this possibility reported a high frequency 
of false-positive and false-negative results (Poli et al., 1992), while a more recent study . 
found a good correlation between salivary antibody and salivary PCR results (Chang-
Fung-Martel et al., 2013). 
Chapter 4 reports the testing of the same cats recruited for Chapter 3 using the same three 
FIV antibody kits currently available in Australia, with saliva utilised instead of blood as 
the diagnostic specimen. 
1.8. The FIV vaccine 
The commercial release of a FIV vaccine (Fel-O-Vax FIV)
1
 for use in domestic cats (USA 
in 2002; Australia in 2004) was the first time a vaccine had been registered for preventing 
infection by a Lentivirus in either human or veterinary medicine. More than 5,000 
laboratory cats were used over 14 years to develop a dual-subtype (A and D) IWC and 
IWV vaccine. A further 689 client-owned cats were used for safety testing in the field 
before the vaccine was released commercially. The result was a vaccine registered with a 
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‘preventable fraction’ (efficacy) of 68%, based on combined results from two laboratory-
based efficacy studies involving 105 cats (52 FIV-vaccinated, 53 FIV-unvaccinated) 
challenged one year after receiving three FIV vaccinations administered three weeks apart 
(Yamamoto et al., 2007). However, the vaccine wasn’t registered in many jurisdictions 
(e.g. Europe), owing in part to concerns related to the production of antibodies in FIV-
vaccinated cats indistinguishable from those produced in response to natural FIV infection. 
To date, a total of 262 cats have been tested using the current commercial FIV vaccine in 
laboratory-based efficacy studies (including the 105 cats from the pre-registration studies), 
with an overall preventable fraction of 66% (Table 6.1) (Huang et al., 2004; Kusuhara et 
al., 2005; Pu et al., 2005; Dunham et al., 2006b; Yamamoto et al., 2007; Huang et al., 
2010; Yamamoto et al., 2010; Coleman et al., 2014). Extremely high challenge doses, 
intravenous (IV) challenge (which avoids innate immunity barriers), and the use of highly 
pathogenic strains for challenge (e.g. FIVUK8), have been proffered as possible 
explanations for the variation in reported protection rates (Hosie and Beatty, 2007; 
Yamamoto et al., 2007). It has therefore been suggested that Fel-O-Vax FIV efficacy may 
have been underestimated and there has been speculation that field trials involving natural 
challenge might report a preventable fraction in excess of 66-68% (Hosie and Beatty, 
2007; Yamamoto et al., 2010). 
The global estimate of cats infected with FIV (35 million) is similar to the estimated 
number of humans infected with HIV-1 (www.who.int/gho/hiv/en/). The FIV-cat model is 
often advocated as a ‘test-bed’ for HIV infection, and the FIV vaccine used as a ‘proof of 
concept’ for the development of sterilizing immunity against lentiviruses such as HIV-1 
(Yamamoto et al., 2007; Lecollinet and Richardson, 2008; Bienzle, 2014). The successful 
development of a FIV vaccine would certainly provide encouragement for researchers 
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attempting to develop a HIV-1 vaccine. As some investigators have pointed out, however, 
the potential ‘road map’ provided by the development of the FIV vaccine has not been 
heeded by investigators in the HIV field. Indeed, the lack of translation of knowledge 
between fields has been described as being akin to ‘flying without a compass’ (Dunham, 
2006a; Lecollinet and Richardson, 2008). 
Chapter 6 reports the first ever field study investigating the effectiveness (‘protective rate’) 
of the FIV vaccine and discusses the significance of the observed findings in relation to 
both veterinary medicine and the development of a HIV vaccine. 
1.9. Discovery and prevalence of FeLV 
FeLV was first reported in 1964 following the recognition of a temporo-spatial cluster of 
lymphoma cases in a cattery (Jarrett et al., 1964). In this seminal study, electron 
microscopy enabled veterinary pathologist Bill Jarrett to identify a virus-like particle, 
similar in structure to murine leukaemia virus, in the mesenteric lymph node of a cat with 
lymphosarcoma (lymphoma). Jarrett’s work later inspired an American biomedical 
researcher to search for a viral agent associated with human T-cell leukaemias, ultimately 
leading to the discovery of human T-cell leukaemia virus type 1 and HIV-1 (Willett and 
Hosie, 2013). 
In many countries, feline leukemia virus (FeLV) infection is considered less prevalent, 
although no less pathogenic, than it was in the 1970s and 1980s (Levy et al., 2008; Lutz et 
al., 2009). This is the result of veterinary interventions, including rigorous testing and 
isolation of infected animals (Lutz et al., 2009; Willett and Hosie, 2013), pushing FeLV 
‘back into nature’ (www.sockfip.info/about-fip/all-articles/67-about-fip). Yet recent 
prevalence serosurveys have demonstrated FeLV infection is still common in certain 
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regions, such as Malaysia (12%) (Bande et al., 2012), Singapore (16%) (Chan et al., 2013) 
and Thailand (25%) (Sukhumavasi et al., 2012), remaining an important agent of disease in 
domestic cats. Of client-owned cats presented to university veterinary hospitals and tested 
for FeLV antigenaemia (p27) using various test kits and for an assortment of reasons, 
FeLV-positivity based on antigenaemia (‘progressive-infections’) was 6% in east Austria 
(249/4,465; 1996–2011) (Firth and Möstl, 2015) and 4% in Canada (50/1,205; 1996–2006) 
(Ravi et al., 2010). FeLV-positivity in large mixed populations of client-owned and shelter 
cats was 2% in North America (409/18,038; 2004) (Levy et al., 2006) and 3% in Canada 
(383/11,144; 2007) (Little et al., 2009). Indeed, the risk of FeLV infection remains 
sufficiently high to result in shelter guidelines recommending FeLV testing of all incoming 
cats prior to re-homing (Möstl et al., 2013). FeLV has not disappeared completely, and 
should definitely not be forgotten. 
In Australia, FeLV infection is considerably less prevalent than FIV infection in healthy 
client-owned cats (0-2% versus 8%) (Malik et al., 1997; Norris et al., 2007). Similarly, 
New Zealand and Singapore have reported lower seroprevalences of FeLV compared to 
FIV (6% versus 10% in a convenience sample of sick cats in New Zealand [Jenkins et al., 
2013]; 9% versus 16% in healthy cats tested at a Singaporean veterinary clinic [Chan et al., 
2013]). The difference between FeLV and FIV seroprevalences in New Zealand cats is 
likely to be greater than first reported; it was later discovered using PCR testing that many 
FeLV-positive results were actually false-positives (Severine Tasker, personal 
communication). The disparity between FeLV and FIV infection rates in domestic cats in 
Australia, New Zealand and Singapore seems out of step with other developed nations in 
Europe and North America, where the infection rates of FeLV and FIV are comparable 
(2% and 3% in North America (Levy et al., 2006), 3% and 4% in Canada (Little et al., 
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2009), 5% and 6% in the United Kingdom (Hosie et al., 1989) and 4% and 3% in Germany 
(Gleich et al., 2009b) respectively). 
An updated serosurvey of FeLV prevalence rates in both client-owned and shelter cats in 
Australia forms the basis of the work presented in Chapter 2. 
1.10. FeLV transmission and disease associations 
The main cellular target of FeLV is circulating lymphocytes, with additional cell tropism 
dependent on the FeLV subgroup present. FeLV-subtype A, which is involved in every 
infection and binds to target cells through an interaction with the thiamine transporter 
THTR1, has broad cellular tropism since THTR1 is expressed widely in feline tissues. 
FeLV-subtype B, which arises following recombination of FeLV-A with endogenous 
FeLV, attaches to cells via receptors Pit-1 and Pit-2 found on T-lymphocytes. FeLV-
subtype C, which results from a mutation in the env gene, utilises the haem transporters 
FLVCR1 and FLVCR2 expressed widely in haematopoietic tissues for viral entry. As a 
consequence of these viral receptors having different transport functions and being 
expressed by different cells, infection with different FeLV subtypes results in distinct 
clinical manifestations (Lutz et al., 2009; Willett and Hosie, 2013) 
FeLV is known as the ‘friendly cat disease’ since transmission only requires close contact 
in the form of allogrooming or shared food and watering stations. Bite wounds, however, 
are an increasingly recognised source of FeLV transmission (Goldkamp et al., 2008; 
Gleich et al., 2009b; Lutz et al., 2009). Vertical transmission of FeLV in the field is 
common and associated with high kitten mortality (Lutz et al., 2009).  
FeLV-infected cats with persistent (progressive) infections have a 62-fold increased risk of 
developing lymphoma or leukaemia compared with cats not infected with FeLV, with 
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FeLV-B infections responsible for the majority of FeLV-induced lymphoma (Hartmann, 
2012; Willett and Hosie, 2013). FeLV infection can also cause severe non-regenerative 
macrocytic anaemia (FeLV-A) and aplastic anaemia (FeLV-C), the latter often being fatal 
within weeks (Willett and Hosie, 2013). FeLV-infected cats are more to likely develop 
disorders of haematopoiesis (including aplastic anaemia, thrombocytopenia, neutropenia 
and lymphocytosis) compared to FeLV-uninfected cats (Gleich and Hartmann, 2009a). The 
survival rate for progressively FeLV-infected cats is estimated at 50% by two years and 
20% by three years after infection (Lutz et al., 2009; Hartmann, 2012). Co-infection with 
FIV is common in certain regions (e.g. Malaysia, Singapore, Thailand) and generally 
results in more serious clinical outcomes (Shelton et al., 1990; Courchamp et al., 1997).  
The impact of transient (regressive) FeLV infections on the health of cats is largely 
unknown. Some authors have suggested regressively FeLV-infected cats have a similar 
life-expectancy to cats never exposed to FeLV and do not seem to develop FeLV-
associated disease (Lutz et al., 2009; Willett and Hosie, 2013). However, despite 
apparently clearing the viraemia and ‘recovering’, reactivation of regressive FeLV 
infection contained in the bone marrow has been demonstrated experimentally with and 
without the administration of corticosteroids (Rojko et al., 1982; Hofmann-Lehmann et al., 
2007; Helfer-Hungerbuehler et al., 2015), and care is suggested when treating regressively 
FeLV-infected cats with immunosuppressive medication (e.g. chemotherapy, 
chlorambucil, ciclosporin) (Torres et al., 2005; Hartmann, 2012). Long-term follow up of 
five regressively-infected cats (following experimental inoculation) found all cats had 
detectable provirus and viral RNA (vRNA) loads in almost all of 27 tested tissues, even up 
to 12 years after virus exposure (Helfer-Hungerbuehler et al., 2015). Research in Australia 
and Canada has suggested a correlation between regressive FeLV infections and the 
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occurrence of lymphoma, with two studies reporting 80% (56/70) and 26% (25/97) of 
lymphomas were PCR-positive for FeLV provirus, respectively (Jackson et al., 1993; 
Gabor et al., 2001a). Furthermore, regressively-infected cats are capable of transmitting 
FeLV infection to recipient cats by blood transfusion, an important reminder that potential 
blood donors need to be tested for FeLV provirus, regardless of p27 antigen status using 
point-of-care test kits (Nesina et al., 2015). 
1.11. Categories of FeLV infection 
The host-pathogen interaction for FeLV in cats is complex and best represented as a 
spectrum of outcomes following exposure. The development of molecular methods for 
FeLV diagnosis, specifically qPCR testing to detect low levels of proviral DNA and qRT 
(reverse-transcription)-PCR to detect low levels of viral RNA in blood, has enriched our 
understanding of the cat-FeLV relationship, adding nuances to the diagnosis, pathogenesis 
and categorization of FeLV infection.  
Currently, four putative outcomes are defined for cats following FeLV challenge: (i) At 
one end of the spectrum, some cats mount a timely and appropriate immune response and 
eliminate virus before it progresses beyond local replication in oropharyngeal tissue – so-
called abortive-infection (20-30% of cases under laboratory conditions using specific 
pathogen free [SPF] cats); (ii) at the other end of the spectrum, some cats become 
persistently viraemic (progressive-infection; 30-40% of experimental infections); (iii) 
between these extremes, some cats are transiently viraemic before mounting a partial 
immune response to eliminate the viraemia after 2-16 weeks, but not before a latent 
infection is established as DNA provirus, predominantly in lymphoid cells in the bone 
marrow (regressive-infection; 30-40% of experimentally inoculated cats); and (iv) a small 
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number of cats follow an atypical course involving a latent state with variable 
antigenaemia and viraemia due to local foci of infection, e.g. in the eyes, bladder or 
mammary tissue (atypical/focal infection; 5%) (Lutz et al., 2009; Englert et al., 2012; 
Hartmann, 2012). From the lymphoma studies cited earlier, where results from blood 
ELISA testing and tissue FeLV PCR testing were both available in the same cat, latent 
infections (regressive/focal) were identified in 27% (7/26) and 22% (19/86) of cases, 
respectively (i.e. ELISA negative, PCR positive) (Jackson et al., 1993; Gabor et al., 
2001a). Such a range of possible outcomes following FeLV exposure makes defining the 
expectations of diagnostic test kits important, before attempting to evaluate the 
performance of a given test (Chapter 7). 
Chapter 8 investigates the prevalence of both progressive and regressive FeLV-infections 
in three groups of cats in Australia, including one group representative of the general cat 
population and two groups of group-housed rescue cats where index cases of FeLV 
infection had been identified. 
1.12. Diagnosis of progressive FeLV infection using blood 
While antibody detection has been the mainstay of FIV testing historically, antigen 
detection has been the most common method of FeLV diagnosis. This can be done via 
screening with a point-of-care ELISA/IC test kit (to detect viral capsid protein p27), direct 
IFA testing or VI, although confirmatory IFA testing is now rarely performed owing to the 
ready availability and superior sensitivity of real-time PCR (qPCR) testing to detect FeLV 
provirus, while VI is confined mainly to the research setting (Lutz et al., 2009; Adam and 
Dandrieux, 2011).  
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Prior to the commercial availability of qPCR assays, studies of four commercially 
available point-of-care FeLV antigen test kits (1989–1991) reported almost 100% 
sensitivity and 100% specificity for all kits compared to IFA testing (Lopez et al., 1989b; 
Hawks et al., 1991) but reduced sensitivity compared to VI (Hawks et al., 1991). 
Furthermore, discordant results were observed between test results for whole blood and 
serum due to a combination of false-positive (whole blood) and false-negative (serum) 
results (Hawks et al., 1991). Subsequent research (1998–2001) using a later generation of 
test kits reported 5/6 point-of-care FeLV antigen kits tested using serum (including SNAP 
FIV/FeLV Combo
2
 and Witness FeLV/FIV
3
) to have good sensitivity and specificity using 
VI as the ‘gold standard’ (Hartmann et al., 2001), and SNAP FIV/FeLV Combo and 
Witness FeLV/FIV both performed well when tested side-by-side (Robinson et al., 1998). 
In one of the studies, SNAP FIV/FeLV Combo testing using whole blood instead of serum 
increased the number of equivocal results and was therefore advised against by the authors, 
despite the manufacturer’s recommendations that whole blood could be used (Hartmann et 
al., 2001). More recently (2007–2010), testing of eight of the latest generation point-of-
care FeLV antigen test kits (including SNAP FIV/FeLV Combo and Witness FeLV/FIV) 
with serum found all but one kit had similarly high sensitivity and specificity when 
compared to VI (Hartmann et al., 2007), while a separate study reported Anigen Rapid 
FIV/FeLV
4
 to have comparable diagnostic accuracy to SNAP FIV/FeLV Combo using 
provirus PCR testing as the gold standard (Sand et al., 2010). Witness FeLV/FIV was 
found to have ‘a high number of tests that were difficult to interpret’ (14%) (Hartmann et 
al., 2007), although exactly what is meant by that is difficult to interpret. 
Chapter 7 investigates the performance of three FeLV antigen test kits available in 
Australia using whole blood as the diagnostic specimen, and proviral PCR testing as the 
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gold standard. Of particular interest, considering the low prevalence of FeLV in Australia 
in the general cat population, was the PPV of each kit and the frequency of false-positive 
results encountered consequently (Hawkins, 1991; Beatty et al., 2011; Möstl et al., 2013). 
1.13. Diagnosis of progressive FeLV infection using saliva 
Diagnosis of FeLV infection using samples other than blood has been investigated using 
both laboratory-based ELISA testing and commercial point-of-care FeLV test kits. Saliva 
is the obvious alternative diagnostic specimen, as it is often easier to collect than blood, 
especially from fractious cats, and saliva contains on average five-times more FeLV per 
mL than plasma (Francis et al., 1977). Results from saliva testing have, however, been 
contradictory. One early study of experimentally infected and sick client-owned cats using 
laboratory-based ELISA testing found false-positive FeLV results occurred rarely (5/1,117; 
0.4%) but false-negative results occurred in 23% (39/167) of FeLV-infected sick cats (Lutz 
and Jarrett, 1987). A later study from Switzerland, using the same sandwich ELISA, 
reported false-positive FeLV results in 5% (19/367) of FeLV-uninfected cats (Gomes-
Keller et al., 2006). Other studies have investigated FeLV diagnosis using point-of-care 
ELISA saliva testing, finding a concordance of 98% (552/564) between saliva and serum 
tested concurrently using ViraChek FeLV
7
 (Lewis et al., 1987), and 92% (94/102) between 
saliva and plasma using ClinEase-Virastat
7
 (Lopez et al., 1990). Both studies concluded 
saliva testing was a useful rapid screening procedure using these kits, but recommended 
confirmatory testing (Lewis et al., 1987; Lopez et al., 1990). Despite these promising 
results, the American Association of Feline Practitioners (AAFP) declared that ‘antigen 
tests should not be performed on tears or saliva because these tests are prone to more 
errors’ (Levy et al., 2008a). 
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Chapter 7 also investigates the performance of three FeLV antigen test kits available in 
Australia using saliva as the diagnostic specimen, and proviral PCR testing as the gold 
standard. 
1.14. Impetus for this thesis: an explanation 
The aforementioned literature review covers the two clinically important retroviral diseases 
of cats in a classic historical perspective. The background and impetus to the studies 
included within this thesis are outlined below, to provide some insights into the 
chronology. 
Two of my supervisors (Norris and Malik) had been approached by Boehringer Ingelheim, 
the distributors of the FIV vaccine (originally developed by Fort Dodge), to conduct a field 
study to assess the effectiveness of this vaccine in an Australian setting. There had been, to 
date, no confirmed reports of ‘vaccine breakthroughs’, and it was anticipated that the data 
generated would provide further support for vaccination of at risk cats in an Australian 
setting. Although Norris and Malik argued persuasively for a prospective study of vaccine 
effectiveness, the commercial realities dictated to start the investigation using a 
retrospective study design to provide data in a timelier manner, and the samples required 
for this investigation form the major study cohort for this PhD dissertation. The 
requirement for stringent FIV testing of cats in this study mandated a highly structured 
study design, and the testing of cats provided an opportunity for head-to-head testing of the 
latest generation of test kits for FIV against the commercial qPCR offered by IDEXX 
Laboratories as the gold standard, although in some discordant cases it was necessary to 
utilise virus isolation in specialist laboratories as the final arbiter of FIV status. As most of 
the kits also tested for FeLV antigen, it was logical to examine the prevalence of FeLV in 
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the same study cohort, to get an appreciation of the occurrence of so-called progressive 
versus regressive infections in the field. Further, additional minimally-invasive sample 
collection facilitated an examination of the accuracy of testing using saliva versus whole 
blood as the diagnostic specimen for these test kits. 
Early results suggested that some of the test kits for FIV could provide a reliable indication 
of true FIV status even in cats who had been given the complete course of FIV 
vaccinations, and the reasons for this unexpected observation provided a fertile ground for 
the more detailed prospective experiments in Chapter 5. 
Finally, the serendipitous discovery of two ‘hot spots’ for FeLV disease, based on clinical 
investigation of FeLV related disease by colleagues in practice, provided us with the 
impetus to compare and contrast the epidemiology of FIV and FeLV in these small rescue 
facilities, against the overall wider client-owned feline population. 
                                                 
1
 Fel-O-Vax
®
 FIV, Boehringer Ingelheim, Fort Dodge, IA, USA. 
2
 IDEXX Laboratories, Westbrook, ME, USA. 
3
 Zoetis Animal Health, Lyon, France. 
4
 BioNote, Gyeonggi-do, Korea.  
5
 OraSure Technologies Inc, PA, USA. 
6
 www.fda.gov/ForConsumers/ConsumerUpdates/ucm310545.htm 
7
 Synbiotics Corporation, San Diego, CA, USA 
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CHAPTER 2.  THE PREVALENCE OF FIV and FeLV IN 
DOMESTIC CATS IN AUSTRALIA 
2.1 ABSTRACT 
The aims were to (i) determine the current seroprevalence of FIV and FeLV in three large 
cohorts of cats from Australia and (ii) investigate potential risk factors for retroviral 
infection. Cohort 1 (n = 2,151 for FIV, n = 2,241 for FeLV) consisted of cats surrendered 
to a shelter on the west coast of Australia (Perth, WA). Cohort 2 (n = 2,083 for FIV, n = 
2,032 for FeLV) consisted of client-owned cats with outdoor access recruited from around 
Australia through participating veterinary clinics. Cohort 3 (n = 169 for FIV, n = 166 for 
FeLV) consisted of cats presenting to MUVH for a variety of reasons. Fresh whole blood 
was collected and tested using a commercially available point-of-care lateral flow ELISA 
kit that detects p27 FeLV antigen and antibodies to FIV antigens (p15 and p24) (Cohorts 1 
and 2), or one of two lateral flow IC kits that detect p27 antigen and antibodies to FIV 
antigen (p24 and/or gp40) (Cohort 3). Data recorded for cats in Cohort 2 included 
signalment, presenting complaint and postcode, allowing investigation of risk factors for 
FIV or FeLV infection as well as potential geographic ‘hot spots’ for infection. The 
seroprevalence of FIV was 6% (Cohort 1), 15% (Cohort 2) and 14% (Cohort 3) while the 
seroprevalence of FeLV was 1%, 2% and 4% in the same respective cohorts. Risk factors 
for FIV infection among cats in Cohort 2 included age (> 3 years), sex (male), neutering 
status (entire males) and location (WA had a significantly higher FIV seroprevalence 
compared with the ACT, NSW and VIC). Risk factors for FeLV infection among cats in 
Cohort 2 included health status (‘sick’) and location (WA cats were approximately three 
times more likely to be FeLV-infected compared with the rest of Australia). No geographic 
Dr. Mark Edward Westman Faculty of Veterinary Science  
Thesis 2016 The University of Sydney  
25 
 
hot spots of FIV infection were identified. Both FIV and FeLV remain important infections 
among Australian cats. WA has a higher seroprevalence of both feline retroviruses 
compared to the rest of Australia, which has been noted in previous studies. A lower de-
sexing rate for client-owned male cats is likely responsible for the higher seroprevalence of 
FIV infection in WA cats, while the reason for the higher seroprevalence of FeLV in WA 
cats is currently unknown. 
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2.2 INTRODUCTION 
To date, there has been one reported investigation of retroviral infection in Australian 
shelter cats. This was an underpowered study of only 20 cats from Melbourne, Victoria, 
which found six cats, with a median age of 3 years, to be FIV-positive (30%) (Friend et al., 
1990). FeLV status was not investigated in that study (Friend et al., 1990). Consequently, a 
larger study into the retroviral status of Australian shelter cats has been long overdue. 
While there has been a paucity of studies investigating the retroviral status of Australian 
shelter cats, there have been several investigations into the retroviral status of client-owned 
cats. These studies vary considerably in relation to location, design and recruitment, 
resulting in considerable variation in the reported seroprevalences of FIV and FeLV 
infection (Sabine et al., 1988; Belford et al., 1989; Friend et al., 1990; Robertson et al., 
1990b; Thomas et al., 1993b; Malik et al., 1997; Winkler et al., 1999; Norris et al., 2007; 
Chang-Fung-Martel et al., 2013). The seroprevalence of FIV infection in these prior 
studies varies between 0-29% (for ‘healthy’ cats) and 4-32% (for ‘sick’ cats). The 
seroprevalence of FeLV infection in these prior studies varies between 0-7% (for ‘healthy’ 
cats) and 0-11% (for ‘sick’ cats) (Tables 2.1 and 2.2). Two of these studies investigated 
FIV and FeLV infection in WA cats: a 1990 study found seroprevalence rates of 29% 
(FIV) and 7% (FeLV) in ‘healthy’ cats, and 28% (FIV) and 11% (FeLV) in ‘sick’ cats 
(Robertson et al., 1990b); while a 1993 study found seroprevalence rates of 24% (FIV) and 
6% (FeLV) in ‘sick’ cats (Thomas et al., 1993b). 
The aim of this study was to determine the seroprevalence of FIV and FeLV in three 
different Australian feline cohorts: cats surrendered to a rescue facility (shelter) in WA 
(Cohort 1), client-owned cats recruited from around Australia through participating 
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veterinary clinics (Cohort 2) and cats presenting to MUVH (Perth, WA) (Cohort 3) for a 
variety of reasons (mostly illness-related). This third cohort was recruited to provide 
further insights into the high seroprevalence of FIV and FeLV in WA detected in 
preliminary data analysis of cats from Cohort 2, and reported in previous studies 
(Robertson et al., 1990b; Thomas et al., 1993b). Detailed information was recorded for cats 
in the second cohort, which permitted investigation of risk factors for retroviral infection as 
well as the use of spatial statistical methods to identify potential geographic ‘hot spots’ of 
infection in Australia. 
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Table 2.1 Summary of previous Australian studies investigating FIV and progressive FeLV infection amongst ‘healthy’ cats. 
Reference Location Study design Age FIV prevalence FeLV prevalence 
 Sabine et al. 
(1988) 
Sydney, NSW ‘Healthy’ cats (n = 30), serum/plasma supplied by 
Webster’s Vaccine Company 
NP 2/30; 7% 2/30; 7% 
Robertson et 
al. 
(1990b) 
Perth, WA ‘Healthy’ client-owned cats (n = 72), recruited by 
random selection of households from the Perth 
electoral rolls 
NP 21/72; 29% 5/72; 7% 
Malik et al. 
(1997) 
Sydney, NSW ‘Healthy’ client-owned cats (n = 200), prospective 
sampling from four veterinary clinics 
Median age 4 
years 
15/200; 8% 4/200; 2% 
Norris et al. 
(2007) 
Sydney, NSW ‘Healthy’ client-owned cats (n = 170), prospective 
sampling from 3 veterinary clinics stringently 
designed to reflect a typical hospital population 
Median age 7 
years 
 
13/170; 8% 4/170; 2% 
(unpublished 
data) 
Beatty et al. 
(2011) 
Sydney, NSW ‘Healthy’ client-owned cats (n = 169), most acquired 
from rescue societies), prospective sampling from 3 
veterinary clinics 
Mean age 3 
months (all < 
1 year) 
0/169; 0% 0/169; 0% 
Chang-Fung-
Martel et al. 
(2013) 
Townsville, 
QLD 
‘Healthy’ cats (n = 96), door-to-door survey using a 
random sampling approach, saliva collected 
Median age 5 
years 
 
10/96; 10% NP 
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Table 2.2 Summary of previous Australian studies investigating FIV and progressive FeLV infection amongst ‘sick’ cats. 
Reference Location Study design Age FIV prevalence FeLV prevalence 
 Sabine et al. 
(1988) 
Sydney, NSW ‘Sick’ cats (n = 23), convenience sample using 
serum/plasma sent to VPDS, The University of Sydney 
with many specimens dating back to the 1970s 
NP 1/23; 4% 2/23; 9% 
Belford et 
al. (1989) 
QLD and 
northern NSW 
‘Sick’ cats and in-contact cats (n = 65), convenience 
sampling using serum/plasma sent to VPS from cats 
suspected to be FIV infected based on clinical or 
laboratory findings (break up of sick versus in-contact 
cats not specified) 
NP 21/65; 32% NP 
Robertson et 
al. (1990b) 
Perth, WA ‘Sick’ client-owned cats (n = 211), convenience sample 
using serum sent to MUVH Clinical Pathology 
Laboratory for diagnostic work up of clinical disease 
(not specifically suggestive of FIV) 
NP 59/211; 28% 23/211;  
11% 
Friend et al. 
(1990) 
Melbourne, 
VIC 
‘Sick’ cats (n = 467, consisting of 447 client-owned and 
20 shelter cats), convenience sample using serum sent to 
CVDL or SVS, most cats displaying clinical disease 
compatible with immunodeficiency 
NP 120/467; 26% 16/467;  
3% 
Thomas et 
al. (1993b) 
WA ‘Sick’ client-owned cats (n = 326), convenience sample 
using blood sent to a private laboratory for diagnostic 
work up of clinical disease 
NP 78/326; 24% 21/326;  
6% 
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Malik et al. 
(1997) 
NSW ‘Sick’ client-owned cats (n = 894), convenience sample 
using serum sent to a private clinical pathology 
laboratory for diagnostic work up of suspected 
immunodeficiency (not all samples tested for both FIV 
and FeLV) 
NP 148/711; 21% 11/761;  
1% 
Winkler et 
al. (1999) 
Adelaide, SA Client-owned cats of unknown health status (n = 389), 
convenience sample using serum sent to VPS 
(presumably cats ‘sick’ and sampled for diagnostic work 
up of their illness) 
NP 39/389; 10% NP 
Norris et al. 
(2007) 
Sydney, NSW ‘Sick’ client-owned cats (n = 170), prospective sampling 
from three veterinary clinics stringently designed to 
reflect a typical hospital population, cats were 
‘systemically unwell’ and sampled for diagnostic work 
up of their illness 
Median age 
7 years 
14/170;  
8% 
4/170; 2% 
(unpublished data) 
Beatty et al. 
(2011) 
Sydney, NSW ‘Sick’ client-owned cats (n = 75), convenience sample 
using cats presented to VCCC for further work up of 
anaemia, cytopenia, lymphoma and other illnesses 
Mean age 
11.5 years 
8/75; 11% 0/75; 0% 
NP = not provided; VPDS = Veterinary Pathology Diagnostic Services; VPS = Veterinary Pathology Services; MUVH = Murdoch University Veterinary Hospital; CVDL 
= Central Veterinary Diagnostic Laboratory; SVS = School of Veterinary Science, University of Melbourne; VCCC = Valentine Charlton Cat Centre, University of 
Sydney. 
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2.3 MATERIALS AND METHODS 
2.3.1 Sample population 
Cohort 1 consisted of cats surrendered to a shelter on the west coast of Australia in Perth, 
WA between January 2011 and March 2013. Entire male cats older than 7 months of age 
were tested routinely, while entire female cats older than 7 months of age were tested at the 
discretion of the attending veterinarian (personal communication). Age was determined 
either by paperwork completed by the surrendering owner or estimated by the veterinarian, 
based on dentition. 
Cohort 2 consisted of client-owned cats recruited through participating veterinary clinics in 
Australia between January 2012 and December 2012. Clinics from five Australian states 
and one territory participated (New South Wales [NSW], Victoria [VIC], Queensland 
[QLD]. South Australia [SA], West Australia [WA] and Australian Capital Territory 
[ACT]); only one poorly populated island state (Tasmania [TAS]) and one sparsely 
populated territory (Northern Territory [NT]) were not included in the study design (Figure 
2.2). BI technical representatives offered to supply selected clinics with up to 30 free point-
of-care FIV/FeLV test kits, on the condition that veterinary staff recorded in a spreadsheet 
test results and basic information, including signalment, postcode, reason for presentation 
and a subjective assessment of ‘sick’ versus ‘healthy’ on all cats sampled. Veterinarians 
were instructed to test cats only if individuals were 2 years of age or older (although this 
criterion was not strictly adhered to), had some level of outdoor access and had not been 
vaccinated against FIV. This scheme was part of a BI marketing program to raise the 
profile of a FIV vaccine
8
 in Australia by demonstrating presence of FIV infection to 
clinicians in their local area, and thus to cat owners. Clinics selected included both those 
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which already recommended FIV vaccination and others that didn’t routinely recommend 
FIV vaccination owing to a perceived low prevalence of FIV in their vicinity. A free map 
of the local area displaying the location of FIV-positive cats was offered as an inducement 
to participating clinics at the conclusion of the study with the intent of encouraging owners 
to vaccinate against FIV (Figure 2.1). 
Cohort 3 consisted of cats presenting to MUVH between January 2011 and December 
2013. The majority were cats presenting to the emergency or feline medicine units for 
signs of non-specific illness; other reasons for FIV/FeLV testing included health 
assessments of stray animals or prior to blood donation or commencement of 
immunosuppressive therapy. 
2.3.2 Serological testing 
Whole blood was collected by cephalic or jugular venipuncture for immediate in-clinic 
testing. All cats in Cohorts 1 and 2 were tested using SNAP FIV/FeLV Combo
9
 according 
to the manufacturer’s instructions. This kit is a lateral flow ELISA that detects antibodies 
to FIV matrix protein (p15) and FIV capsid protein (p24), and FeLV antigen (specifically 
core viral capsid protein p27). Cats in Cohort 3 were tested using either Witness 
FeLV/FIV
10
 or SensPERT FeLV/FIV.
11
 Both of these kits use lateral flow IC to either 
detect antibodies to FIV glycoprotein (gp40) and FeLV antigen (p27) (Witness), or 
antibodies to FIV capsid protein (p24) and FIV glycoprotein (gp40), and FeLV antigen 
(p27) (SensPERT). 
2.3.3 Data collection 
Results from cats in Cohort 1 were entered into a database at the time of testing by 
veterinary staff. A summary of results was retrieved in May 2013 using a summary search 
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function.
12
 Pertinent data such as signalment, medical history, vaccination history and 
information on previous outdoor access was unavailable for these cats. 
Results from cats in Cohort 2 were entered into a spreadsheet at the time of testing by 
veterinary staff, collated at the end of the testing period by a BI employee and then 
supplied to the first author for analysis. Signalment information (excluding breed), clinic 
postcode, primary presenting complaint and a subjective assessment of ‘healthy’ versus 
‘sick’ made by the attending veterinarian were recorded alongside the cat’s FIV and FeLV 
results. Based on the reason for presentation, cats in Cohort 2 were reclassified as ‘healthy’ 
or ‘sick’ according to previously published definitions.(Malik et al., 1997; Norris et al., 
2007) ‘Healthy’ cats were those for whom the purpose of blood collection was not disease 
investigation; rather, it was as part of a routine health check, for routine testing prior to the 
dispensing of behaviour modifying medication, for routine pre-anaesthetic testing prior to 
sedation or general anaesthesia for de-sexing, grooming, dental disease or cat fight abscess 
treatment, or investigation and treatment of traumatic injuries. Dental disease was not 
graded by the attending veterinarian and so this category may have included minor teeth 
scaling and polishing to remove tartar, as well as extensive extractions attributable to 
periodontal disease. ‘Sick’ cats were those for whom the reason for presentation was 
suggestive of systemic illness, such as vomiting, diarrhoea, weight loss, respiratory signs, 
neoplasia, and severe illness warranting euthanasia. Cats were classified as ‘unknown’ if 
the reason for presentation did not easily fit either the ‘healthy’ or ‘sick’ definitions. 
Results from cats in Cohort 3 were entered into the patient’s medical records at the time of 
testing by the attending veterinarian and a summary of results retrieved in May 2015 by 
searching for invoiced FIV and FeLV point-of-care test kits.
13
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2.3.4 Statistical analysis 
Numerical analyses were performed using a commercial statistical software package
14
 with 
P values < 0.05 considered significant, and 95% CIs were calculated based on a normal 
approximation and the Wald method.
15
 Probability of infection was used, where possible, 
since the measured outcome was binomial. Univariate and multivariate logistic regression 
modelling was performed to determine the effect of age, sex, neutering status, health 
assessment (‘healthy’ versus ‘sick’) and location (state/territory) on the retroviral status of 
cats in cohort 2. A two-tailed Fisher’s exact test was used to investigate whether entire 
male cats were over-represented in WA in Cohort 2. The 2-sample z-test was used to 
compare FIV seroprevalence between ‘healthy’ and ‘sick’ cats in cohort 2 using an online 
calculator.
16
 Potential geographic hot spots of FIV infection based on postcode were 
investigated using the scan statistic (SaTScan version 7). A scanning window of 5% of the 
study area size and a Bernoulli model (case-control) was used.
                                                 
8
 Fel-O-Vax FIV, BI, Fort Dodge, IA, USA. 
9
 IDEXX Laboratories, Maine, USA. 
10
 Zoetis Animal Health, Lyon, France. 
11
 VetAll Laboratories, Gyeonggi-do, Korea. 
12
 Animal Shelter Manager Version 2.8.12. 
13
 RxWorks Version 4.7.3200. 
14
 GenStat 16
th
 Edition for Windows, VSN International, Hemel Hempstead, United Kingdom. 
15
 Microsoft Excel 2010 for Windows, Microsoft, Redmond, WA, USA. 
16
 www.epitools.ausvet.com.au/content.php?page=z-test-2 
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Figure 2.1 Marketing material used by BI to recruit veterinary clinics for the study.  
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2.4 RESULTS 
2.4.1 Cohort 1 (Shelter cats, WA) 
Of 2,151 cats tested, 124 were FIV-positive (6%; 95% CI 4.8-6.7). Of 2,241 cats tested, 22 
cats were FeLV-positive (1%; 95% CI 0.6-1.4). We were unable to determine the 
FIV/FeLV co-infection rate for this cohort, owing to limitations with the summary search 
function. 
2.4.2 Cohort 2 (Client-owned cats, Australia) 
2.4.2.1 Sample population 
A total of 2,222 cats were recruited from 130 veterinary clinics in five states and one 
territory of Australia (Figure 2.2). Cats with incomplete details recorded were excluded 
from the final analyses, as were kittens 6 months of age or younger, owing to the 
possibility of maternal antibodies giving false-positive results with FIV testing (Hosie et 
al., 2009). Some cats had a FIV result recorded but no FeLV result. Ultimately, 2,083 cats 
remained available for analysis, of which 2,032 also had a recorded FeLV result. 
The age of cats recruited ranged from 7 months to 22 years (median age 6 years; 
interquartile range [IQR] 3-11 years). Castrated male cats were the most common category 
(974/2,083; 47%), followed by spayed female cats (671/2,083; 32%), entire male cats 
(245/2,083; 12%) and entire female cats (193/2,083; 9%). Overall, there was a gender bias 
resulting in more males (1,219/2,083; 59%) than females (864/2,083; 41%) being tested 
(Figure 2.3). Entire male cats were significantly over-represented in WA compared to the 
rest of the country (54/239; 23% versus 191/1,844; 11%, P = 0.001). 
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2.4.2.2 Serological testing 
Of 2,083 cats tested, 305 were FIV-positive (15%; 95% CI 13.1-16.2). Of 2,032 cats 
tested, 32 were FeLV-positive (2%; 95% CI 1.0-2.1) (Figure 2.2, Table 2.3). Of the 32 
FeLV-positive cats, 11 also tested FIV-positive (34%), giving a FIV/FeLV co-infection 
rate of 11/2,032 (0.5%; 95% CI 0.2-0.9). The median age of FIV-infected cats was 7 years 
(IQR 4-11 years). The median age of FeLV-infected cats was 6 years (IQR 3-10 years). 
FIV and FeLV seroprevalence rates by location (state/territory), sex and neutering status 
are provided in Tables 2.4.1 and 2.4.2. 
2.4.2.3 Risk factors for FIV seropositivity 
The seroprevalence of FIV infection was significantly higher in cats older than 3 years of 
age compared to cats younger than 3 years of age (P < 0.001). Male cats were significantly 
more likely than female cats to be FIV-infected (P < 0.001), while entire male cats were 
significantly more likely than castrated male cats to be FIV-infected (P = 0.001). 
When FIV seroprevalence was assessed using a multivariate model to account for the 
significant effects of age, sex and neutering status, a significant difference between 
sampling locations was found (P = 0.03). Specifically, the ACT, NSW and VIC had a 
significantly lower FIV seroprevalence compared with WA, while ACT and NSW had a 
significantly lower FIV seroprevalence compared with QLD. When WA was compared 
with the rest of the country, cats domiciled in that state were significantly more likely to be 
FIV-infected (OR 1.7) (Figure 2.4). Although SA had the lowest recorded FIV 
seroprevalence (3/38; 8%), the low sample number and resulting large SE precluded this 
difference from reaching statistical significance. 
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The seroprevalence of FIV infection was not significantly different between ‘healthy’ and 
‘sick’ cats using the aforementioned definitions (14% versus 16%; P = 0.17), although 
when cats classified with dental disease were excluded from analysis there was a trend 
towards significance (P = 0.06). When the attending veterinarian’s assessment of health 
status was considered, however, the prevalence of FIV infection among ‘sick’ cats was 
almost twice that of ‘healthy’ cats (11% versus 20%, P < 0.0001). 
One potential geographical hot spot of FIV infection was identified in WA (postcodes 
6024, 6060, 6090, P = 0.06). When investigated further, this cluster of infections was 
found to be the result of biased sampling, with a higher proportion of entire cats sampled 
compared with the rest of cohort 2 (P < 0.001). Socioeconomic data from the Australian 
Bureau of Statistics (ABS)
17
 for these postcodes was examined and compared to ABS data 
for other postcodes in cohort 2; no significant differences were found between the cluster 
postcodes and other postcodes for socioeconomic disadvantage (P = 0.74), resources (P = 
0.74) or education (P = 0.94). 
2.4.2.4 Risk factors for FeLV seropositivity 
Age, sex and neutering status were not found to be risk factors for FeLV infection (P = 
0.87, 0.50 and 0.63, respectively), and sampling location only just failed to reach 
significance (P = 0.06). When results for WA were compared with the rest of the country, 
cats from that state were approximately three times as likely to be FeLV-infected (OR 3.0) 
(Figure 2.4). ACT did not record any FeLV-infected cats (0/45), while WA recorded the 
highest seroprevalence (9/239; 4%). The seroprevalence of FeLV infection was 
approximately three times higher among ‘sick’ cats than ‘healthy’ cats, using both the 
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aforementioned definitions and the attending veterinarian’s assessment of health status (1% 
versus 3%, P = 0.02; 1% versus 3%, P < 0.001, respectively). 
A summary of significant risk factors for FIV and FeLV infection of cats in cohort 2 is 
provided in Table 2.5. 
2.4.3 Cohort 3 (Cats presenting to MUVH, WA) 
2.4.3.1 Sample population 
A total of 170 cats were tested for FIV and/or FeLV, ranging in age from 2 months to 19 
years (median age 6 years; IQR 2-10 years). These cats comprised 80 castrated males 
(47%), 66 spayed females (39%), 17 entire males (10%) and seven entire females (4%). 
Most were domestic crossbred cats (127/170; 75%); the remainder comprising a range of 
pedigree breeds. The majority of cats were tested as part of a medical work up for non-
specific illness (114/170; 67%), followed by testing prior to commencement of 
immunosuppressive therapy (31/170; 18%), testing prior to blood donation (12/170; 7%) 
health assessment of stray animals (11/170; 7%) and routine testing prior to FIV/FeLV 
vaccination (2/170; 1%). 
2.4.3.2 Serological testing  
Of 169 cats tested for FIV, 24 were positive (14%; 95% CI 8.9-19.5). FIV positive cats 
ranged from 2 months to 13 years (median age 4 years; IQR 2-8 years), comprised mostly 
of domestic crossbred cats (19/24; 79%) with a preponderance of male cats (14 castrated 
males, seven entire males, two spayed females and one entire female). 
Of 166 cats tested for FeLV, 7 cats were positive (4%; 95% CI 1.2-7.3). FeLV positive cats 
ranged from 10 months to 8 years (median age 4 years; IQR 2-8 years), comprised mostly 
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of domestic crossbred cats (6/7; 86%) and entirely male cats (four castrated males and 
three entire males). Of the seven FeLV-positive cats, four also tested FIV-positive (57%), 
giving a FIV/FeLV co-infection rate of 4/165 (2%; 95% CI 0.1-4.7).
18
 
                                                 
17
 www.abs.gov.au. 2011 census data used.  
18
 165/170 cats had both FIV and FeLV results recorded. 
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Figure 2.2 Map of Australia showing the distribution of client-owned cats recruited for testing (Cohort 2). A larger circle indicates a higher 
number of cats sampled in that area. Only one poorly-populated island state (TAS) and one sparsely populated territory (NT) were not 
included in the study. FIV (top line) and FeLV (bottom line) seroprevalence rates are shown for each state/territory. 
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Figure 2.3 Age and sex pyramid for client-owned cats recruited for testing (Cohort 2), 
highlighting the skew towards male cats. The age of cats is displayed on the y-axis, while 
the number of cats of each sex is displayed on either side of the x-axis. 
 
F = female, M = male. 
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Table 2.3 FIV and FeLV seroprevalence amongst client-owned cats (Cohort 2) by location 
(raw data). 
Location FIV seroprevalence FeLV seroprevalence 
ACT 4/45 (9%) 0/45 (0%) 
NSW 95/749 (13%) 9/743 (1%) 
VIC 46/312 (15%) 7/310 (2%) 
QLD 110/700 (16%) 7/657 (1%) 
SA 3/38 (8%) 0/38 (0%) 
WA 47/239 (20%) 9/239 (4%) 
Total 305/2,083 (15%) 32/2,032 (2%) 
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Table 2.4.1 FIV seroprevalence rates amongst client-owned cats (Cohort 2) by location, sex and neutering status (raw data). 
 FIV seroprevalence 
Location Entire male Castrated male Entire female Spayed female TOTAL 
ACT 2/8 (25%) 2/20 (10%) 0/4 (0%) 0/13 (0%) 4/45 (9%) 
NSW 16/94 (17%) 57/327 (17%) 5/81 (6%) 17/247 (7%) 95/749 (13%) 
VIC 8/34 (24%) 30/160 (19%) 3/24 (13%) 5/94 (5%) 46/312 (15%) 
QLD 16/49 (33%) 80/369 (22%) 0/39 (0%) 14/243 (6%) 110/700 (16%) 
SA 1/6 (17%) 1/17 (6%) 0/1 (0%) 1/14 (7%) 3/38 (8%) 
WA 13/54 (24%) 27/82 (33%) 5/44 (11%) 2/59 (3%) 47/239 (20%) 
TOTAL 56/245 (23%) 197/975 (20%) 13/193 (7%) 39/670 (6%) 305/2,083 (15%) 
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Table 2.4.2 FeLV seroprevalence rates amongst client-owned cats (Cohort 2) by location, sex and neutering status (raw data). 
 FeLV seroprevalence 
Location Entire male Castrated male Entire female Spayed female TOTAL 
ACT 0/8 (0%) 0/20 (0%) 0/4 (0%) 0/13 (0%) 0/45 (0%) 
NSW 1/93 (1%) 2/325 (1%) 1/81 (1%) 5/244 (2%) 9/743 (1%) 
VIC 1/34 (3%) 2/159 (1%) 0/24 (0%) 4/93 (4%) 7/310 (2%) 
QLD 0/48 (0%) 5/343 (2%) 0/39 (0%) 2/227 (1%) 7/657 (1%) 
SA 0/6 (0%) 0/17 (0%) 0/1 (0%) 0/14 (0%) 0/38 (0%) 
WA 4/54 (7%) 3/82 (4%) 1/44 (2%) 1/59 (2%) 9/239 (4%) 
TOTAL 6/243 (3%) 12/946 (1%) 2/193 (1%) 12/650 (2%) 32/2,032 (2%) 
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Figure 2.4 FIV and FeLV seroprevalence amongst client-owned cats (Cohort 2) for WA 
compared with the rest of Australia (model adjusted data). The y-axis shows the probability 
of FIV infection at a fixed point in time. SE bars are shown. 
 
 
 
Table 2.5 Summary of statistically significant risk factors (P < 0.05) for retroviral 
infection amongst client-owned cats (Cohort 2). 
FIV infection FeLV infection 
Age (> 3 years) 
Sex (male) 
Neutering status (entire males) 
Location (WA, QLD) 
Health status (‘sick’) 
Location (WA) 
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2.5 DISCUSSION 
This is the largest study to date of FIV and FeLV infection amongst Australian cats and 
provides important epidemiological information regarding feline retroviral infections in 
Australia. Results from feline Cohort 1 in the current study confirmed the notion that FIV 
infection is more common in Australia (6% in the WA shelter) than North America, with a 
large US-based study finding the seroprevalence of FIV infection amongst relinquished 
shelter cats to be just 1% (Levy et al., 2006). The most novel finding from this 
investigation was the higher seroprevalences of both FIV and FeLV in WA cats in Cohort 
2 compared with the rest of Australia. 
Interestingly, like the last Australian FIV serosurvey (Norris et al., 2007), the current study 
did not find a difference in FIV seroprevalence between ‘healthy’ and ‘sick’ client-owned 
cats in Cohort 2 using a similar classification system. This finding does not equate to FIV 
infection being apathogenic in Australian cats, but rather that a different study design 
targeting specific disease associations (e.g. B-cell lymphoma), older cats (due to the long 
asymptomatic phase of FIV infection) and different wild strains (due to variability in 
pathogenicity) is required to investigate the impact of FIV infection on mortality and 
morbidity. When the attending veterinarian’s assessment of ‘healthy’ or ‘sick’ was 
considered, however, a significant difference in FIV seroprevalence was found, suggesting 
that elements of health assessment are subjective, possibly intuitive and without doubt 
informative, although not easily captured by strict objective criteria. The current study 
found a significant difference in FeLV seroprevalence between ‘healthy’ and ‘sick’ client-
owned cats in Cohort 2, regardless of the classification system utilized, reflecting the well-
known impact of FeLV infection on feline health. 
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The comparatively higher FIV and FeLV infection rates (20% and 4%, respectively) 
reported in the current study for WA cats in Cohort 2, compared to the rest of the country, 
appear consistent with earlier studies (Robertson et al., 1990b; Thomas et al., 1993b). In 
the current study, cats in Cohort 2 domiciled in WA were 1.7 times more likely to be FIV-
infected, and 3.0 times more likely to be FeLV-infected compared with the rest of the 
country. The difference in FIV seroprevalence between shelter and client-owned cats in the 
current study (i.e. Cohort 1 versus Cohort 2), and particularly the lower FIV 
seroprevalence in WA shelter cats compared to WA client-owned cats, likely reflects a 
difference in demographics between the two cohorts. Although signalment details for 
shelter cats were unavailable, and Australian data on characteristics of cats entering 
shelters is lacking, one US study found 639/1,200 (53%) adult cats (6 months of age or 
older) entering the shelter were younger than 3 years of age (New et al., 2000). If this trend 
is also true for Australian shelters, which we think likely, and as the cumulative risk for 
acquiring FIV infection increases with age, it is reasonable to assume the lower 
seroprevalence of FIV in shelter cats compared with client-owned cats was due to a lower 
median sampling age in Cohort 1 compared to Cohort 2. Furthermore, based on previous 
Australian studies, it is likely that around a quarter of shelter cats sampled were previously 
housed exclusively indoors and therefore had very low, if any, exposure to FIV, compared 
with the client-owned cats, which because of the study design, all had some level of 
outdoor access (Toribio et al., 2009; Chang-Fung-Martel et al., 2013). Although the skew 
towards male cats in Cohort 2 (59% versus 41%) would have resulted in a slight 
overestimation of FIV seroprevalence, the same likely was likely true for cats in Cohort 1, 
owing to the described sampling bias towards males. 
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This is the first FIV seroprevalence study conducted since the introduction of the FIV 
vaccine in Australia in October 2004 (Norris and collaborators tested blood specimens 
collected prior to the release of the vaccine). FIV vaccination results in the production of 
FIV antibodies indistinguishable from those used for the diagnosis of FIV infection when 
using SNAP FIV/FeLV Combo (Uhl et al., 2002; Chapter 3), so that in the absence of 
additional testing an overestimation of FIV seroprevalence is possible. However, cats 
surrendered to shelters have typically received a lower level of care compared to non-
surrendered cats (Salman et al., 1998), and thus are less likely to have been vaccinated 
against FIV. Furthermore, although not specifically stated in the study instructions 
provided to veterinary clinics by BI, it is our presumption that cats vaccinated against FIV 
would not have been selected by veterinarians for testing. It therefore seems unlikely that 
previous FIV vaccination would have caused sufficient false-positive antibody test results 
to substantially impact the reported FIV seroprevalence for either shelter or client-owned 
cats. 
Seroprevalence studies for FeLV in Australia are impacted by the low FeLV infection rate 
in the general cat population and the resulting low positive predictive value of point-of-
care antigen test kits, despite excellent sensitivity and specificity of the current generation 
of kits (www.idexx.com/files/small-animal-health/products-and-services/snap-
products/snap-fiv-felv-combo/snap-combo-test-accuracy.pdf). The European ABCD 
Guidelines recommend confirmatory testing for suspected cases of FeLV infection using 
proviral PCR, particularly in healthy cats without clinical signs of disease (Lutz et al., 
2009). If a true FeLV seroprevalence of 0.5-1.0% in Australia is postulated, then the 
occurrence of false-positive FeLV results with point-of-care antigen testing is similar to the 
prevalence of FeLV antigenemia (Hartmann et al., 2007; Adam and Dandrieux, 2011; 
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Beatty et al., 2011). Therefore, it is likely that the true FeLV infection rate for both cohorts 
of cats in the current study was actually lower than reported. 
Age, sex and neutering status in males were important risk factors for FIV infection in 
client-owned cats (Cohort 2), reinforcing findings from other studies and confirming that 
fighting between cats continues to be the main mechanism for FIV transmission, 
particularly in Australia where the climate permits outdoor access for most months of the 
year (Norris et al., 2007; Hosie et al., 2009). Conversely, age, sex and neutering status 
were not found to be risk factors for FeLV infection in client-owned cats. The 
susceptibility of cats to infection with FeLV has traditionally thought to be age-dependent, 
with young cats more likely to be FeLV-infected (and older cats more likely to be FIV-
infected) (Norris et al., 2007; Lutz et al., 2009). The current study was not consistent with 
this ‘age effect’ on retroviral status and instead found a similar median age for FIV and 
FeLV infection in client-owned cats (7 years and 6 years, respectively). This finding is 
consistent with recent research from Germany (Gleich et al., 2009b), suggesting a 
changing landscape for FeLV infection, where older cats are as likely to be FeLV-infected 
as younger cats. The resulting impact of FeLV infection on morbidity and mortality in 
older cats needs confirmation and further investigation. 
Dr. Mark Edward Westman Faculty of Veterinary Science 
Thesis 2016 The University of Sydney 
51 
 
2.6 CONCLUSION 
This study reports the largest number of client-owned cats recruited over a large proportion 
of the populated continent to investigate the epidemiology of retroviral infections. FIV 
continues to be a common infection of client-owned cats with outdoor access, making 
Australia an ideal location for testing the effectiveness of the FIV vaccine in the field. FIV 
and FeLV are significantly more common in client-owned cats in Perth, WA, compared 
with the rest of the country. The reasons for this might be related to lower rates of 
neutering, and require further investigation and intervention. FeLV infection, although 
uncommon, should not be forgotten, even in older cats, as a potential cause of feline 
morbidity and mortality, including late ‘downstream’ effects such as lymphomagenesis. 
Owing to the low prevalence of FeLV antigenaemia in Australia, confirmatory testing by 
real-time PCR should always be pursued for any cat testing positive for FeLV antigen 
using point-of-care test kits. In cats infected with FeLV, co-infection with FIV is common. 
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CHAPTER 3.  DIAGNOSIS OF FIV INFECTION IN THE 
DOMESTIC CAT USING BLOOD 
3.1 ABSTRACT 
This study challenges the commonly held view that the FIV infection status of FIV-
vaccinated cats cannot be determined using point-of-care antibody test kits due to 
indistinguishable antibody production in FIV-vaccinated and naturally FIV-infected cats. 
The performance of three commercially available point-of-care antibody test kits was 
compared in a mixed population of FIV-vaccinated (n = 119) and FIV-unvaccinated (n = 
239) cats in Australia. FIV infection status was assigned by considering the results of all 
antibody kits in concert with results from a commercially available PCR assay (FIV 
RealPCR). Two lateral flow IC test kits (Witness FeLV/FIV; Anigen Rapid FIV/FeLV) 
had excellent overall sensitivity (100%; 100%) and specificity (98%; 100%) and could 
discern the true FIV infection status of cats, irrespective of FIV vaccination history. The 
lateral flow ELISA test kit (SNAP FIV/FeLV Combo) could not determine if antibodies 
detected were due to previous FIV vaccination, natural FIV infection, or both. The 
sensitivity and specificity of FIV RealPCR for detection of viral and proviral nucleic acid 
was 92% and 99%, respectively. These results will potentially change the way veterinary 
practitioners screen for FIV in jurisdictions where FIV vaccination is practiced, especially 
in shelter scenarios where the feasibility of mass screening is impacted by the cost of 
testing. 
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3.2 INTRODUCTION 
The introduction of the FIV vaccine in 2002 complicated FIV diagnosis because 
vaccination was reported to result in the production of antibodies to FIV indistinguishable 
from those produced in response to natural infection (Uhl et al., 2002). Consequently, for 
FIV-vaccinated cats and cats of unknown vaccination status, FIV diagnostics shifted 
towards molecular methods such as nucleic acid amplification (Crawford and Levy, 2007; 
Morton et al., 2012). Some studies have also explored alternative methods for FIV 
diagnosis with excellent results, such as a discriminatory ELISA based on antibody 
response to two different FIV antigens (Kusuhara et al., 2007; Levy et al., 2008b), and by 
calculating the CD4:CD8
low
 T-lymphocyte ratio (Litster et al., 2014). 
In this study, we reappraised the assertion that point-of-care kits are unable to distinguish 
antibodies produced following FIV vaccination from antibodies produced in response to 
natural FIV infection, and therefore are unable to determine the true FIV infection status of 
FIV-vaccinated cats, using three commercially available test kits (SNAP FIV/FeLV 
Combo, Witness FeLV/FIV and Anigen Rapid FIV/FeLV) with each antibody kit using a 
different panel of viral epitopes (Figure 3.1 and Table 3.1). 
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Figure 3.1 Schematic of FIV emphasising the different target antigens for antibody testing. 
 
 
 
Table 3.1 Summary of the antibodies detected using four different point-of-care FIV 
antibody test kits.  
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3.3 MATERIALS AND METHODS 
3.3.1 Sample population 
Cats with known FIV vaccination history were recruited through veterinary clinics in 
Australia during 2013-2014, most commonly at the same time as an annual health check or 
some routine procedure (e.g. dental scaling and polishing). Very occasionally, cats were 
sampled during hospitalisation for further work up of systemic illness; however no FIV-
infected cats would have been classified as being in the feline-AIDS (FAIDS) phase of 
infection. Cats or kittens were excluded from the study if they were less than six months of 
age (due to the possibility of maternal antibodies being present), had an unclear FIV 
vaccination history or had a known FIV infection status (due to prior testing). Cats were 
included in the ‘FIV-vaccinated’ group if they had received one or more FIV vaccines at 
any time in their life, regardless of whether or not the administration of vaccine had been 
in accordance with the manufacturer’s guidelines1. Cats were included in the ‘FIV-
unvaccinated’ group if they had never been vaccinated against FIV. Clinical records of all 
patients from both groups were carefully interrogated to enforce this inclusion criterion. 
Cases were recruited from veterinary practices servicing areas where the prevalence of FIV 
infection was perceived to be high (Chapter 2). 
Animal ethics approval was granted by the University of Sydney (Approval number 5920). 
3.3.2 Serological and molecular detection of FIV infection 
Blood was collected by the primary author using jugular venipuncture and immediately 
aliquoted into three EDTA tubes and stored at 4
o
C. Testing for FIV antibodies was 
performed within 24 hours of blood collection
19
 with three commercially available point-
of-care kits tested concurrently, using whole blood from the same EDTA tube, according 
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to the manufacturer’s instructions. The antibody kits tested were SNAP FIV/FeLV 
Combo
2
, Witness FeLV/FIV
3
, and Anigen Rapid FIV/FeLV
4
 (Table 3.1). The antibody 
results panel for each cat was digitally photographed at the time of testing. Blood from this 
tube was also used for routine haematologic examination.
20
 The second EDTA tube was 
centrifuged within 6 h of collection for 3 min at 12,000 x g
 
and the plasma transferred to a 
plain tube using a sterile pipette. Plasma specimens and EDTA cell pellets were stored 
subsequently at -80
o
C for confirmatory testing of discrepant samples at a later time. The 
third EDTA tube was sent for FIV nucleic acid amplification (FIV RealPCR),
21
 a 
commercially available PCR assay targeting a conserved gag region in both viral RNA 
(using cDNA following a reverse transcription step) and proviral DNA. FIV subtype was 
determined in infected cats using subtype specific primer pairs for subtypes A, B, D and F 
(www.idexx.com.au/pdf/en_au/smallanimal/education/realpcr-test-for-fiv.pdf). 
3.3.3 Defining FIV infection status (Table 3.2) 
At the beginning of the study FIV RealPCR
 testing was used as the ‘gold standard’ for FIV 
diagnosis, with a published sensitivity and specificity of 94% and 94% (Litster et al., 
2012). As the study progressed, however, it became clear that two of the antibody 
detection kits were able to determine the true FIV infection status of cats, irrespective of 
FIV vaccination history. In light of this finding, revised definitions for ‘FIV-infected’ and 
‘FIV-uninfected’ were employed, which considered results from all three antibody kits in 
concert with the FIV RealPCR
 
result. Where there was complete agreement between the 
three antibody kits and the FIV RealPCR
 
result (either all negative or all positive), 
assigning a given cat’s FIV infection status was straightforward. Where two of the three 
antibody kits matched the FIV RealPCR
T
result (i.e. three out of four results were in 
agreement), FIV infection status was assigned and it was assumed the conflicting antibody 
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kit was a false-positive or false-negative result. Where all three antibody kits tested 
negative and the FIV RealPCR
 
result was positive, FIV RealPCR
 
testing was repeated 
using either stored sample or a fresh blood specimen (collected at a second venipuncture), 
and the second FIV RealPCR
 
result was taken as being definitive. Where all three antibody 
kits tested positive and the FIV RealPCR
 
result was negative, PCR testing was repeated at 
a second commercial laboratory using stored sample and a methodologically distinct assay 
(www.gribblesvets.com.au/index.php/download_file/view/90/142/)
22
 and FIV RealPCR 
testing was repeated using fresh blood collected at several time points over 12-18 months. 
For such cats, additional fresh blood was also collected into a heparinised tube and sent 
refrigerated to a third laboratory for VI.
23
 The VI result was considered definitive. The 
same additional testing was also undertaken to confirm FIV infection in FIV-vaccinated 
cats that tested positive with all three antibody kits as well as FIV RealPCR, i.e. 
vaccination ‘failures’. Where there were two positive and two negative results, regardless 
of which tests were positive, additional blood was collected into a heparanised tube and 
sent refrigerated to a fourth laboratory for VI,
24
 with the VI result taken as being definitive. 
When determining the results of the antibody test kits, even a faint band or spot was 
subjectively recorded as a ‘faint positive’ result. Although the manufacturer’s instructions 
for Witness FeLV/FIV and Anigen Rapid FIV/FeLV contain no guidelines for interpreting 
faint results, instructions for SNAP FIV/FeLV Combo advise that any colour development 
in the FIV sample spot should be considered significant (www.idexx.com/resource-
library/smallanimal/snap-combo-package-insert-en.pdf). Antibody testing was repeated 
using stored plasma thawed from -80
o
C where there was disagreement between all three 
antibody kits and the FIV RealPCR result, where there were two positive and two negative 
results, and where a ‘faint positive’ result was recorded using any of the antibody kits. 
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For the purpose of this study, SNAP FIV/FeLV Combo, Witness FeLV/FIV and Anigen 
Rapid FIV/FeLV are antibody test kits sold for the sole purpose of diagnosing FIV 
infection. Therefore, by definition, a positive antibody test result in a FIV-uninfected cat, 
regardless of FIV vaccination history, was considered a false-positive result. Conversely, a 
negative antibody test result in a FIV-uninfected cat, regardless of FIV vaccination history, 
was considered a true-negative result. 
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Table 3.2 Determination of FIV infection status of cats in the study. Classification of FIV 
status was based on the overall combination of results from (a) three commercially 
available FIV antibody test kits (SNAP FIV/FeLV Combo, Witness FeLV/FIV and Anigen 
Rapid FIV/FeLV) and FIV RealPCR testing. Additional testing (repeat FIV RealPCR 
testing, PCR testing using different primers and methodology and/or virus isolation) was 
pursued when the results panel was equally divided (two positive results, two negative 
results), when there was complete agreement between antibody results but disagreement 
with the FIV RealPCR result, and to confirm FIV infection in FIV-vaccinated cats. 
 
+ = positive, - = negative, NP = not performed. Red = FIV-infected, yellow = FIV-uninfected. 
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3.3.4 Statistical analysis 
Numerical analyses were performed using a commercial programme (Genstat 16
th
 
Edition).
25
 Statistical significance was considered at P < 0.05 and 95% CIs were calculated 
using Microsoft Excel.
26
 Fisher’s exact test was used to investigate whether SNAP 
FIV/FeLV Combo and Witness FeLV/FIV false-positive results were more common in 
FIV-vaccinated cats than FIV-unvaccinated cats by comparing false-positive and true-
negative results. Fisher’s exact tests were also used to examine whether ‘faint positive’ 
results with any of the three antibody test kits was associated with FIV infection status. A 
two-sample t-test was used to investigate whether there was a correlation between time 
since last FIV vaccination and false-positive antibody results recorded with Witness 
FeLV/FIV in the FIV-vaccinated group. 
                                                 
19
 Faculty of Veterinary Science, The University of Sydney, Sydney, NSW, Australia. 
20
 Veterinary Pathology Diagnostic Services, The University of Sydney, Sydney, NSW, Australia. 
21
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22
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23
 Yamamoto Laboratory, The University of Florida, Gainesville, FL, USA. 
24
 Veterinary Diagnostic Services, The University of Glasgow, Scotland, UK. 
25
 GenStat 16
th
 Edition for Windows, VSN International, Hemel Hempstead, United Kingdom. 
26
 Microsoft Excel 2010 for Windows, Microsoft, Redmond, WA, USA. 
 
 
 
Dr. Mark Edward Westman Faculty of Veterinary Science 
Thesis 2016 The University of Sydney 
61 
 
3.4 RESULTS 
3.4.1 Sample population 
Blood samples were obtained from 358 client-owned cats recruited from 12 veterinary 
clinics distributed over four states of Australia (NSW, VIC, QLD and SA) (Table 3.3). 
A total of 119 FIV-vaccinated cats were recruited, ranging from six months to 18 years 
(median 7 years; IQR 5-10 years). These cats comprised 66 castrated males and 53 spayed 
females. Most were domestic crossbred cats (103/119; 87%); the remainder comprising a 
range of pedigree breeds. Most cats in this cohort (109/119; 92%) had received three 
primary FIV vaccinations, two to four weeks apart (i.e. the protocol recommended by the 
vaccine manufacturer), and three or more annual FIV vaccinations before being sampled. 
For these 109 cats sampling took place between 2 and 462 days following their last FIV 
vaccination (median 237 days; IQR 152-317 days), with 10/109 (9%) cats sampled within 
eight weeks of their last annual FIV vaccination. Seven cats (out of 119) were considered 
overdue for their annual FIV vaccination (more than 15 months since last vaccination; 
median 5.4 years, range 3-7 years), and three cats were overdue for their second or third 
primary FIV vaccination (by 46 days, 74 days and 3 years). 
A total of 239 FIV-unvaccinated cats were recruited, ranging from 2 to 20 years (median 7 
years; IQR 6 to 10 years). These cats comprised 112 castrated males, 123 spayed females, 
and 4 entire males. Most were domestic crossbred cats (207/239; 87%); the remainder 
comprising a range of pedigree breeds. 
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Table 3.3 List of twelve recruited veterinary clinics including clinic address and number of cats tested. 
Name of clinic Clinic details No. of cats  
Great Western Animal Hospital 469 Great Western Hwy, Pendle Hill NSW 2145, (02) 9631 9322 114 
Newtown Veterinary Clinic 121 West Fyans St, Newtown VIC 3220, (03) 5221 5333 47 
Elizabeth Drive Animal Hospital Cnr Elizabeth Drive and Woodlands Rd, Liverpool NSW 2170, (02) 9602 7018 46 
Campbelltown Animal Hospital 15 Chamberlain St, Campbelltown NSW 2560, (02) 4626 4222 33 
Bankstown Veterinary Hospital 14 Marshall St, Bankstown NSW 2200, (02) 9790 1101 32 
Fulham Gardens Veterinary Surgery 441 Tapleys Hill Rd, Fulham Gardens SA 5024, (07) 8355 5475 24 
Mt Annan Veterinary Hospital 17/2-4 Main St, Mt Annan NSW 2567, (02) 4647 7722 21 
Casula Veterinary Hospital 674 Hume Hwy, Casula NSW 2170, (02) 9602 9863 18 
The Cat Clinic 189 Creek Road, Mt Gravatt, QLD 4122, (07) 3349 0811 13 
Kardinia Veterinary Clinic 355 Moorabool St, Geelong VIC 3220, (03) 5221 5122 7 
RSPCA Veterinary Hospital 201 Rookwood Rd, Yagoona NSW 2199, (02) 9770 7555 2 
Sylvania Veterinary Hospital 335 Princes Hwy, Sylvania NSW 2224, (02) 9522 7088 1 
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3.4.2 Serological and molecular detection of FIV infection 
3.4.2.1 FIV-vaccinated cohort (n = 119, Tables 3.4 and 4.5) 
All FIV-vaccinated cats (119/119) tested FIV positive using SNAP FIV/FeLV Combo. In 
contrast, only a small number of the 119 FIV-vaccinated cats tested FIV positive using 
Witness FeLV/FIV (11 cats) and Anigen Rapid FIV/FeLV (5 cats) (Figures 3.2 and 3.3). 
All five cats that tested FIV positive using Anigen Rapid FIV/FeLV also tested FIV 
positive with the other two antibody kits. Initial FIV RealPCR testing confirmed 3/5 cats to 
be FIV-infected, which was further confirmed by VI in two of these cats (one cat was 
unavailable for further sampling). The remaining two cats were initially negative with both 
FIV RealPCR and PCR testing at the second laboratory. Subsequent resampling and re-
testing, however, found both cats positive with FIV RealPCR and VI. Thus, all five cats 
testing FIV positive using Anigen Rapid FIV/FeLV were truly FIV-infected. Of the five 
FIV-infected cats, three were castrated males and two were spayed females. 
The six cats that tested FIV positive with SNAP FIV/FeLV Combo and Witness 
FeLV/FIV, but FIV negative with Anigen Rapid FIV/FeLV and FIV RealPCR, were 
considered to be FIV-uninfected based on VI results (i.e. the positive antibody kit results 
were false-positives).
27
 Another FIV-vaccinated cat had FIV RealPCR testing repeated due 
to possible contamination in the PCR facility; this cat, which initially was FIV RealPCR 
positive, subsequently tested FIV RealPCR negative and was ultimately considered to be 
FIV-uninfected. 
No false-negative FIV results were recorded with any of the antibody kits. 
                                                 
27
 Only 5/6 cats had VI performed due to the unfortunate death (unrelated to this study) of one of the cats.  
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Figure 3.2 Photograph of test kit results from a FIV-vaccinated/FIV-infected cat, showing 
three positive FIV antibody test kit results: (a) Anigen Rapid FIV/FeLV, (b) Witness 
FeLV/FIV, and (c) SNAP FIV/FeLV Combo. For both IC kits the top strip is for FIV 
antibody testing and the bottom strip is for FeLV antigen testing. One band in the FIV or 
FeLV strip indicates a negative result, while two bands in the FIV or FeLV strip indicates a 
positive result. For SNAP FIV/FeLV Combo, two spots in the displayed formation 
indicates a positive FIV result. This result was obtained in 5/119 cats. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dr. Mark Edward Westman Faculty of Veterinary Science 
Thesis 2016 The University of Sydney 
65 
 
Figure 3.3 Photograph of test kit results from a FIV-vaccinated/FIV-uninfected cat, 
showing two negative FIV antibody test kit results: (a) Anigen Rapid FIV/FeLV, and (b) 
Witness FeLV/FIV; and one positive FIV antibody test kit result, (c) SNAP FIV/FeLV 
Combo. For both IC kits the top strip is for FIV antibody testing and the bottom strip is for 
FeLV antigen testing. One band in the FIV or FeLV strip indicates a negative result, while 
two bands in the FIV or FeLV strip indicates a positive result. For SNAP FIV/FeLV 
Combo, two spots in the displayed formation indicates a positive FIV result. This result 
was obtained in 108/119 cats. 
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Table 3.4 Summary of results from FIV-vaccinated cats (n = 119), highlighting general trends as well as discrepant results. Only 2/3 FIV-
vaccinated/FIV-infected, initially FIV RealPCR positive, cats had virus isolation performed. Both FIV-vaccinated/FIV-infected, initially FIV 
RealPCR negative, cats had blood sent to a second commercial laboratory for confirmatory PCR testing. Cat #102 was negative with repeat 
FIV RealPCR testing as well as PCR testing at the second commercial laboratory. Discordant cats were re-tested at a later date using thawed 
plasma stored at -80
o
C. 
Category SNAP 
Combo 
Witness Anigen 
Rapid 
PCR 
(initial) 
VI 
FIV-vaccinated/FIV-uninfected (n = 107) + - - - NP 
FIV-vaccinated/FIV-infected (n = 3) + + + + + (2/3) 
FIV-vaccinated/FIV infected (n = 2) + + + - + (2/2) 
FIV-vaccinated/FIV-uninfected discordant cats (n = 7)      
(i) Cat #97 + Faint + - - - 
(ii) Cat #173 + Faint + - - NP
27
 
(iii) Cat #340 + Faint + - - - 
(iv) Cat #341 + Faint + - - - 
(v) Cat #345 + Faint + - - - 
(vi) Cat #350 + Faint + - - - 
(vii) Cat #102 + - - + NP 
+ = positive, - = negative, NP = not performed. 
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Table 3.5 Results of three point-of-care FIV antibody test kits in FIV-vaccinated cats (n = 
119). Confidence intervals (95%) are given in brackets. 
Test kit SNAP Combo Witness Anigen Rapid 
True positive 5 5 5 
False negative 0 0 0 
True negative 0 108 114 
False positive 114 6 0 
Sensitivity (%) 5/5 = 100 5/5 = 100 5/5 = 100 
Specificity (%) 0/114 = 0 108/114 = 95 
(91-99) 
114/114 = 100 
 
PPV (%) 5/119 = 4 
(0-8) 
5/11 = 45 
(16-75) 
5/5 = 100 
NPV (%) 0/0 = 0 108/108 = 100 114/114 = 100 
 
3.4.2.2 FIV-unvaccinated cohort (n = 239, Tables 3.6 and 3.7) 
In this group of FIV-unvaccinated cats, 21 cats tested FIV positive with all three antibody 
kits and were confirmed to be FIV-infected with FIV RealPCR testing. Of 21 FIV-infected 
cats, 15 were male (14 castrated, one entire) and 6 were spayed females. 
Of the remaining 218 FIV-uninfected cats in this group, most (212/218) tested FIV 
negative with all three antibody kits. Six false-positive FIV results were recorded using 
SNAP FIV/FeLV Combo, one false-positive was recorded using Witness FeLV/FIV, while 
no false-positive results were recorded using Anigen Rapid FIV/FeLV. 
One FIV-uninfected cat in this group (cat #305) tested FIV positive with both SNAP 
FIV/FeLV Combo and Witness FeLV/FIV, but FIV negative with Anigen Rapid 
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FIV/FeLV and FIV RealPCR; VI was subsequently performed and confirmed the negative 
FIV status. 
Three cats tested negative with all three antibody kits but initially positive with FIV 
RealPCR with varying CT values: cat #126 tested positive for subtype A (CT 32), cat #259 
subtype F (CT 39) and cat #277 subtype D (CT 32). Repeat FIV RealPCR testing found all 
three cats to be FIV-uninfected and presumably there was contamination at the PCR 
facility. 
No false-negative FIV results were recorded with any of the antibody kits. 
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Table 3.6 Summary of results from FIV-unvaccinated cats (n = 239), highlighting general trends as well as discrepant results. Cat #126, cat 
#259 and cat #277 were negative with repeat FIV RealPCR testing. Discordant cats were re-tested at a later date using thawed plasma stored at 
-80
o
C. 
Category SNAP Combo Witness Anigen 
Rapid 
PCR 
(initial) 
VI 
FIV-unvaccinated/FIV-uninfected (n = 209) - - - - NP 
FIV-unvaccinated/FIV-infected (n = 21) + + + + NP 
FIV-unvaccinated/FIV-uninfected discordant cats (n = 9)      
(i) Cat #60 Faint + - - - NP 
(ii) Cat #263 Faint + - - - NP 
(iii) Cat #280 Faint + - - - NP 
(iv) Cat #326 Faint + - - - NP 
(v) Cat #335 + - - - NP 
(vi) Cat #305 + Faint + - - - 
      (vii) Cat #126 - - - + NP 
      (viii) Cat #259 - - - + NP 
      (ix) Cat #277 - - - + NP 
+ = positive, - = negative, NP = not performed. 
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Table 3.7 Results of three point-of-care FIV antibody test kits in FIV-unvaccinated cats (n 
= 239). Confidence intervals (95%) are given in brackets. 
Test kit SNAP Combo Witness Anigen Rapid 
True positive 21 21 21 
False negative 0 0 0 
True negative 212 217 218 
False positive 6 1 0 
Sensitivity (%) 21/21 = 100 21/21 = 100 21/21 = 100 
Specificity (%) 212/218 = 97 
(95-99) 
217/218 = 100 
(99-100) 
218/218 = 100 
PPV (%) 21/27 = 78 
(62-93) 
21/22 = 95 
(87-100) 
21/21 = 100 
NPV (%) 212/212 = 100 217/217 = 100 218/218 = 100 
 
3.4.2.3 Combined FIV-vaccinated and FIV-unvaccinated cohorts (n = 358, Table 3.8) 
In total there were 120 false-positive FIV results recorded with SNAP FIV/FeLV Combo, 
seven false-positive FIV results recorded with Witness FeLV/FIV, and no false-positive 
FIV results recorded with Anigen Rapid FIV/FeLV. False-positive FIV results were 
significantly more common in FIV-vaccinated cats than FIV-unvaccinated cats for both 
SNAP FIV/FeLV Combo (114/120; 95%; P < 0.001) and Witness FeLV/FIV (6/7; 86%; P 
= 0.007). For Witness FeLV/FIV 10/33 (30%) positive results were recorded as ‘faint 
positives’, while 7/146 (5%) positive SNAP FIV/FeLV Combo and 7/26 (27%) positive 
Anigen Rapid FIV/FeLV results were recorded as ‘faint positives’. ‘Faint positive’ results 
with Witness FeLV/FIV were strongly associated with absence of FIV infection and thus 
likely to be false-positive results (P < 0.001); only 3/26 FIV-infected cats recorded a ‘faint 
positive’ result with Witness FeLV/FIV, and 7/7 (100%) of false-positive Witness 
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FeLV/FIV results were recorded as ‘faint positives’. There was no association between 
‘faint positive’ results and absence of FIV infection (i.e. false-positive results) for either 
the SNAP FIV/FeLV Combo or Anigen Rapid FIV/FeLV kit (P = 1.000 for both). Time 
between last FIV vaccination and sampling was not a risk factor for false-positive FIV 
results with Witness FeLV/FIV (P = 0.82 with outliers [more than 15 months since last 
vaccination] removed); only 1/11 recently vaccinated cats (8 weeks or less since last FIV 
vaccination, cat #173) tested false-positive with Witness FIV/FeLV. The other five false-
positive FIV results with Witness FeLV/FIV in vaccinated cats were recorded 139, 196, 
259, 337 and 354 days after last FIV vaccination. All 6 FIV-vaccinated cats that had a 
false-positive FIV result with Witness FeLV/FIV had a ‘faint positive’ result recorded. 
Discrepant samples that underwent repeat antibody testing with stored plasma thawed from 
-80
o
C recorded almost identical antibody results as fresh whole blood tested initially (27 
samples re-tested using 81 antibody test kits with 80/81 [99%] agreement). 
Based on this study’s definition for FIV positivity (Table 3.2), and considering only the 
initial FIV RealPCR result, molecular detection of FIV using RealPCR testing produced 
four false-positive and two false-negative results, giving a sensitivity of 92% (95% CI 82.1 
to 100) and specificity of 99% (95% CI 97.7 to 99.9). One false-positive result and the two 
false-negative results were from the FIV-vaccinated group, while three false-positive 
results were from the FIV-unvaccinated group. Repeat FIV RealPCR testing, either using 
the original sample or a subsequent sample, was able to correctly assign FIV status in all 
six cats. Subtyping results for the 26 FIV-infected cats are given in Table 3.9, and CT 
values are given in Table 3.10. Two subtypes were identified in almost half of FIV-
infected cats (11/26 cats; 42%). Infection with FIV subtype A was identified most 
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commonly (22/26 cats; 85%), followed by subtype F (12/26 cats; 46%) and subtype D 
(3/26 cats; 12%). Subtype B was not identified in any FIV-infected cats. 
Table 3.8 Combined results of three point-of-care FIV antibody test kits in FIV-vaccinated 
and FIV-unvaccinated cats (n = 358). Note that this composite population was biased by 
FIV-vaccinated cats (119/358; 33%). In practice, the percentage of vaccinated cats in an 
area will be heavily dependent on the vaccination protocols of local veterinary clinics and 
may differ considerably from this value. Confidence intervals (95%) are given in brackets. 
Test kit SNAP Combo Witness Anigen Rapid 
True positive 26 26 26 
False negative 0 0 0 
True negative 212 325 332 
False positive 120 7 0 
Sensitivity (%) 26/26 = 100 26/26 = 100 26/26 = 100 
Specificity (%) 212/332 = 64 
(59-69) 
325/332 = 98 
(96-99) 
332/332 = 100 
PPV (%) 26/146 = 18 
(12-24) 
26/33 = 79 
(65-93) 
26/26 = 100 
NPV (%) 212/212 = 100 325/325 = 100 332/332 = 100 
Overall accuracy 
(%) 
238/358 = 66 
(62-71) 
351/358 = 98 
(97-99) 
358/358 = 100 
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Table 3.9 Subtyping results from FIV RealPCR testing (n = 26). Primers pairs for FIV 
subtypes A, B, D and F were included in the PCR reaction. 
FIV subtype Frequency 
FIV A only 14/26 = 54% 
FIV B only 0 
FIV D only 0 
FIV F only 1/26 = 4% 
FIV A/F 8/26 = 31% 
FIV D/F 3/26 = 12% 
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Table 3.10 CT values by FIV subtype from qPCR testing of FIV-infected cats using blood (n = 26). 
Cat Group qPCR CT by FIV subtype
a
 
Cat #1
b,c
 FIV-vaccinated FIV A 31.7 
Cat #19
c
 FIV-vaccinated FIV A 32.23 
Cat #106
b,c
 FIV-vaccinated FIV A 32.01, FIV5UTR 31.15 
Cat #152
c
 FIV-vaccinated FIV A 29.73, FIV5UTR 29.24 
Cat #297 FIV-vaccinated FIVA 31.5, FIVF 36.99, FIV5UTR 29.92 
Cat #33 FIV-unvaccinated FIV A 30.8, FIV F 38.34, FIV5UTR 29.38 
Cat #62 FIV-unvaccinated FIV A 28.02, FIV5UTR 26.84 
Cat #80 FIV-unvaccinated FIV D 30.0, FIV F 29.12, FIV5UTR 28.31 
Cat #85 FIV-unvaccinated FIV A 28.6, FIV5UTR 28.63 
Cat #92 FIV-unvaccinated FIV D 29.0, FIV F 29.23 FIV5UTR 29.75 
Cat #127 FIV-unvaccinated FIV A 32.08, FIV5UTR 31.03 
Cat #157 FIV-unvaccinated FIV A 30.53, FIV5UTR 30.27 
Cat #163 FIV-unvaccinated FIV A 32.50, FIV5UTR 31.62 
Cat #190 FIV-unvaccinated FIV A 32.50, FIV5UTR 33.1 
Cat #192 FIV-unvaccinated FIV F 32.31, FIV5UTR 32.35 
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Cat #203 FIV-unvaccinated FIV A 29.26, FIV F 36.14, FIV5UTR 30.06 
Cat #208 FIV-unvaccinated FIV A 32.87, FIV5UTR 32.86 
Cat #209 FIV-unvaccinated FIV A 30.57, FIV F 36.14, FIV5UTR 31.11 
Cat #218 FIV-unvaccinated FIV A 31.15, FIV F 35.93, FIV5UTR 30.13 
Cat #250 FIV-unvaccinated FIV A 31.04, FIV5UTR 31.64 
Cat #272 FIV-unvaccinated FIV A 31.48, FIV5UTR 30.84 
Cat #274 FIV-unvaccinated FIV D 35.00, FIV F 34.31, FIV5UTR 31.17 
Cat #279 FIV-unvaccinated FIV A 30.88, FIV F 36.00, FIV5UTR 30.21 
Cat #281 FIV-unvaccinated FIV A 32.00, FIV5UTR 31.37 
Cat #303 FIV-unvaccinated FIV A 28.39, FIV F 35.53, FIV5UTR 28.46 
Cat #319 FIV-unvaccinated FIV A 30.44, FIV F 35, FIV5UTR 30.09 
a
FIV subtyping was determined using subtype specific primers. Primers pairs for FIV subtypes A, B, D and F were included in the qPCR reaction.  
5UTR = five prime untranslated region (also known as the ‘Leader Sequence’).  
b
Cats were sampled and tested three times before positive PCR results were produced.  
c
Confirmed with VI performed by Yamamoto Laboratory. 
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3.5 DISCUSSION 
FIV infection was reliably diagnosed in FIV-vaccinated and FIV-unvaccinated cats using 
two inexpensive, fast, simple to use antibody detection kits made by different 
manufacturers (Witness FeLV/FIV
 
and Anigen Rapid FIV/FeLV). If results of the two IC 
kits were considered together there was agreement in 351/358 (98%) of cats, with FIV 
RealPCR testing and VI required to clarify the FIV status of only seven cats. 
Consequently, a potential algorithm for FIV screening in a group of cats of known or 
unknown FIV vaccination history is (i) start with Anigen Rapid FIV/FeLV or Witness 
FeLV/FIV testing; (ii) repeat testing with the other antibody kit if a positive FIV test result 
is encountered; (iii) pursue further confirmatory testing such as PCR (or VI) for cats only 
when there is disagreement between the two test kits or a high index of suspicion for FIV 
remains due to the clinical presentation, such as sequential opportunistic infections or 
wasting syndromes (Figure 3.4). 
This finding will facilitate veterinary practices and shelters to quickly and confidently 
determine the FIV infection status of cats, regardless of FIV vaccination history, thereby 
providing a less expensive option than testing using serology and confirmatory testing with 
a PCR assay. 
Immediately following the release of the FIV vaccine in the USA, one study demonstrated 
that FIV-vaccinated cats tested FIV positive using SNAP FIV/FeLV Combo as early as 
three weeks after the second primary FIV vaccine, and that vaccinated cats would remain 
seropositive for at least 12 months post vaccination (Uhl et al., 2002). This finding was 
recapitulated when another group found that 26 FIV-vaccinated cats all tested FIV positive 
using SNAP FIV/FeLV Combo within three weeks of the third primary FIV vaccine. In the 
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same study, all 26 FIV-vaccinated cats also tested positive using a microwell plate ELISA 
(Petchek FIV, IDEXX Laboratories) at 14 weeks after the third primary FIV vaccine (Levy 
et al., 2004). At this time, registration restrictions limited the availability of other FIV 
antibody test kits for use in these studies in North America. Later research found it was 
possible to accurately distinguish FIV-vaccinated from FIV-infected cats using a 
discriminatory ELISA that considered antibody response to both formalin-treated whole 
FIV and a synthetic transmembrane (TM) peptide (Kusuhara et al., 2007; Levy et al., 
2008b). Recently, investigation using the CD4:CD8
low
 T-lymphocyte ratio to differentiate 
between FIV-vaccinated and FIV-infected cats showed promise (Litster et al., 2014). 
However, both of these methods are currently unavailable to veterinarians in practice. To 
our knowledge, the current study is the first to extensively investigate the performance of 
Witness FeLV/FIV
 
and Anigen Rapid FIV/FeLV antibody test kits in FIV-vaccinated cats. 
The Witness FeLV/FIV
 
and Anigen Rapid FIV/FeLV antibody kits demonstrated excellent 
sensitivity and specificity using our definition for FIV positivity, even in a study 
population where 33% of cats (119/358) were FIV-vaccinated. The cause of the seven 
false-positive FIV results with the Witness FeLV/FIV kit may be a lower threshold for 
antibody detection compared to the Anigen Rapid FIV/FeLV kit, as most (6/7) were in 
FIV-vaccinated cats. Presumably there is a low titre of antibody to gp40 following FIV 
vaccination that is detectable in a small subset of cats using Witness FeLV/FIV, 
manifesting as a ‘faint positive’ test result. In another diagnostic study, faint results were 
classified as equivocal if the colour change for the sample spot was less than 50% of the 
positive control, as determined by a plate reader (Pinches et al., 2007a). 
It was not possible to attribute false-positive FIV results with the Witness FeLV/FIV kit as 
a result of recent FIV vaccination; false-positive results actually occurred most frequently 
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in cats not recently vaccinated (5/6 cats had not been vaccinated for at least four months). 
In contrast, a recent abstract reported a high proportion of false-positive FIV results using 
the Witness FeLV/FIV kit in experimentally vaccinated kittens in a research colony. For 
example, five weeks after FIV vaccination 14/19 (74%) tested FIV positive, while by 34 
weeks after vaccination all kittens tested FIV negative (Lappin, 2015). Clearly, further 
research needs to be conducted to better understand humoral immune response following 
FIV vaccination, in particular the time course of antibody production directed against 
gp40. 
All FIV-infected and FIV-vaccinated cats tested FIV positive using SNAP FIV/FeLV 
Combo. Critically, this antibody kit was not able to distinguish the 114 FIV-
vaccinated/FIV-uninfected cats from the five FIV-vaccinated/FIV-infected cats, in 
agreement with previous reports. The FIV-vaccinated group included cats that had not 
been vaccinated for up to seven years, demonstrating that vaccination induces production 
of antibodies which are detectable using this kit for an extended period of time. A previous 
study found 100% of cats tested (n = 5) still had detectable FIV antibodies over two years 
after initial vaccination (Levy et al., 2004). In adult cats of unknown FIV-vaccination 
status, a positive FIV test result with SNAP FIV/FeLV Combo could therefore indicate 
FIV vaccination, FIV infection, or both. A major consequence of this uncertainty is in a 
shelter setting where incorrect diagnosis of FIV infection can result in euthanasia 
(Crawford and Levy, 2007; Levy et al., 2008a). It should be noted that the reported 
specificity of SNAP FIV/FeLV Combo for the entire study population (64%; 95% CI 59-
69%; Table 3.7) was directly affected by the inclusion of 119 FIV-vaccinated cats to create 
a composite population of FIV-vaccinated (119/358; 33%) and FIV-unvaccinated 
(239/358; 67%) cats. As the percentage of FIV-vaccinated cats in a population decreases 
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from 33%, the specificity of SNAP FIV/FeLV Combo will progressively increase (and 
vice versa). In practice, the percentage of vaccinated cats in an area will be heavily 
dependent on the vaccination protocols of local veterinary clinics and may differ 
considerably from the 33% of this study cohort. The performance of SNAP FIV/FeLV 
Combo was comparable to the performance of the two IC test kits in FIV-unvaccinated 
cats. 
Fel-O-Vax
®
 FIV vaccine contains formalin-inactivated whole virus and infected Fet-J cells 
(Coleman et al., 2014). One possible explanation for the variation in results between the 
ELISA-based kit (SNAP FIV/FeLV Combo) and IC kits (Witness FeLV/FIV
 
and Anigen 
Rapid FIV/FeLV) in FIV-vaccinated cats is that relevant antigenic determinants of p15 
may be well preserved in the formalin-fixed vaccine, whereas vaccine production may 
render p24 and gp40 less persistently immunogenic. This would result in the production of 
a high titre of host antibodies to p15 following FIV vaccination, indistinguishable from 
antibodies produced against p15 in response to natural FIV infection, but lower titres, less 
persistent titres, or even no production of antibodies to p24 or gp40. A similar hypothesis 
was suggested by the researchers who developed a discriminatory ELISA measuring 
antibody response to two different FIV antigens, formalin-treated whole FIV and a 
synthetic TM peptide, the latter which may closely resemble the gp40 capture antigen used 
in the Witness FeLV/FIV antibody test kit. This group, however, was unable to distinguish 
FIV-vaccinated from FIV-infected cats using only one type of antigen. On further review, 
this inability to distinguish FIV vaccination from FIV infection may have been a 
consequence of including results from 16 recently infected cats that when first tested, only 
had low levels of detectable antibodies to gp40, but when sampled 3-4 weeks later had 
much higher antibody responses to gp40 (Kusuhara et al., 2007). There are major 
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methodological differences between western blot, ELISA and IC which presumably lead to 
threshold differences in the level of detection of antibodies for each method; these 
differences may help explain variation in results between the current study and earlier 
work conducted into antibody production in FIV-vaccinated cats (Uhl et al., 2002). 
The accuracy of FIV RealPCR testing in the current study was comparable to results for a 
group of FIV-unvaccinated cats (Litster et al., 2012). Initially, false-negative PCR results 
were obtained from two FIV-vaccinated cats that tested positive with all antibody kits and 
later were proven to be FIV-infected by VI. However, serial sampling of these two cats 
eventually resulted in positive results with FIV RealPCR, suggesting that the initial 
viraemia was below the limit of detection for the assay. Interestingly, both of these cats 
also initially tested negative using a methodologically distinct PCR assay at a second 
commercial laboratory. False-positive results with RealPCR were produced in one FIV-
vaccinated cat and three FIV-unvaccinated cats; retesting of these samples produced 
negative results. False-positive PCR results are usually thought to occur as a result of 
contamination during testing. 
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Figure 3.4 Suggested algorithm for diagnosis of FIV infection. If there is the possibility of 
recent FIV infection, re-testing is recommended due to delays in seroconversion and 
potentially low viral loads early in infection. Repeat testing on negative cats should be 
performed at least 8 weeks later for antibody testing and 4 weeks later for PCR testing 
following last potential exposure. Currently, virus isolation is not commercially available 
for diagnostic samples in Australia. 
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3.6 CONCLUSION 
Two point-of-care FIV antibody test kits (Witness FeLV/FIV and Anigen Rapid 
FIV/FeLV) could reliably identify natural FIV infection in client-owned cats in Australia, 
irrespective of their FIV vaccination history. Where FIV vaccination is practiced, there is 
an advantage to using these kits for initial screening of FIV infection, particularly in 
shelters where large numbers of cats need to be assessed quickly and affordably and where 
vaccination history is often unknown. A third point-of-care FIV antibody test kit (SNAP 
FIV/FeLV Combo) was useful for confirming a humoral response to FIV vaccination, but 
could not distinguish FIV-vaccinated from FIV-infected cats. All three antibody detection 
kits gave comparable and highly accurate results in determining FIV infection status in 
FIV-unvaccinated cats. 
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CHAPTER 4.  DIAGNOSIS OF FIV IN THE CAT USING 
SALIVA 
4.1 ABSTRACT 
Chapter 3 showed that two IC point-of-care FIV antibody test kits (Witness FeLV/FIV and 
Anigen Rapid FIV/FeLV) were able to correctly assign FIV infection status, irrespective of 
FIV vaccination history, using whole blood as the diagnostic specimen. A third FIV 
antibody test kit, SNAP FIV/FeLV Combo (a lateral-flow ELISA), was unable to 
differentiate antibodies produced in response to FIV vaccination from those incited by FIV 
infection. The aim of this study was to determine if saliva is a suitable diagnostic specimen 
using the same well characterized feline cohort. FIV infection status of these cats had been 
determined previously using a combination of serology, PCR testing and VI. This final 
assignment was then compared to results obtained using saliva as the diagnostic specimen 
utilizing the same three point-of-care FIV antibody test kits and commercially available 
PCR assay (FIV RealPCR). In a population of cats where one third (117/356; 33%) were 
FIV-vaccinated, both IC test kits accurately diagnosed FIV infection using saliva via a 
centrifugation method, irrespective of FIV vaccination history. For FIV diagnosis using 
saliva, the specificity of Anigen Rapid FIV/FeLV and Witness FeLV/FIV was 100%, while 
the sensitivity of these kits was 96% and 92% respectively. SNAP FIV/FeLV Combo had a 
specificity of 98% and sensitivity of 44%, while FIV RealPCR testing had a specificity of 
100% and sensitivity of 72% using saliva. A revised direct method of saliva testing was 
trialed on a subset of FIV-infected cats (n = 14), resulting in 14, 7 and 0 FIV positive 
results using Anigen Rapid FIV/FeLV, Witness FeLV/FIV and SNAP FIV/FeLV Combo, 
respectively. These results demonstrate that saliva can be used to diagnose FIV infection, 
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irrespective of FIV vaccination history, using either a centrifugation method (Anigen 
Rapid FIV/FeLV and Witness FeLV/FIV) or a direct method (Anigen Rapid FIV/FeLV). 
Collection of a saliva specimen therefore provides an acceptable alternative to 
venipuncture (i) in fractious cats where saliva may be easier to obtain than whole blood, 
(ii) in settings when a veterinarian or trained technician is unavailable to collect blood and 
(iii) in shelters where FIV testing is undertaken prior to adoption but additional blood 
testing is not required. 
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4.2 INTRODUCTION 
Whole saliva is composed mainly of fluid produced by the salivary glands, which contains 
small amounts of locally produced Ig molecules (mainly IgA, but also IgM and IgG), and 
crevicular fluid (Brandtzaeg, 2007). Crevicular fluid is derived from the capillary bed 
beneath the buccal mucosa, has an antibody content similar to that of plasma, and is 
responsible for most of the IgM and IgG content of whole saliva (Chappel et al., 2009). 
Consequently, saliva may be regarded as a transudate of plasma (Parry et al., 1987). In 
people, the concentration of total IgG in whole saliva is approximately 1000 times less 
than in plasma (Connell et al., 1993). Investigation of total IgG in cat saliva using healthy 
subjects found whole saliva contained 190 times less IgG than serum using a radial 
immunodiffusion assay, and 340 times less total IgG than serum using an ELISA. There 
were no cats in which salivary IgG could not be detected using these methodologies 
(Harley et al., 1998). The same researchers found that both salivary and serum total IgG 
were higher in cats with chronic gingivostomatitis (Harley et al., 2003), a disease process 
FIV-infected cats are more likely to have and to have more severely than FIV-negative cats 
(Tenorio et al., 1991; Ravi et al., 2010).  
Despite IgG being reliably detectable in cat saliva (Harley et al., 1998), only three studies 
have investigated using saliva to diagnose FIV infection in cats. Poli and colleagues 
reported that detection of FIV antibodies in saliva using ELISA was extremely unreliable, 
with a high frequency of false-positive and false-negative results, although the exact 
numbers and details of the commercial ELISA kits used were not provided (Poli et al., 
1992). In contrast, an indirect immunofluorescence assay and Western blot testing (WB-
IgG) detected FIV antibodies in the saliva of 15/16 (94%) FIV-seropositive cats and no 
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false-positive results were recorded amongst the 16 FIV-seronegative cats (Poli et al., 
1992). Matteucci et al., (1993) attempted to isolate FIV from the saliva, plasma and 
peripheral blood mononuclear cells (PBMC) of naturally FIV-infected cats; the isolation 
rate of FIV from saliva was considerably lower than from PBMC (18% versus 81% of 
cats) (Matteucci et al., 1993). The third study investigating saliva testing to diagnose FIV 
infection was a prevalence survey of client-owned cats using a later generation of a 
commercially available ELISA kit (SNAP FIV/FeLV Combo) to detect FIV antibodies in 
addition to utilizing nucleic acid amplification (PCR testing) to detect proviral DNA 
(Chang-Fung-Martel et al., 2013). Although blood was not obtained in the main study, 
preliminary evaluation using three FIV-infected and two FIV-uninfected cats found results 
for FIV antibody testing using the ELISA kit to be identical when blood and saliva from 
the same cat were tested concurrently. There was also good correlation between the ELISA 
antibody test kit results and combined results from the three PCR assays using saliva 
(Kappa value 0.76; 95% confidence interval [CI] 0.64-0.87) (Chang-Fung-Martel et al., 
2013). 
The aim of the present study was to systematically investigate the use of saliva to diagnose 
FIV infection in FIV-vaccinated and FIV-unvaccinated cats, using three point-of-care FIV 
antibody (IgG) detection kits and a commercially available real-time qPCR assay, in a well 
characterized cohort. 
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4.3 MATERIALS AND METHODS 
4.3.1 Sample population 
Client-owned cats from Chapter 3 were recruited. Briefly, cats of known FIV vaccination 
history were recruited through veterinary clinics and classified as ‘FIV-vaccinated’ (had 
received at least one FIV vaccine at any time in their life) or ‘FIV-unvaccinated’ (had 
never received a FIV vaccine). Clinical records were interrogated to enforce this criterion. 
Practices where the prevalence of FIV infection was perceived to be high were targeted. 
Animal ethics approval was granted by The University of Sydney (Approval number 
N00/1-2013/3/5920). 
4.3.2 Blood collection, blood testing and defining FIV infection status 
The procedures for blood collection, FIV antibody testing of whole blood using three 
point-of-care test kits, nucleic acid amplification of blood (FIV RealPCR), use of VI in rare 
discrepant cases and final assignment of FIV status were described in Chapter 3.  
All three FIV antibody kits tested in the current study, despite differing methodology, 
detect IgG. SNAP FIV/FeLV Combo is a lateral flow ELISA that detects antibodies to FIV 
matrix protein (p15) and capsid protein (p24), Witness FeLV/FIV uses IC to detect 
antibodies to FIV surface glycoprotein (gp40) and Anigen Rapid FIV/FeLV uses IC to 
detect antibodies to p24 and gp40.  
Consideration of all four FIV test results (three antibody tests and PCR testing) led to FIV 
status being assigned when there was a majority, either of negative or positive FIV results 
(i.e. 3-1 or 4-0). In seven cases, where test results were equally split (i.e. 2-2), VI was 
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undertaken as the ‘tie-breaker’. VI was also undertaken to confirm FIV-vaccinated/FIV-
infected cats, even though in all cases there was a clear FIV-positive test majority. 
Four FIV-vaccinated cats (4/117; 3%) were determined to be FIV-infected. All four cats 
tested FIV-positive using whole blood with SNAP FIV/FeLV Combo, Witness FeLV/FIV 
and Anigen Rapid FIV/FeLV. Two of the four cats tested FIV-negative with FIV RealPCR 
initially, although with repeat testing (three times over 18 months) these two cats 
eventually tested positive with FIV RealPCR. Serial re-testing was undertaken following 
positive VI results to investigate whether FIV RealPCR would be sensitive enough to 
detect FIV infection in these two cats. 
Of the 113 FIV-vaccinated/FIV-uninfected cats, SNAP FIV/FeLV Combo recorded zero 
FIV-negative results (i.e. all 113 cats tested FIV-positive using this kit), Witness 
FeLV/FIV recorded 107 FIV-negative results and Anigen Rapid FIV/FeLV recorded 113 
FIV-negative results. A total of 112/113 cats tested FIV-negative with FIV RealPCR. 
Twenty-one of the 239 FIV-unvaccinated cats (9%) were determined to be FIV-infected. 
All 21 cats tested FIV-positive using whole blood with SNAP FIV/FeLV Combo, Witness 
FeLV/FIV, Anigen Rapid FIV/FeLV and FIV RealPCR. Of the 218 FIV-
unvaccinated/FIV-uninfected cats, SNAP FIV/FeLV Combo recorded 212 FIV-negative 
results, Witness FeLV/FIV recorded 217 FIV-negative results and Anigen Rapid recorded 
218 FIV-negative results. A total of 215/218 cats tested FIV-negative with FIV RealPCR. 
4.3.3 Saliva collection and saliva testing 
Saliva collection was performed immediately following blood collection. Two sterile, 
individually cased cotton swabs mounted on plastic rods
28
 were used to obtain saliva. Each 
swab was rubbed one after the other against the buccal mucosa on each side of the mouth, 
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with the cheek pressed gently against the upper dental arcade while slowly twisting the 
swab, for approximately 10 s per side. Swabs with frank blood on the cotton tip due to 
gingivitis were noted. The average weight of a total of ten saliva swabs from five cats after 
sampling was determined using a Precision Plus electronic balance
29
 and compared to the 
average weight of ten unused swabs. Both saliva swabs were then refrigerated at 4
o
C. One 
of the saliva swabs (selected randomly) was used for FIV antibody testing
30
 within 24 
hours of collection by cutting the plastic rod approximately 2 cm from the cotton tip and 
transferring it to a sterile microcentrifuge tube.
28
 After placing the cotton tip in the tube, 
with the plastic rod at the bottom of the tube, 450 µL of sterile phosphate buffered saline 
(PBS) was added and the tube shaken vigorously by hand for 10 s. The tube, still 
containing the cut cotton swab, was centrifuged for 30 s at 10,000 g.
31
 The swab was then 
removed from the tube using forceps and the supernatant tested using three FIV antibody 
test kits designed for FIV antibody detection in whole blood, plasma or serum (SNAP 
FIV/FeLV Combo, Witness FeLV/FIV and Anigen Rapid FIV/FeLV). Testing was 
performed per manufacturers’ instructions except that an equivalent volume of saliva-
containing supernatant was substituted for blood in the test protocol. None of the 
manufacturers endorses using saliva as a diagnostic specimen for their test kits. The 
primary author performed FIV antibody testing using saliva immediately following FIV 
antibody testing using blood, meaning samples were not blinded for saliva antibody 
testing. 
The manufacturer’s instructions for SNAP FIV/FeLV Combo advise that any colour 
development in the FIV sample spot should be considered significant.
32
 Although the 
manufacturers’ instructions for Anigen Rapid FIV/FeLV and Witness FeLV/FIV contain 
no guidelines for interpreting faint results using whole blood, plasma or serum, a faint band 
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(IC) or spot (ELISA) was recorded as a positive result. This was the same criteria used for 
our previous study using blood (Chapter 3). 
The second saliva sample was stored at -80
o
C within 24 hours of collection. At the 
conclusion of the study, stored samples were shipped on dry ice for nucleic acid extraction 
and FIV testing using a commercially available qPCR assay (FIV RealPCR).
33
 Primers for 
this assay target the conserved gag region in both viral RNA (using cDNA following a 
reverse transcription step) and proviral DNA. FIV subtype was determined using subtype 
specific primer pairs for subtypes A, B, D and F.
34
 The laboratory does not endorse using 
saliva as a diagnostic specimen for FIV RealPCR testing. Laboratory technicians 
performing FIV RealPCR testing using saliva were blind to saliva FIV antibody test 
results. 
At the conclusion of the study a small subset of FIV-infected cats was resampled using 
three new cotton swabs and the aforementioned collection technique. However, instead of 
using PBS and centrifugation to extract a supernatant sample, a single cotton swab was 
used exclusively for each antibody test kit (randomly ordered), using a revised and simpler 
methodology. For each test kit the saliva swab was directly applied to the sample well spot, 
soaking the cotton tip with twice the volume of buffer recommended in the manufacturers’ 
instructions, and rolling the cotton tip on the sample spot for 10 s while the buffer was 
added. The result was read 10 min later. This revised ‘direct application’ technique for 
antibody testing using saliva was investigated to determine the accuracy of a more 
practical method for patient-side use. 
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4.3.4 Statistical analysis 
Numerical analyses were performed using a commercial program (Genstat 16
th
 Edition).
35
 
Statistical significance was considered at P < 0.05 and 95% CI were calculated based on a 
normal approximation and the Wald method using Microsoft Excel.
36
 PPV and NPV were 
calculated using the standard formulas (PPV = ‘number of true positives’ / (‘number of 
true positives’ + ‘number of false positives’); NPV = ‘number of true negatives’ / (‘number 
of true negatives’ + ‘number of false negatives’)). Overall test accuracy was determined by 
the formula (‘number of true positives’ + ‘number of true negatives’ / total number of cats 
sampled). Two-tailed Fisher’s exact tests were used to investigate whether false-positive 
and false-negative FIV results were more common in FIV-vaccinated cats than FIV-
unvaccinated cats, and whether false-positive FIV results were more common in cats 
returning a blood-tinged saliva swab than a non-bloody swab. Binomial logistic regression 
with a logit link function was conducted on the test results to determine if there was a 
significant difference in sensitivity between test methodologies using saliva, and also to 
compare sensitivity and specificity between blood and saliva for each test methodology. 
Cohen’s Kappa Index Value (κ) for each test methodology was determined to calculate 
agreement between blood and saliva using the standard formula (κ = 1 – (1 – Po) / (1 – Pe)), 
where Po was the observed agreement and Pe was the expected agreement (0.5). 
                                                 
28
 Sarstadt, Mawson Lakes, South Australia, Australia (Plastic Stem Cotton Tip Catalogue No. 80.625; 1.5 
mL Micro Tube Catalogue No. 72.706.400). 
29
 Ohaus, Parsippany, NJ, USA. 
30
 Faculty of Veterinary Science, The University of Sydney, Sydney, NSW, Australia. 
31
 Eppendorf AG, Hamburg, Germany (Model 5424). 
32
 www.idexx.com/resource-library/smallanimal/snap-combo-package-insert-en.pdf 
33
 IDEXX Laboratories, East Brisbane, Queensland, Australia. 
34
 www.idexx.com.au/pdf/en_au/smallanimal/education/realpcr-test-for-fiv.pdf 
35
 GenStat 16
th
 Edition for Windows, VSN International, Hemel Hempstead, United Kingdom. 
36
 Microsoft Excel 2010 for Windows, Microsoft, Redmond, WA, USA. 
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4.4 RESULTS 
4.4.1 Sample population 
Blood and saliva samples were obtained from 356 client-owned cats recruited from eleven 
veterinary clinics distributed over four states of Australia (NSW, VIC, QLD and SA). 
A total of 117 FIV-vaccinated cats were recruited, ranging from 2 to 18 years (median 7 
years; IQR 5–10 years). This is two less cats than reported in our previous study, because 
saliva was not obtained from two cats at the same time as blood was collected. These cats 
comprised 64 castrated males and 53 spayed females. Most were domestic crossbred cats 
(101/117; 86%), the remainder comprising a range of pedigree breeds. Most cats in this 
cohort (109/117; 93%) had received three primary FIV vaccinations, two to four weeks 
apart, and three or more annual FIV vaccinations before being sampled. For these 109 cats, 
sampling took place between 2 and 462 days following their last FIV vaccination (median 
237 days; IQR 152–317 days). Seven cats were considered overdue for their annual FIV 
vaccination (more than 15 months since last vaccination; median 5 years, range 3-7 years) 
and one cat was 3 years overdue for its second primary FIV vaccination. 
A total of 239 FIV-unvaccinated cats were recruited, ranging from 2 to 20 years (median 7 
years; IQR 6–10 years). These cats comprised 112 castrated males, 123 spayed females 
and 4 entire males. Most were domestic crossbred cats (207/239; 87%), the remainder 
comprising a range of pedigree breeds. 
4.4.2 Saliva testing 
The median weight of saliva collected per cotton swab was 0.07 g (IQR 0.03–0.11 g), 
based on the five cats where this was studied. 
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4.4.2.1 FIV-vaccinated cohort (n = 117) 
Of the four FIV-vaccinated/FIV-infected cats, three tested FIV-positive with SNAP 
FIV/FeLV Combo (i.e. there was one false-negative result), two tested FIV-positive with 
Witness FeLV/FIV and all four tested FIV-positive with Anigen Rapid FIV/FeLV. Two of 
the four cats tested FIV-positive with FIV RealPCR; the same two cats that were initially 
FIV-negative with FIV RealPCR testing using blood were also FIV-negative using saliva. 
Considering the 113 FIV-vaccinated/FIV-uninfected cats, SNAP FIV/FeLV Combo 
recorded 107 FIV-negative results (i.e. there were six false-positive results), while both 
Witness FeLV/FIV and Anigen Rapid FIV/FeLV recorded 113 FIV-negative results. Four 
of the six false-positive FIV results recorded with SNAP FIV/FeLV Combo were in cats 
that returned a blood-tinged saliva swab. All 113 cats tested negative with FIV RealPCR. 
A summary of results for each test methodology in FIV-vaccinated cats, including 
sensitivity, specificity, PPV and NPV, is provided in Table 4.1. 
4.4.2.2 FIV-unvaccinated cohort (n = 239) 
Of the 21 FIV-unvaccinated/FIV-infected cats, eight tested FIV-positive with SNAP 
FIV/FeLV Combo (i.e. there were 13 false-negative results), 21 tested FIV-positive with 
Witness FeLV/FIV and 20 tested FIV-positive with Anigen Rapid FIV/FeLV. A 
photograph of one of the eight FIV-unvaccinated/FIV-infected cats that tested positive 
with all three antibody kits (cat #92) is shown in Figure 4.1. A total of 16/21 cats tested 
FIV-positive with FIV RealPCR. 
Of the 218 FIV-unvaccinated/FIV-uninfected cats, SNAP FIV/FeLV Combo recorded 217 
FIV-negative results (one false-positive result from a non-bloody swab) while Witness 
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FeLV/FIV, Anigen Rapid FIV/FeLV and FIV RealPCR all recorded 218 FIV-negative 
results. 
A summary of results for each test methodology in FIV-unvaccinated cats, including 
sensitivity, specificity, PPV and NPV, is provided in Table 4.2. 
4.4.2.3 Combined FIV-vaccinated and FIV-unvaccinated cohorts (n = 356) 
Combined results for saliva testing of both cohorts, including overall accuracy of each test 
methodology, are summarized in Table 4.3.  
False-positive results were significantly more common using SNAP FIV/FeLV Combo in 
FIV-vaccinated cats (6/113; 5%) than FIV-unvaccinated cats (1/218; 0.5%) (P = 0.007). 
There was no significant difference in the proportion of false-negative results using SNAP 
FIV/FeLV Combo between FIV-vaccinated (1/4; 25%) and FIV-unvaccinated cats (13/21; 
62%) (P = 0.29). False-positive FIV results using SNAP FIV/FeLV Combo were 
significantly more common in FIV-vaccinated cats that returned a blood-tinged swab 
(4/20; 20%) compared to a non-bloody swab (2/93; 2%) (P = 0.009). Blood contamination 
of swabs did not lead to an increased number of false-positive results in FIV-unvaccinated 
cats using SNAP FIV/FeLV Combo (0/24 versus 1/194; P = 1.00). 
The specificity of all four test methodologies (SNAP FIV/FeLV Combo, Witness 
FeLV/FIV, Anigen Rapid FIV/FeLV and FIV RealPCR) using saliva was comparable, 
while a significant effect of test methodology on sensitivity was found (P < 0.001). 
Witness FeLV/FIV and Anigen Rapid FIV/FeLV had comparable sensitivities (P = 0.55), 
Anigen Rapid FIV/FeLV was significantly more sensitive than FIV RealPCR (P = 0.038), 
and all three methodologies were significantly more sensitive than SNAP FIV/FeLV 
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Combo (Witness FeLV/FIV and Anigen Rapid FIV/FeLV [P = 0.001]; FIV RealPCR [P = 
0.048]).  
Subtyping results and CT values from FIV RealPCR testing of both blood and saliva from 
the 25 FIV-infected cats are provided in Tables 4.4 and 4.5. 
4.4.2.4 Repeat saliva testing using revised technique (n = 14) 
More than half of the FIV-infected cats (14/25; 56%) were available for repeat testing with 
saliva using the revised ‘direct application’ technique. With initial centrifugation testing, 
7/14 (50%) of these cats tested FIV positive with SNAP FIV/FeLV Combo, 12/14 (86%) 
tested FIV positive with Witness FeLV/FIV and 13/14 (93%) tested FIV positive with 
Anigen Rapid FIV/FeLV. Using the direct application technique, 0/14 (0%) of these cats 
tested FIV-positive with SNAP FIV/FeLV Combo, 7/14 (50%) tested FIV-positive with 
Witness FeLV/FIV and 14/14 (100%) tested FIV-positive with Anigen Rapid FIV/FeLV. 
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Figure 4.1 Photograph of data from a FIV-infected cat (cat #92) using saliva as the 
diagnostic specimen, showing three positive FIV antibody test kit results using: (a) Anigen 
Rapid FIV/FeLV, (b) Witness FeLV/FIV, and (c) SNAP FIV/FeLV Combo. For both IC 
kits, the top strip is for FIV antibody testing and the bottom strip is for FeLV antigen 
testing. One band in the FIV or FeLV strip indicates a negative result, two bands in the 
FIV or FeLV strip indicates a positive result. For the SNAP FIV/FeLV Combo kit, two 
spots in the illustrated conformation indicates a positive FIV result. This result was found 
in 11/25 FIV-infected cats. 
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Table 4.1 (FIV-vaccinated cohort) Results of testing using three point-of-care FIV 
antibody kits and FIV RealPCR testing in FIV-vaccinated cats using saliva (n = 117; 
comprising 113 FIV-uninfected and 4 FIV-infected cats). PPV = positive predictive value, 
NPV = negative predictive value. Confidence intervals (95%) are given in brackets. 
Test kit SNAP Combo Witness Anigen Rapid FIV Real PCR 
True positive 3 2 4 2 
False negative 1 2 0 2 
True negative 107 113 113 113 
False positive 6 0 0 0 
Sensitivity (%) 3/4 = 75 
(33-100) 
2/4 = 50 
(1-99) 
4/4 = 100 2/4 = 50 
(1-99) 
Specificity (%) 107/113 = 95 
(91-99) 
113/113 = 
100 
113/113 = 100 113/113 = 100 
PPV (%) 3/9 = 33 
(2-64) 
2/2 = 100 
 
4/4 = 100 2/2 = 100 
NPV (%) 107/108 = 99 
(97-100) 
113/115 = 98 
(96-100) 
113/113 = 100 113/115 = 98 
(96-100) 
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Table 4.2 (FIV-unvaccinated cohort) Results of testing using three point-of-care FIV 
antibody kits and FIV RealPCR testing in FIV-unvaccinated cats using saliva (n = 239; 
comprising 218 FIV-uninfected and 21 FIV-infected cats). PPV = positive predictive 
value, NPV = negative predictive value. Confidence intervals (95%) are given in brackets. 
Test kit SNAP Combo Witness Anigen Rapid FIV Real PCR 
True positive 8 21 20 16 
False negative 13 0 1 5 
True negative 217 218 218 218 
False positive 1 0 0 0 
Sensitivity (%) 8/21 = 38 
(17-59) 
21/21 = 100 20/21 = 95 
(86-100) 
16/21 = 76 
(58-94) 
Specificity (%) 217/218 = 
99.5 
(99-100) 
218/218 = 100 218/218 = 100 218/218 = 100 
PPV (%) 8/9 = 89 
(68-100) 
21/21 = 100 20/20 = 100 16/16 = 100 
NPV (%) 217/230 = 94 
(91-97) 
218/218 = 100 218/219 = 99.5 
(99-100) 
218/223 = 98 
(96-100) 
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Table 4.3 Combined results of three point-of-care FIV antibody test kits in FIV-vaccinated 
and FIV-unvaccinated cats using saliva (n = 356). Note that this composite population was 
biased by the inclusion of many FIV-vaccinated cats (117/356; 33%). In practice, the 
percentage of FIV-vaccinated cats in an area will be heavily dependent on the vaccination 
protocols of the local veterinary clinics and may differ considerably from this value. PPV = 
positive predictive value, NPV = negative predictive value. Confidence intervals (95%) are 
given in brackets. 
Test kit SNAP 
Combo 
Witness Anigen Rapid FIV Real PCR 
True positive 11 23 24 18 
False negative 14 2 1 7 
True negative  324 331 331 331 
False positive 7 0 0 0 
Sensitivity (%) 11/25 = 44 
(25-64) 
23/25 = 92 
(81-100) 
24/25 = 96 
(88-100) 
18/25 = 72 
(54-90) 
Specificity (%) 324/331 = 98 
(96-99) 
331/331 = 100 331/331 = 100 331/331 = 100 
PPV (%) 11/18 = 61 
(39-84) 
23/23 = 100 24/24 = 100 18/18 = 100 
NPV (%) 324/338 = 96 
(94-98) 
331/333 = 99 
(99-100) 
331/332 = 99.7 
(99-100) 
331/338 = 98 
(96-99) 
Overall accuracy 
(%) 
335/356 = 94 354/356 = 99 355/356 = 99.7 349/356 = 98 
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Table 4.4 Subtyping results from FIV RealPCR testing of FIV-infected cats using saliva as 
the diagnostic specimen (n = 18). Primers pairs for FIV subtypes A, B, D and F were 
included in the qPCR reaction.  
FIV subtype Frequency 
FIV A 11/18 = 61% 
FIV B 0 
FIV D 0 
FIV F 0 
FIV A/F 2/18 = 11% 
FIV D/F 2/18 = 11% 
5UTR only 3/18 = 17% 
5UTR = five prime untranslated region (also known as the ‘Leader Sequence’). 
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Table 4.5 CT values by FIV subtype from FIV RealPCR testing of FIV-infected cats using blood and saliva (n = 25). 
Cat Group CT value – BLOOD
a
 cDNA QC – 
BLOOD 
CT value - SALIVA
a
 cDNA QC – 
SALIVA Cat #1
b,c
 FIV-vaccinated FIV A 31.7 15.62 - 24.96 
Cat #19
c
 FIV-vaccinated FIV A 32.23 22.31 FIV A 32.0 25.02 
Cat #106
b,c
 FIV-vaccinated FIV A 32.01, FIV5UTR 31.15 14.98 - 22.44 
Cat #152
c
 FIV-vaccinated FIV A 29.73, FIV5UTR 29.24 21.8 FIV5UTR 33.57 24.06 
Cat #33 FIV-unvaccinated FIV A 30.8, FIV F 38.34, 
FIV5UTR 29.38 
16.58 FIV A 33.29 25.2 
Cat #62 FIV-unvaccinated FIV A 28.02, FIV5UTR 26.84 17.18 FIV A 31.83, FIV5UTR 
32.13 
22.72 
Cat #80 FIV-unvaccinated FIV D 30.0, FIV F 29.12, 
FIV5UTR 28.31 
16.94 FIV D 35.11, FIV F 
36.65, FIV5UTR 32.97 
22.91 
Cat #85 FIV-unvaccinated FIV A 28.6, FIV5UTR 28.63 14.37 FIV A 30.23, FIV5UTR 
32.74 
22.26 
Cat #92 FIV-unvaccinated FIV D 29.0, FIV F 29.23 
FIV5UTR 29.75 
14.6 FIV D 31.89, FIV F 36.6, 
FIV5UTR 33.94 
24.06 
Cat #127 FIV-unvaccinated FIV A 32.08, FIV5UTR 31.03 17.35 - 23.44 
Cat #157 FIV-unvaccinated FIV A 30.53, FIV5UTR 30.27 19.39 FIV A 31.0, FIV5UTR 
32.07 
24.5 
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Cat #163 FIV-unvaccinated FIV A 32.50, FIV5UTR 31.62 21.51 FIV5UTR 33.05 24.2 
Cat #190 FIV-unvaccinated FIV A 32.50, FIV5UTR 33.1 16.04 - 22.15 
Cat #192 FIV-unvaccinated FIV F 32.31, FIV5UTR 32.35 16.01 - 24.77 
Cat #203 FIV-unvaccinated FIV A 29.26, FIV F 36.14, 
FIV5UTR 30.06 
15.01 - 23.09 
Cat #208 FIV-unvaccinated FIV A 32.87, FIV5UTR 32.86 15.6 - 21.35 
Cat #209 FIV-unvaccinated FIV A 30.57, FIV F 36.14, 
FIV5UTR 31.11 
14.3 FIV A 32.0, FIV5UTR 
31.69 
21.28 
Cat #218 FIV-unvaccinated FIV A 31.15, FIV F 35.93, 
FIV5UTR 30.13 
23.04 FIV A 30.82, FIV F 
37.72, FIV5UTR 31.29 
19.27 
Cat #250 FIV-unvaccinated FIV A 31.04, FIV5UTR 31.64 21.67 FIV A 32.00, FIV5UTR 
31.72 
19.66 
Cat #272 FIV-unvaccinated FIV A 31.48, FIV5UTR 30.84 15.78 FIV A 33.02, FIV5UTR 
32.45 
21.6 
Cat #274 FIV-unvaccinated FIV D 35.00, FIV F 34.31, 
FIV5UTR 31.17 
15.99 FIV5UTR 33.32 22.59 
Cat #279 FIV-unvaccinated FIV A 30.88, FIV F 36.00, 17.34 FIV A 32.0, FIV5UTR 22.1 
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FIV5UTR 30.21 32.75 
Cat #281 FIV-unvaccinated FIV A 32.00, FIV5UTR 31.37 23.61 FIV A 32.5, FIV5UTR 
32.78 
22.25 
Cat #303 FIV-unvaccinated FIV A 28.39, FIV F 35.53, 
FIV5UTR 28.46 
17.79 FIV A 32.66, FIV5UTR 
32.2 
24.02 
Cat #319 FIV-unvaccinated FIV A 30.44, FIV F 35, 
FIV5UTR 30.09 
18.7 FIV A 32.84, FIV F 
37.14, FIV5UTR 32.5 
21.2 
a
FIV subtyping was determined using subtype specific primers. Primers pairs for FIV subtypes A, B, D and F were included in the qPCR reaction.  
5UTR = five prime untranslated region (also known as the ‘Leader Sequence’). 
b
Cats were sampled and tested three times before positive PCR results were produced.  
c
Confirmed with VI performed by Yamamoto Laboratory. 
- = negative result. 
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4.4.3 Comparing blood and saliva results (n = 356) 
Considering the four FIV-vaccinated/FIV-infected cats, SNAP FIV/FeLV Combo did not 
identify one cat as FIV-positive (i.e. one false-negative result) using saliva as the 
diagnostic specimen instead of blood, Witness FeLV/FIV recorded two false-negative 
results using saliva and Anigen Rapid FIV/FeLV recorded zero false-negative results using 
saliva (i.e. saliva testing was equivalent to blood testing). FIV RealPCR did not identify 
two cats as FIV-positive using saliva; the same two cats that were FIV-negative with FIV 
RealPCR using saliva were also FIV-negative with initial FIV RealPCR testing using 
blood. 
In the 113 FIV-vaccinated/FIV-uninfected cats, saliva testing was equivalent to blood 
testing using the Anigen Rapid FIV/FeLV kit. For SNAP FIV/FeLV Combo, Witness 
FeLV/FIV and FIV RealPCR testing, using saliva instead of blood reduced the number of 
false-positive results (107, 6 and 1 less false-positive results, respectively). 
Considering the 21 FIV-unvaccinated/FIV-infected cats, saliva testing was equivalent to 
blood testing using the Witness FeLV/FIV kit (i.e. 21 true-positive results). However, 13 
cats were not identified as FIV-positive (i.e. 13 false-negative results) with SNAP 
FIV/FeLV Combo using saliva, Anigen Rapid FIV/FeLV recorded one false-negative 
result using saliva and FIV RealPCR recorded five false-negative results using saliva. 
In the 218 FIV-unvaccinated/FIV-uninfected cats, saliva testing was equivalent to blood 
testing using the Anigen Rapid FIV/FeLV kit. For SNAP FIV/FeLV Combo, Witness 
FeLV/FIV and FIV RealPCR testing, using saliva instead of blood resulted in a reduced 
number of false-positive results (5, 1 and 3 less false-positive results, respectively). 
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In total, considering both saliva and blood results for each test methodology at the same 
time, saliva testing and blood testing of cats correctly identified the FIV infection status in 
223/356 (63%) using SNAP FIV/FeLV Combo (κ = 0.29), 347/356 (97%) using Witness 
FeLV/FIV (κ = 0.95), 355/356 (99.7%) using Anigen Rapid FIV/FeLV (κ = 0.99) and 
345/356 (97%) using FIV RealPCR (κ = 0.95). 
A full comparison of blood and saliva results is provided in Table 4.6, while a comparison 
of sensitivity and specificity for each antibody test kit and FIV RealPCR testing using 
blood and saliva is found in Table 4.7. Using saliva instead of blood for testing with SNAP 
FIV/FeLV Combo significantly increased specificity (P < 0.001) but concurrently reduced 
sensitivity (P = 0.002), while using saliva instead of blood for FIV RealPCR testing 
trended towards reduced sensitivity (P = 0.081). All other comparisons were statistically 
similar. 
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Table 4.6 Comparing blood (Chapter 3) and saliva results (n = 356). The non-highlighted number indicates how many cats tested FIV-
positive.  
FIV vaccination and 
FIV infection status 
SNAP Combo 
 
Witness Anigen Rapid FIV RealPCR 
BLOOD SALIVA BLOOD SALIVA BLOOD SALIVA BLOOD SALIVA 
FIV-vaccinated/FIV-
infected (n = 4) 
 
4 3                  
(1)              
4 2                   
(2)              
4 4 2         
(2) 
2                     
(2) 
FIV-vaccinated/FIV-
uninfected (n = 113) 
 
113    
(113) 
6                  
(6) 
6             
(6) 
0 0 0 1             
(1) 
0 
FIV-unvaccinated/FIV-
infected (n = 21) 
 
21 8                
(13) 
21 21 21 20                   
(1) 
21 16                   
(5) 
FIV-unvaccinated/FIV-
uninfected (n = 218) 
 
6             
(6) 
1                  
(1) 
1             
(1) 
0 0 0 3             
(3) 
0 
Yellow = number of false-positive results in FIV-uninfected cats. Witness FeLV/FIV, Anigen Rapid and FIV RealPCR did not record any false-positive results using 
saliva as the diagnostic specimen. SNAP Combo FIV/FeLV (as well as Witness FeLV/FIV and FIV RealPCR) recorded less false-positive results using saliva as the 
diagnostic specimen instead of blood.  
Green = number of false-negative results in FIV-infected cats. 
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Table 4.7 Comparison of overall sensitivity and specificity for the three antibody test kits and FIV RealPCR testing for blood (Chapter 3) and 
saliva (n = 356). Note that this composite population was biased by the inclusion of many FIV-vaccinated cats (117/356; 33%). In practice, 
the percentage of FIV-vaccinated cats in an area will be heavily dependent on the vaccination protocols of the local veterinary clinics and may 
differ considerably from this value.  
 SNAP Combo Witness Anigen Rapid FIV RealPCR 
 BLOOD SALIVA BLOOD SALIVA BLOOD SALIVA BLOOD SALIVA 
Sensitivity 
 
100
a
 44
a
 
(25-64) 
100 92 
(81-100) 
100 96 
(88-100) 
92
c
 
(82-100) 
72
c
 
(54-90) 
Specificity 
 
 
 
64
b
 
(59-69) 
98
b
 
(96-99) 
98 
(96-99) 
100 100 100 99  
(98-100) 
100 
a
P = 0.002. 
b
P = 0.001.  
c
P = 0.081. 
CIs (95%) are given in brackets. 
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4.5 DISCUSSION 
All three FIV antibody detection kits were able to detect IgG in whole saliva from FIV-
infected cats, with varying accuracy. SNAP FIV/FeLV Combo had similar specificity to 
Witness FeLV/FIV and Anigen Rapid FIV/FeLV using saliva but significantly lower 
sensitivity. Despite the similar specificity, SNAP FIV/FeLV Combo produced seven false-
positive FIV results (7/356; 2%), and these false-positive results were significantly more 
common in FIV-vaccinated cats than FIV-unvaccinated cats. Interestingly, 4/6 (67%) false-
positive FIV results in the FIV-vaccinated cohort were recorded in cats that returned a 
blood-tinged saliva swab. False-positive FIV responses in FIV-vaccinated cats were 
described for SNAP FIV/FeLV Combo and Witness FeLV/FIV when testing whole blood 
(Chapter 3) and we theorized that p15 retains immunogenicity during FIV vaccine (Fel-O-
Vax FIV) production to a greater extent and/or for a longer period of time compared to p24 
or gp40. If this is the case, SNAP FIV/FeLV Combo would be unable to differentiate p15 
antibodies produced in response to FIV vaccination from natural FIV infection. 
Interestingly, this phenomenon of false-positive results in FIV-vaccinated cats was much 
less obvious when saliva was used instead of blood (6 false-positive results compared to 
113), presumably because the concentration of anti-FIV IgG in whole saliva in FIV-
vaccinated/FIV-uninfected cats fell below the detection threshold of the SNAP FIV/FeLV 
Combo kit due to the dilution of crevicular fluid by saliva. However, this inability of the 
SNAP FIV/FeLV kit to detect low levels of anti-FIV IgG in saliva resulted in a 
significantly lower sensitivity than Witness FeLV/FIV and Anigen Rapid FIV/FeLV, with 
14 false-negative FIV results recorded (out of 25 FIV-infected cats). 
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The current study provides a large, rigorous and systematic study design for the evaluation 
of saliva as a diagnostic specimen for determining FIV infection status. We found it 
possible to accurately determine the FIV status of both FIV-vaccinated and FIV-
unvaccinated cats using IC methodology, without the need for further confirmatory testing 
such as nucleic acid amplification. The two IC antibody test kits did not produce any false-
positive FIV results (0/356) and thus a positive result with either test kit represented a true-
positive result. Witness FeLV/FIV produced two false-negative test results (2/356; 0.6%), 
while Anigen Rapid FIV/FeLV produced only one false-negative test result (1/356; 0.3%). 
These three false-negative results occurred in three different cats. This slight reduction in 
test kit sensitivity when using saliva instead of blood (8% reduction for Witness 
FeLV/FIV, 4% reduction for Anigen Rapid FIV/FeLV) is similar to the 2% reduction 
reported with the OraQuick Advance Rapid HIV-1/2 In-Home HIV Test which is 
commercially available over the counter for private use (Pai et al., 2012). 
Two previous studies evaluating the detection of FIV antibodies in saliva as a means of 
diagnosing FIV infection had contradictory findings. The first study reported a high 
frequency of false-positive and false-negative results (Poli et al., 1992). Our belief is that 
the high number of erroneous results was attributable to limitations in the test kits used, as 
point-of-care test kits available in the early 1990s were far less refined than kits currently 
available. A subsequent study conducted more recently found a good correlation between 
salivary antibody and salivary PCR results (Chang-Fung-Martel et al., 2013), in accord 
with the present results. Chang-Fung-Martel and colleagues reported a higher proportion of 
false-positive FIV results in FIV-vaccinated cats using SNAP FIV/FeLV Combo (2/9; 22% 
versus 6/113; 5%) and a lower proportion of false-negative FIV results in FIV-infected cats 
(3/10; 30% versus 14/25; 56%) than the current study, although neither difference was 
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statistically significant (Fisher’s exact test; P = 0.11 and 0.26, respectively) (Chang-Fung-
Martel et al., 2013). 
The main challenge to the routine use of salivary antibody testing is the requirement to 
purchase specific consumables, such as microcentrifuge tubes and a centrifuge. A cotton 
swab mounted on a plastic rod, rather than a cotton or wooden rod, is required to avoid 
absorption of saline by the rod in order to collect sufficient sample for testing. The 
centrifugation method for salivary antibody testing outlined in the present study was 
chosen as it had proved effective in a previous study (Chang-Fung-Martel et al., 2013). 
Unfortunately the centrifugation method is more complicated than the process required for 
antibody testing of whole blood and this may be off-putting for some veterinarians. 
Simplifying the testing process, as described in a subset of cats that were retested, 
potentially provides a method far more suitable for use in a busy practice or animal shelter.  
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4.6 CONCLUSION 
Two point-of-care FIV antibody test kits (Witness FeLV/FIV and Anigen Rapid 
FIV/FeLV) could accurately identify natural FIV infection in client-owned Australian cats 
using saliva as the diagnostic specimen, irrespective of FIV vaccination history. In areas 
where FIV vaccination is practiced, and when venipuncture is not possible without skilled 
physical restraint or heavy sedation, collecting and testing saliva for the presence of FIV 
antibodies using either of these two kits is an accurate method for diagnosing FIV 
infection. This methodology may prove particularly helpful in shelters where large 
numbers of cats need to be screened for FIV infection quickly and affordably, additional 
haematologic tests are not indicated and vaccination history is often unknown. 
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CHAPTER 5.  DURATION OF ANTIBODY RESPONSE 
FOLLOWING PRIMARY FIV VACCINATION 
5.1 ABSTRACT 
Chapter 3 reported that two point-of-care FIV antibody test kits (Anigen Rapid and 
Witness) were able to differentiate FIV-vaccinated from FIV-infected cats at a single time 
point, irrespective of the gap between testing and last vaccination (0–7 years). The aim of 
the current study was to systematically investigate anti-FIV antibody production over time 
in response to the recommended primary FIV vaccination series. First, residual plasma 
from Chapter 3 was tested using a laboratory-based ELISA to determine whether negative 
results with point-of-care testing were due to reduced as opposed to absent antibodies to 
gp40. Second, a prospective study was performed using immunologically naïve client-
owned kittens and cats given a primary FIV vaccination series using a commercially 
available inactivated whole cell/inactivated whole virus vaccine (Fel-O-Vax FIV, three 
subcutaneous injections at four week intervals) and tested systematically (up to 11 times) 
over six months, using four commercially available point-of-care FIV antibody kits (SNAP 
FIV/FeLV Combo [detects antibodies to p15/p24], Anigen Rapid FIV/FeLV [p24/gp40], 
Witness FeLV/FIV [gp40], and VetScan FeLV/FIV Rapid [p24]). ELISA testing showed 
cats from the original study vaccinated within the previous 0–15 months had detectable 
levels of antibodies to gp40, despite testing negative with two kits that use gp40 as a 
capture antigen (Anigen Rapid and Witness kits). The prospective study showed that 
antibody-testing with SNAP Combo and VetScan Rapid was positive in all cats two weeks 
after the second primary FIV vaccination, and remained positive for the duration of the 
study (12/12 and 10/12 cats positive, respectively). Antibody-testing with Anigen Rapid 
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and Witness was also positive in a high proportion of cats two weeks after the second 
primary FIV vaccination (7/12 and 8/12, respectively), but antibody levels declined below 
the level of detection in most cats (10/12) by one month after the third (final) primary FIV 
vaccination. All cats tested negative using Anigen Rapid and Witness six months after the 
third primary FIV vaccination. This study has shown that a primary course of FIV 
vaccination does not interfere with FIV antibody-testing in cats using Anigen Rapid or 
Witness, provided primary vaccination has not occurred within the previous six months, 
but the findings following annual booster FIV vaccination need to be determined. The 
mechanism for the variation in FIV antibody test kit performance remains unclear. 
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5.2 INTRODUCTION 
Areas of the FIV genome capable of evoking host antibody response (B-cell epitopes) have 
been identified in the p15, p24, p7, gp40 and gp120 domains, with immunodominant 
epitopes located in the highly variable region (V3) of gp120 (Lecollinet and Richardson, 
2008; Yamamoto et al., 2010). A cascade of antibody responses occurs following natural 
FIV infection, with antibodies to p24 and gp40 detectable within three weeks of infection 
and antibodies to p15 detectable within four weeks of infection using Western blot analysis 
(Yamamoto et al., 1988; O'Connor et al., 1989).  
Results from Chapter 3 led to speculation that p15 retains immunogenicity during FIV 
vaccine production to a greater extent than p24 or gp40. This finding was questioned by 
another researcher, who used only Witness kits and a small cohort of kittens (n = 19) given 
a primary FIV vaccination series not in accordance with the manufacturer’s 
recommendations (two injections administered instead of three), with a high FIV false-
positive rate reported using Witness (Lappin, 2015). Another larger study (n = 104), 
however, confirmed the ability of the Anigen Rapid and Witness kits to differentiate FIV-
vaccinated and FIV-infected cats, but poor results from a fourth test kit that only detects 
antibodies to p24 (VetScan FeLV/FIV Rapid) challenged the notion that the ability of test 
kits to differentiate is solely linked to the choice of FIV antigen for antibody capture 
(Crawford, 2016). Further work is therefore required to precisely and prospectively 
determine the antibody response following FIV vaccination in relation to point-of-care test 
kit methodology. 
The aims of the current study were (i) to determine if FIV-vaccinated cats produce 
antibodies to gp40 at concentrations below the detection threshold of Anigen Rapid 
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FIV/FeLV and Witness FeLV/FIV FIV/FeLV kits, using a laboratory well-based ELISA; 
and (ii) to investigate semi-quantitatively the duration of antibody response to p15, p24 and 
gp40 in cats following a primary course of FIV vaccination using four point-of-care FIV 
antibody test kits (SNAP FIV/FeLV Combo, Anigen Rapid FIV/FeLV, Witness FeLV/FIV 
and VetScan FeLV/FIV Rapid). 
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5.3 MATERIALS AND METHODS 
5.3.1 Sample population (Study 1) 
Residual blood from Chapter 3 was utilized for the first arm of this study. A total of 118 
FIV-vaccinated cats had been recruited, comprising 4 FIV-infected and 114 FIV-
uninfected cats. The median age of these cats was seven years (range 2–18 years, IQR 5–
10 years) and the procedure for final assignment of FIV status was described in Chapter 3. 
All recruited cats had received a primary course of FIV vaccination consisting of three 
vaccines 2–4 weeks apart, in accordance with the manufacturer’s recommendations, and a 
minimum of two annual booster vaccines, with no more than 15 months gap between 
annual vaccinations. 110/118 had received three or more annual boosters. Most cats 
(105/118) had been vaccinated within one year of sampling, and all cats had been 
vaccinated within 15 months of sampling (range 2–443 days, median 215 days, IQR 126–
308 days) (Figure 5.1). Seven cats from the original study overdue for their annual FIV 
vaccination by 3–7 years were not tested. Of the 114 FIV-uninfected cats, 114 had tested 
FIV-positive with SNAP Combo, six with Witness and zero with Anigen Rapid. Each cat 
was only available for sampling at a single time point, although occasionally a discordant 
cat had subsequent follow-up testing. A total of 23 FIV-unvaccinated/FIV-infected cats 
from the original study were also tested for inclusion as positive controls (Chapter 3). 
Plasma stored at -80
o
C was transported on ice to Veterinary Diagnostic Services, The 
University of Glasgow for a laboratory-based gp40 ELISA. Approval was granted by The 
University of Sydney Animal Ethics Committee (Approval number N00/1-2013/3/5920). 
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Figure 5.1 Categorization of FIV-uninfected cats from Study 1 based on time (days) 
elapsed since last FIV vaccination (n = 114). Of the 114 FIV-uninfected cats, 114 had 
tested FIV-positive with SNAP Combo, six with Witness and zero with Anigen Rapid. The 
six FIV false-positive results obtained with Witness occurred at the following intervals 
after FIV vaccination: 0–30 days (1), 121–150 days (1), 181–210 days (1), 241–270 days 
(1) and 331–360 days (2). 
 
 
5.3.2 Sample population (Study 2) 
Four FIV-unvaccinated/FIV-uninfected kittens (< 6 months-of-age) and 12 FIV-
unvaccinated/FIV-uninfected cats (> 6 months) were recruited from two veterinary clinics 
and two animal shelters in Sydney, Australia. The median age of all recruited cats was two 
years (range 0.3–8 years, IQR 1–4 years), significantly younger than cats in study 1 (P < 
0.001; Mann-Whitney U-test). Recruited cats were given a primary course of three FIV 
vaccines subcutaneously, four weeks apart (weeks 0, 4 and 8), in accordance with the 
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manufacturer’s recommendations, and antibody-tested regularly (up to 11 times) using four 
rapid FIV antibody test kits for 34 weeks (238 days; Table 5.2). Antibody testing at weeks 
14, 16 and 20 was only pursued in cats that tested FIV-positive with Anigen Rapid or 
Witness at the previous sampling, given the high likelihood of negative results with Anigen 
Rapid/Witness and positive results with SNAP Combo/VetScan in the other cats; only one 
of these cats was lost to follow-up and unable to be tested at week 16 and 20. PCR testing 
was performed by a commercial laboratory (FIV RealPCR)
37
 at the start of the study (week 
0; prior to the first FIV vaccine being given), and at the end of the study (week 34), to 
ensure FIV infection had not occurred during the course of vaccinations and period of 
antibody-testing.  
Owners were offered free testing and FIV vaccination in return for enrolling their cat in the 
study. Cats were housed with their owners for the duration of the study; outdoor access 
was not regulated and was at the owners’ discretion. One cat tested FIV-positive with an 
antibody test kit at week 0 (Anigen Rapid)
38
 and was ultimately withdrawn at the 
conclusion of the study owing to uncertainty regarding its FIV status, and three other cats 
were withdrawn during the study for various reasons unrelated to blood sampling or FIV 
vaccination (one cat was hit by a car and died between week 0 and week 2; one was 
withdrawn at the owner’s request after week 4 due to transport difficulties; and one cat was 
euthanased by the shelter after week 20 as the cat was re-surrendered following an incident 
of human-directed aggression at home). All cats tested FeLV-negative with the four kits. 
Approval was granted by The University of Sydney Animal Ethics Committee (Approval 
number N00/1-2015/858). 
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5.3.3 Detection of antibodies to gp40 using a laboratory ELISA 
A peptide ELISA, using a nine amino acid sequence (CNQNQFFCK)
39
 from the highly 
conserved immunodominant TM2 domain of gp40, was used to detect antibodies 
(Avrameas et al., 1993). Plasma samples were first complement inactivated by incubation 
at 56
o
C for 30 min. The wells of 96-well microtitre plates
40
 were coated with 250 ng/well 
of lyophilized gp40 epitope,
41
 diluted in sodium carbonate bicarbonate binding buffer 
(0.2M anhydrous sodium carbonate, 0.2M sodium carbonate and deionized water at a ratio 
of 1:11.5:4, respectively). The plates were incubated at 4
o
C overnight whilst being agitated 
at 30 rpm. The following day the wells were aspirated and washed five times with 200 µL 
of phosphate buffered saline (PBS) supplemented with 0.1% Tween (PBST). Unabsorbed 
sites were blocked following incubation with 200 µL of 2% low fat milk powder in PBST 
(MP/PBST) for one hour at room temperature. The wells were then aspirated and washed 
five times with 200 µL of PBST, and 100 µL of plasma added to the wells at a dilution of 
1/200 (MP/PBST). The plates were sealed and incubated at room temperature for one hour 
before being washed five times with 200 µL of PBST, after which 100 µL of biotinylated 
goat anti-cat secondary antibody
42
 was added to each well at a dilution of 1/1000 
(MP/PBST). The plates were sealed and incubated at room temperature for one hour. Wells 
were then aspirated and washed five times with 200 µL of PBST, and 100 µL of 
horseradish peroxidase conjugated to streptavidin
g
 added to each well at a dilution of 
1/1000 (MP/PBST). The plates were sealed and incubated at room temperature for 20 min, 
aspirated and washed five times with 200 µL of PBST, and then 100 µL of 3’,3’,5’,5’-
tetramethylbenzidine liquid (TMB)
43
 added to each well. Plates were again sealed and 
incubated at room temperature for 30 min before being read at 650 nm using a microplate 
reader
44
 and OD values recorded.  
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Positive and negative controls were included on each test plate. The positive control 
plasma was collected from a cat, infected experimentally with the biological isolate of 
FIVGL8, which tested FIV-positive by Western blot and virus isolation. The negative 
control plasma was collected from an uninfected, specific pathogen free cat that had been 
confirmed FIV-negative by Western blot and virus isolation. ELISA results were not 
categorised as ‘positive’ or ‘negative’, but rather the range of antibody responses against 
gp40 were compared amongst the FIV-vaccinated cats tested. 
5.3.4 Detection of antibodies using FIV point-of-care test kits 
Blood was collected via jugular or cephalic venipuncture and stored in an EDTA tube at 
4
o
C. FIV antibody-testing was performed using four commercially available point-of-care 
kits within 24 hours of sampling, in accordance with the manufacturers’ recommendations. 
The kits tested were SNAP FIV/FeLV Combo,
45
 Anigen Rapid FIV/FeLV
46
, Witness 
FeLV/FIV
47
 and VetScan FeLV/FIV Rapid.
48
 SNAP Combo is a lateral-flow ELISA kit 
while the other three kits use IC to detect different FIV antibodies (Table 5.1). The fourth 
kit (VetScan Rapid) was added to the three kits tested previously (Chapter 3) to include a 
methodology detecting antibodies to p24 alone. The results panel for each cat was 
photographed digitally at the time of testing. It is important to note that all four kits are 
marketed for the diagnosis of FIV infection, rather than the detection of antibodies 
produced in response to FIV vaccination as used in the current study. 
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Table 5.1 FIV target antigen for the antibodies detected using the four different point-of-
care FIV antibody kits tested in Study 2. 
 
5.3.5 Statistical analysis 
Numerical analyses were performed at the conclusion of the study using statistical software 
(Genstat 16
th
 Edition).
49
 Significance was considered at P < 0.05. A Shapiro-Wilk test was 
used to assess data for normality; since data was not normally distributed (age of cats in 
study 1 and study 2, days post FIV vaccination in study 1 and gp40 ELISA OD values) 
medians were reported and Mann-Whitney U-tests used for comparisons. ANOVA testing 
was used on loge transformed data to compare gp40 ELISA OD values grouped according 
to months since last annual FIV vaccination (0–3, 3–6, 6–9 and 9–15 months), number of 
annual booster FIV vaccinations administered (2–8) and age of cat at testing (grouped < 5 
years, 5–10 years, > 10 years). Simple linear regression modelling was also performed with 
loge OD values as the outcome and days since last annual FIV vaccination, or age of cat at 
testing, as explanatory variables. Multivariate regression modelling was performed to 
consider the combined effect of days elapsed since last vaccination and number of annual 
booster vaccinations administered. 
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37
 IDEXX Laboratories, East Brisbane, Queensland, Australia. 
38
 This cat was inexplicably FIV-negative on PCR testing at week 0 and week 34, and remained FIV-positive 
with Anigen Rapid throughout the 34 weeks. Antibody-testing at week 0 was negative with SNAP Combo, 
Witness and VetScan.  
39
 Cysteine-asparagine-glutamine-asparagine-glutamine-phenylalanine-phenylalanine-cysteine-lysine 
40
 Immulon 2 HB, Thermo Fisher Scientific, Waltham, MA, USA. 
41
 AltaBioscience, Birmingham, UK. 
42
 Vector Laboratories, Peterborough, UK. 
43
 TMB Super Slow, Sigma Aldrich, St. Louis, MO, USA. 
44
 MultiSkan Ascent Plate Reader (spectrophotometer), MTX Lab Systems, Bradenton, FL, USA. 
45
 IDEXX Laboratories, Westbrook, ME, USA. 
46
 BioNote, Gyeonggi-do, Korea. 
47
 Zoetis Animal Health, Lyon, France. 
48
 Abaxis, Union City, CA, USA 
49
 GenStat 16
th
 Edition for Windows, VSN International, Hemel Hempstead, United Kingdom. 
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5.4 RESULTS 
5.4.1 FIV gp40 laboratory quantitative ELISA (Study 1) 
FIV-infected cats (n = 4) tested positive for antibodies to gp40, irrespective of FIV 
vaccination status (P = 0.93 compared to [cf:] positive control, P < 0.001 cf: negative 
control). FIV-vaccinated/FIV-uninfected cats that tested FIV true-negative with Witness 
kits in the original study (n = 108) also tested antibody positive (P < 0.001 cf: negative 
control), but antibody levels for these cats were lower compared to FIV-infected cats (P < 
0.001). FIV-vaccinated/FIV-uninfected cats that tested FIV false-positive with Witness kits 
in the original study (n = 6) tested antibody positive (P = 0.001 cf: negative control), with 
higher antibody concentrations compared to the 108 Witness true-negative group (P = 
0.007) (Figure 5.2). This distinction, however, was not crisp; for example, the upper range 
of the 108 Witness true-negative cats encompassed the six Witness false-positive cats apart 
from one individual. When time since last vaccination was analysed as a possible factor in 
the 114 FIV-vaccinated/FIV-uninfected cats, no significant effect was found (P = 0.42 
[days], P = 0.071 [grouped by month]) (Figure 5.3). When age of cat at testing was 
considered as a possible factor in the 114 FIV-vaccinated/FIV-uninfected cats, no 
significant effect was found (P = 0.21 [years], P = 0.20 [grouped by category < 5, 5–10, > 
10]) (Figure 5.4). There was no significant difference found when cats were grouped 
according to number of annual FIV vaccinations administered (P = 0.43) Figure 5.5). 
When days since last vaccination and number of annual vaccinations were considered 
together, there was no significant effect observed (P ≥ 0.61). 
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Figure 5.2 Results from ELISA testing for antibodies against gp40 peptide (Study 1), 
including 4 FIV-vaccinated/FIV-infected cats, 6 FIV-vaccinated/FIV-uninfected cats (FIV 
false-positive with Witness) and 108 FIV-vaccinated/FIV-uninfected cats (FIV true-
negative with Witness). Positive controls (FIV-infected/FIV-unvaccinated) and negative 
controls (FIV-uninfected/FIV-unvaccinated) are shown. The OD is displayed on the y-axis. 
Mean and SEM bars are shown. 
 
*represents significant difference (P < 0.01). 
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Figure 5.3 Results from ELISA testing for antibodies against gp40 peptide (Study 1) of 
114 FIV-vaccinated/FIV-uninfected cats according to time (days) elapsed since last annual 
FIV vaccination. Positive controls (FIV-infected/FIV-unvaccinated) and negative controls 
(FIV-uninfected/FIV-unvaccinated) are shown. The OD is displayed on the y-axis. Mean 
and SEM bars are shown. No significant effect was found (P = 0.42). 
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Figure 5.4 Results from ELISA testing for antibodies against gp40 peptide (Study 1) of 
114 FIV-vaccinated/FIV-uninfected cats according to age of cat (years) at the time of 
sampling. Positive controls (FIV-infected/FIV-unvaccinated) and negative controls (FIV-
uninfected/FIV-unvaccinated) are shown. The OD is displayed on the y-axis. Mean and 
SEM bars are shown. No significant effect was found (P = 0.21). 
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Figure 5.5 Results from ELISA testing for antibodies against gp40 peptide (Study 1) of 
114 FIV-vaccinated/FIV-uninfected cats according to number of annual booster FIV 
vaccinations received. Positive controls (FIV-infected/FIV-unvaccinated) and negative 
controls (FIV-uninfected/FIV-unvaccinated) are shown. The OD is displayed on the y-axis. 
Mean and SEM bars are shown. No significant effect was found (P = 0.43). 
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5.4.2 FIV point-of-care testing (Study 2) 
Sixteen cats commenced the study and were vaccinated against FIV, with 12/16 cats 
completing the study. Table 5.3 provides a summary of results for these 12 cats. Table 5.4 
provides a summary of results for all 16 cats (i.e. including the 4 exclusions), Table 5.5 
results for kittens < 6 months-of age (n = 4) and Table 5.6 results for cats > 6 months (n = 
8). 
Considering the 12 cats, FIV antibodies were detected as early as two weeks after the first 
vaccination using SNAP Combo and Witness, and as early as four weeks using Anigen 
Rapid and VetScan Rapid. Two weeks after the second vaccination (week 6), all cats 
(12/12) tested FIV-positive with SNAP Combo and VetScan Rapid, 7/12 (58%) tested 
FIV-positive with Anigen Rapid and 8/12 (67%) tested FIV-positive with Witness. At the 
completion of the study, six months after the third vaccination (week 34), all cats (12/12) 
were FIV sero-positive with SNAP Combo, two cats had become FIV-negative with 
VetScan Rapid and all cats were FIV-negative with Anigen Rapid and Witness (Figure 
5.6). 
Three cats were tested between weeks 14 and 20 as a consequence of testing FIV-positive 
with Anigen Rapid and/or Witness at week 12: 
(i) One cat tested FIV-positive with Anigen Rapid at week 12 and 14, but became sero-
negative using this kit at week 20; 
(ii) One cat tested FIV-positive with Witness and Anigen Rapid at week 12, 14, and 16, but 
FIV-negative with both kits at week 20; 
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(iii) One cat tested FIV-positive with Witness at week 12 and 14, then was lost to follow-
up until week 34 when it tested FIV-negative with Witness. 
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Table 5.2 Outline of the prospective study design (Study 2), showing time points for three primary FIV vaccinations (week 0, 4 and 8), PCR 
testing (week 0 and 34) and antibody-testing (up to 11 times between week 0 and 34). Antibody-testing was not performed at weeks 14, 16 or 
20 for cats that were FIV-negative at week 12 with Anigen Rapid and Witness. T = time. 
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Table 5.3: Summary of FIV PCR and FIV antibody test results from the prospective study (Study 2) at various time points (n = 12). Four cats 
were withdrawn from the study (see text for details); results from these cats are not included here but are provided in Table 6.4. T = time. 
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Table 5.4 Summary of FIV PCR and FIV antibody test results from the prospective study (Study 2) at various time points (n = 16), including 
four cats withdrawn from the study at various time points (after week 0, 4, 20 and 34). T = time. 
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Table 5.5 Summary of FIV PCR and FIV antibody test results from the prospective study (Study 2) at various time points for kittens < 6 
months-of-age (n = 4). T = time. 
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Table 5.6 Summary of FIV PCR and FIV antibody test results from the prospective study (Study 2) at various time points for cats > 6 months-
of-age (n = 8). T = time. 
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Figure 5.6 Summary of FIV antibody test results from the prospective study (Study 2) at 
various time points (n = 12). The FIV target capture antigen/s for each point-of-care 
antibody test kit is included in brackets. A primary FIV vaccination course was 
administered at 0, 4 and 8 weeks. 
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5.5 DISCUSSION 
The complexity of the antibody response following vaccination with a commercial 
IWC/IWV FIV vaccine was further described in this study. Laboratory-based ELISA 
quantification of antibodies to gp40 demonstrated FIV-vaccinated cats had a detectable 
humoral response to gp40 for at least 15 months after FIV vaccination, despite a gp40 
point-of-care test kit (Witness) testing negative in 95% of these samples (108/114) 
(Chapter 3). It was surprising not to find a quantitative decrease in gp40 antibody 
concentration over time since last FIV vaccination as determined by the ELISA OD value, 
especially when the Witness results from the second arm of the study are considered. The 
explanation for this is unknown, and may relate to the older age of cats in Study 1 
compared to Study 2 as well as reduced immunogenicity of the FIV vaccine with repeated 
booster vaccinations. Serial antibody-testing using four different kits showed that six 
months after a primary course of FIV vaccines was administered, Anigen Rapid FIV/FeLV 
and Witness FeLV/FIV tested FIV-negative in 100% of cats, while SNAP FIV/FeLV 
Combo and VetScan FeLV/FIV Rapid tested FIV-positive in 100% and 83% of cats, 
respectively. 
At first glance, the Witness gp40 antibody results from Study 2 and the original study 
(Chapter 3) appear contradictory. Study 2 found that a proportion of immunologically 
naïve cats administered a primary course of FIV vaccines produced levels of antibodies to 
gp40 detectable by Witness for up to six months following vaccination, yet the original 
study found a very low level of FIV-positive results with Witness (6/114) in a cohort of 
FIV-vaccinated cats, including a FIV-positive rate of only 1/16 in recently inoculated cats 
(vaccinated within the previous 12 weeks). Results obtained from the current study with 
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Witness testing were similar to results obtained by another researcher who concluded that 
Witness testing alone could not be relied on to distinguish natural FIV infection and FIV 
vaccination shortly after a primary FIV vaccination course (Lappin, 2015). In that study 
(Lappin 2015), it was reported that 100% of FIV-vaccinated cats during their primary 
course tested FIV-positive with Witness four weeks after the second FIV vaccination, 50% 
tested FIV-positive five weeks after the second vaccination and 0% tested FIV-positive 30 
weeks after the second vaccination (Lappin, 2015). 
The explanation for this seeming discrepancy with Witness testing is possibly two-fold. 
Firstly, age may be a factor; cats recruited for Chapter 3 (which became the cats in Study 1 
in this manuscript) were substantially older than cats in Study 2 (median age 7 versus 2 
years; P < 0.001) due to the large proportion of kittens (4/12), and Lappin only tested 
kittens (Lappin, 2015). DOI studies are sparse in the veterinary literature, and most are 
only concerned with protection from challenge rather than antibody quantitation for 
diagnostic purposes (Schultz, 2006). Flow cytometry studies have demonstrated an age-
related remodeling of the immune system in cats, with a gradual decline in relative 
percentage of lymphocytes (Heaton et al., 2002), and an absolute reduction in B-cells in 
senior cats (10–14 years) compared to young cats (2–5 years) (Campbell et al., 2004). DOI 
studies are more common in the human literature, where it is generally accepted that older 
people sometimes have a lower humoral response after vaccination than younger people. 
For example, one study investigating antibody response in people administered an 
inactivated H1N1 vaccine found pre- and post-vaccination titres were generally lower in 
the elderly (> 70 years-of-age) than the young (< 30 years) (de Bruijn et al., 1999). 
Secondly, some studies have reported a lower antibody response in people being re-
vaccinated compared to those being vaccinated for the first time. Govaert and colleagues 
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found older people (> 60 years) re-vaccinated with an inactivated influenza vaccine had a 
‘strikingly’ lower humoral immune response compared to people who had not previously 
been vaccinated (Govaert et al., 1994). We postulate that the accuracy of the Witness kit to 
correctly assign FIV infection status in FIV-vaccinated cats reported previously may be 
explained by a relatively low level of gp40 antibodies in older cats following booster FIV 
vaccination, compared to the younger cats in both Study 2 and Lappin’s study, whereby 
they were vaccinated against FIV for the first time. Contrary to this theory is the absence 
of a trend in Study 1 for gp40 antibody concentration to diminish with increased age of cat 
at testing and/or number of annual FIV booster vaccinations administered (Figures 6.4 and 
6.5), nor was there a noticeable trend for kittens to test false-positive with Witness more 
often than adult cats in Study 2 (Tables 5.5 and 5.6). Inadequate sample sizes for both 
studies may have been responsible.  
Sequential semi-quantitative antibody testing following FIV vaccination with Anigen 
Rapid and Witness showed peak antibody production occurred during and shortly after a 
primary course of FIV vaccination (three injections at four week intervals). Two weeks 
after the second vaccination (week 6), 58% (7/12) and 67% (8/12) cats tested seropositive 
for FIV antibodies using Anigen Rapid and Witness, respectively. By four weeks after the 
third vaccination (week 12), only 17% (2/12) cats tested seropositive with Anigen Rapid or 
Witness, and by six months after the third vaccination (week 34) p24 and gp40 antibody 
levels had decreased below the detection limit for both kits. Peak antibody production to 
p24 and gp40 six to 12 weeks after the first primary FIV vaccination (in a series of three), 
as demonstrated by these results, supports results from previous studies (Huang et al., 
2004; Kusuhara et al., 2005; Huang et al., 2010). The reason why ELISA gp40 testing in 
the current study (Study 1) did not show a peak (and subsequent fall) in antibody 
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production (Figure 5.3), similar to ELISA testing by Huang et al. and Kusuhara et al., is 
uncertain. It may also relate to a reduced antibody response in older cats following annual 
booster FIV vaccination, rather than younger cats receiving a primary course of FIV 
vaccination (Govaert et al., 1994; de Bruijn et al., 1999). 
The study by Lappin had some design concerns which made the results difficult to 
interpret, including (i) only two FIV vaccinations were administered (instead of the 
recommended three) and (ii) there was a high dropout rate during the study. Furthermore, 
of the 19 kittens that were enrolled, only four kittens were tested at four weeks, eight 
kittens were tested at five weeks and 11 kittens were at 30 weeks post-vaccination (Lappin, 
2015). In response, we set out to carefully determine the antibody response following FIV 
vaccination in cats using systematic sequential sampling and multiple test kits (rather than 
just one), including the Witness kit used by Lappin. Our results did confirm that care needs 
to be exercised in the period immediately following primary FIV vaccination using Anigen 
Rapid and Witness, with seropositive results occurring using both. In light of our findings, 
we suggest an amendment to our previous conclusion (Chapter 3) and recommend that 
antibody testing to detect FIV infection in FIV-vaccinated cats is reliable using Anigen 
Rapid and Witness, providing primary vaccination against FIV has not occurred within the 
preceding six months. If a positive FIV-antibody result is obtained in a cat where recent 
primary vaccination is possible, submitting seropositive specimens for confirmatory FIV 
PCR testing is recommended. A negative FIV test result with either Anigen Rapid or 
Witness remains robustly reliable and is recommended as the screening test of choice, 
except in cases of recent infection, when repeat testing two months later is recommended 
(Levy et al., 2008a). 
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Results from sequential antibody testing in this study challenge our previous notion that 
p15 is more immunogenic than p24 and gp40 in the FIV vaccine. SNAP Combo (which 
detects antibodies to both p15 and p24) gave a seropositive result in 12/12 vaccinated cats 
from six weeks after the first FIV vaccination and all 12 cats remained FIV-positive for the 
duration of the study (34 weeks). Additionally, VetScan Rapid (which detects antibodies to 
p24 but not p15) tested seropositive in 12/12 vaccinated cats from six weeks after the first 
FIV vaccination and 10/12 (83%) remained seropositive at the end of the study. If the 
difference in performance between SNAP Combo and Anigen Rapid/Witness was solely 
attributable to p15 being more immunogenic in the FIV vaccine, then VetScan Rapid 
would have performed comparably well to Anigen Rapid or Witness in the current study. 
The differing performance of VetScan Rapid infers that the difference in kit performance 
may rely more on factors related to testing methodology (e.g. ELISA versus IC, the 
antibody threshold at which the test is set and how the capture antigen is prepared) than 
factors related to the FIV vaccine (i.e. immunogenicity of different epitopes). For this 
reason, care must be taken when selecting an appropriate antibody kit to avoid false-
positive results in FIV-vaccinated cats, and our findings cannot be extrapolated to other 
antibody kits without appropriate additional testing being performed. 
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5.6 CONCLUSION 
The complexity of antibody production following FIV vaccination was further described 
using both laboratory-based ELISA and an extended range of point-of-care test kits. 
Antibodies to p15, p24 and gp40 were detectable early (within four weeks of the first FIV 
vaccination) using various test kits. SNAP Combo and VetScan Rapid tested persistently 
positive for six months in cats given a primary course of FIV vaccination, while Anigen 
Rapid and Witness tested negative in all cats by six months following primary FIV 
vaccination. The limit of detection at which these antibody kits are calibrated appears to be 
the critical factor, since antibodies to gp40 (and likely p15 and p24) persist for at least 15 
months after FIV vaccination and kits that are biased towards sensitivity (e.g. SNAP 
Combo, VetScan Rapid) will detect these antibodies in addition to those produced by 
natural FIV infection. An advantage of Anigen Rapid and Witness over SNAP Combo and 
VetScan is that their detection of seropositivity following primary FIV vaccination is 
transient (up to six months), permitting annual testing for FIV infection prior to annual FIV 
vaccination boosters; although this must be balanced by the risk of missing early FIV 
infection and FIV infection in cats with low antibody production. 
Dr. Mark Edward Westman Faculty of Veterinary Science 
Thesis 2016 The University of Sydney 
142 
 
CHAPTER 6.  EFFECTIVENESS OF THE FIV VACCINE IN 
THE FIELD IN AUSTRALIA 
6.1 ABSTRACT 
A case-control field study was undertaken to determine the level of protection conferred to 
client-owned cats in Australia against FIV using a commercial vaccine (Fel-O-Vax FIV
®
). 
440 cats with outdoor access from five Australian states/territories underwent testing, 
comprising 139 potential cases (complete course of primary FIV vaccinations and annual 
boosters for three or more years), and 301 potential controls (age, sex and postcode 
matched FIV-unvaccinated cats). FIV status was determined using a combination of 
antibody testing (using point-of-care test kits) and PCR testing, as well as VI in cases 
where results were discordant and in all suspected FIV-vaccinated/FIV-infected cats 
(‘vaccine breakthroughs’). Stringent inclusion criteria were applied to both ‘cases’ and 
‘controls’; 89 FIV-vaccinated cats and 212 FIV-unvaccinated cats ultimately satisfied the 
inclusion criteria. Five vaccine breakthroughs (5/89; 6%), and 25 FIV-infected controls 
(25/212; 12%) were identified, giving a vaccine protective rate of 56% (95% CI -20 to 84). 
The difference in FIV prevalence rates between the two groups was not significant (P = 
0.14). Findings from this study raise doubt concerning the effectiveness of Fel-O-Vax 
FIV
®
 under field conditions. Screening for FIV infection may be prudent before annual 
FIV re-vaccination and for sick FIV-vaccinated cats. Owners should not rely on 
vaccination alone to protect cats against the risk of acquiring FIV infection; other measures 
such as cat curfews, the use of ‘modular pet parks’ or keeping cats exclusively indoors, are 
recommended. 
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6.2 INTRODUCTION 
An estimated 14.5 million pet cats are infected with FIV worldwide, and 33.5 million if 
feral cats are included (Yamamoto et al., 2007), which is similar to the estimated number 
(35 million) of individuals infected with HIV-1 globally (www.who.int/gho/hiv/en/). The 
FIV-cat model is advocated as a ‘test-bed’ for HIV infection and HIV-1 vaccine 
development, and Australia, which has one of the highest FIV prevalence rates in the world 
(8-15% in client-owned cats with outdoor access; 20-25% in feral cats), is an excellent 
setting to study FIV transmission and its prevention by vaccination (Malik et al., 1997; 
Norris et al., 2007; Chapter 2). 
To date, a total of 262 cats (139 FIV-vaccinated, 123 FIV-unvaccinated) have been tested 
using the current commercial FIV vaccine in laboratory-based efficacy studies (including 
105 cats from two pre-registration studies), with reported vaccine efficacy of between 0 
and 100%, and an overall preventable fraction of 66% (Huang et al., 2004; Kusuhara et al., 
2005; Pu et al., 2005; Dunham et al., 2006b; Yamamoto et al., 2007; Huang et al., 2010; 
Yamamoto et al., 2010; Coleman et al., 2014) (Table 6.1). Despite uncertain efficacy, 
millions of FIV vaccine doses have been sold worldwide, with no unequivocal ‘vaccine 
breakthroughs’ reported following in-field use in Australia (personal communication, Dr. 
Phillip McDonagh [Head of Regulatory Affairs for Animal Health, Boehringer Ingelheim 
Australia] and Dr. Elvira Currie [Australian Pesticides and Veterinary Medicines 
Authority]) or elsewhere (Yamamoto et al., 2007; Yamamoto et al., 2010). 
The aim of this study was to determine the ‘protective rate’ (effectiveness) for the Fel-O-
Vax FIV
®
 vaccine in the field in Australia. 
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Table 6.1 Summary of laboratory-based efficacy studies in which Fel-O-Vax FIV
®
 was given according to the manufacturer’s guidelines 
(three subcutaneous injections 2-4 weeks apart, followed by a single annual booster in the long-term studies). Experimental vaccine efficacy 
(preventable fraction) = ([percentage viraemia in controls – percentage viraemia in vaccinates] / percentage viraemia in controls) (Yamamoto 
et al., 2007). Studies where Fel-O-Vax FIV
®
 was modified before administration, where Fel-O-Vax FIV
®
 was administered via non-registered 
routes (e.g. intranasally) and where non-commercial vaccines (e.g. single subtype FIV vaccines) were trialed are excluded (with one 
exception, see notes beneath table). FDAH = the parent company that developed and registered Fel-O-Vax FIV
®
 (the FDAH vaccine range has 
since been acquired in Australia by BI). CID50 = cat infectious dose 50, which is equivalent to the amount of virus required to cause infection 
in half of susceptible subjects. IM = intramuscular, IV = intravenous. Origins of homologous challenges: FIVPet (A) = California, USA; FIVShi 
(D) = Shizuoka, Japan, FIVUK8 (A) = Glasgow, UK. Origins of heterologous challenges: FIVFD/US (A) = California, USA; FIVFC1 (B) = Florida, 
USA; FIVAo2 (B) (Aomori) = Aomori, Japan; FIVNZ1 (F’/C) = Auckland, New Zealand (prime sign represents that a full sequence of subtype F 
has yet to be identified)(Yamamoto et al., 2010); FIVFD/DutA (A) = Netherlands; FIVBang (A/B) = Massachusetts, USA. NA = not available. 
Author Challenge Virus, 
clade,  
% difference from 
vaccine env sequence  
(FIVPet and FIVShi)  
Source Dose           
(x CID50),   
route  
Time after 
final 
vaccination 
Viraemia in 
FIV-
vaccinated 
cats 
Viraemia in 
placebo 
controls 
Vaccine 
efficacy 
(Preventable 
fraction, %) 
Study 1 for USDA 
license approval
a
 
(Pu et al., 2005; 
Yamamoto et al., 2010) 
FIVFD/US, A, 9% and 
20% 
 
In vitro 
 
x 1.47, IM 
 
1 year 
 
9/27 (PCR) 
 
25/34 (PCR) 
 
55 
 
Study 2 for USDA 
license approval 
(Huang et al., 2004; 
Yamamoto et al., 2010) 
FIVFD/US, A, 9% and 
20% 
(overall 11% 
difference in sequence) 
In vitro x 1.79/11
b
, 
IM 
375 days 4/25 (PCR) 17/19 (PCR) 82 
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Pu et al., 2005 FIVFC1, B, 19% and 
19.2% 
In vivo x 15, IV 21 days 0/8 (VI) 9/9 (VI) 100 
Kusuhara et al., 2005 FIVAo2, B, 18.5% and 
19.6% 
In vitro Natural, 
biting 
21 days-19 
months 
0/6 (nested 
PCR) 
4/8 (nested 
PCR) 
100 
Dunham et al., 2006b FIVUK8, A, NA NA x 10, IM  28 days 5/5 (VI, RT-
PCR) 
6/6 (VI, RT-
PCR) 
0 
Pu et al., 2005; 
Yamamoto et al., 2007 
FIVFC1, B, 19% and 
19.2% 
NA x 100, IV 3-4 weeks ¾ 4/4 25 
Yamamoto et al., 2010 FIVFD/DutA, A, NA NA x 1.73, IM NA 3/24 13/15 86 
Pu et al., 2005; Huang et 
al., 2010 
FIVFC1, B, 19% and 
19.2% 
In vivo x 1000 
PMBC, IV 
54 weeks  4/14 (PCR, 
RT-PCR) 
5/5 (PCR, RT-
PCR) 
71 
Pu et al., 2005; Coleman 
et al., 2014 
(i) FIVBang, A/B, NA 
(ii) FIVFC1, B, 19% 
and 19.2% 
(iii) FIVFC1, B, 19% 
and 19.2% 
(iv) FIVNZ1, F’/C, NA 
In vivo 
In vivo 
In vivo 
In vivo 
NA, IV 
NA, IV 
NA (higher 
than [iii]), IV 
NA, IV 
3-4 weeks 
3-4 weeks 
3 weeks 
3-4 weeks 
3/4 (VI, PCR) 
0/8 (VI, PCR) 
7/9 (VI, PCR) 
3/5 (VI, PCR) 
4/4 (VI, PCR) 
4/4 (VI, PCR) 
5/5 (VI, PCR) 
10/10 (VI, 
PCR) 
25 
100 
22 
40 
TOTAL     41/139 106/123 66% 
a
Fel-O-Vax FIV
®
 used in the first trial for USDA (United States Department of Agriculture) approval was a slightly different version to what was eventually registered and 
released commercially
a
 (Uhl et al., 2002; Kusuhara et al., 2005). 
b
Conflicting CID50 doses are both presented
b
 (Huang et al., 2004; Yamamoto et al., 2010). 
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6.3 MATERIALS AND METHODS 
6.3.1 Sample population 
Criteria for recruitment were described in Chapter 3. Briefly, client-owned cats were 
recruited through veterinary clinics in Australia during 2013-15, most commonly at the 
same time as an annual health check or routine procedure (e.g. dental procedures). Two 
groups of cats were recruited: a FIV-vaccinated group (‘cases’) and a FIV-unvaccinated 
group matched to cases for age, sex and postcode (‘controls’). Cats in the FIV-vaccinated 
group had been FIV antibody-tested before FIV vaccination was commenced (unless 
younger than six months-of-age when first vaccinated, due to the low risk of FIV infection 
and the possibility of false-positive antibody results from maternal antibodies) (Callanan et 
al., 1991), given a primary course of three FIV vaccinations 2-4 weeks apart, and 
vaccinated annually against FIV for at least three years. Cats were excluded from the FIV-
vaccinated group if FIV nucleic acid amplification (PCR) testing had been performed 
instead of FIV antibody-testing before FIV vaccination was commenced (due to the PCR 
assay’s lower sensitivity) (Hartmann et al., 2007; Litster et al., 2012; Chapter 3), if any 
primary FIV vaccinations were more than two weeks overdue (i.e. greater than 6 weeks 
interval between vaccinations), and if any of the annual FIV vaccinations were more than 
three months overdue (i.e. greater than 15 months interval between vaccinations). Cats 
included in the FIV-unvaccinated group had never been given the FIV vaccine. Outdoor 
access was a requirement for cats in both groups. Information pertaining to outdoor access, 
as well as number of suspected cat fights based on medical records and owner recollection, 
was collected at the time of sampling via a questionnaire. Owners of cats meeting the 
criteria of either group were offered free FIV testing in return for enrolling their cat in the 
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study, and participating clinics were given free vaccines (FIV and/or non-FIV core 
vaccines) as an inducement, in return for their assistance recruiting cats. 
Animal ethics approval was granted by the University of Sydney (Approval number 
N00/1-2013/3/5920). 
6.3.2 Blood collection and determining FIV infection status 
Procedures for venipuncture, FIV antibody testing of EDTA blood using point-of-care test 
kits (SNAP FIV/FeLV Combo
50
, Witness FeLV/FIV
51
 and Anigen Rapid FIV/FeLV
52
 
concurrently), nucleic acid amplification of blood using a commercial PCR assay that 
detects proviral DNA and viral RNA by targeting a conserved region of the gag gene (FIV 
RealPCR)
53
, collection of blood for VI
54,55
 and final assignment of FIV status were 
described in Chapter 3. All FIV-vaccinated/FIV-infected cats (‘vaccine breakthroughs’) 
were confirmed by VI, RT assay and proviral PCR testing using primers targeting the env 
gene. For cats where FIV was isolated in cell culture, sequencing of the env product was 
performed and compared to sequences in GenBank to determine the clade of breakthrough 
FIV isolate.
56
 For all FIV-infected cats, FIV subtype was determined by FIV RealPCR 
testing using subtype-specific primer pairs for clades -A, -B, -D and -F 
(www.idexx.com.au/pdf/en_au/smallanimal/education/realpcr-test-for-fiv.pdf). 
6.3.3 Statistical analysis 
Sample size calculations were made using statistical software (Minitab 16
th
 Edition)
57
 
based on projected FIV prevalence rates of 3% and 16% in the FIV-vaccinated and FIV-
unvaccinated groups, respectively, and statistical power of 80%. A study design aiming for 
a 1:3 vaccinate (case) to control ratio was chosen to improve the power (Grimes and 
Schulz, 2005). Numerical analyses were performed at the conclusion of the study using 
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commercial software (Genstat 16
th
 Edition).
58
 Significance was considered at P < 0.05 and 
95% CIs were calculated using Microsoft Excel.
59
 Shapiro-Wilk tests were used to assess 
data for normality. When data was normally distributed, means were reported and a two-
sample t-test (two-sided) used (days between last FIV vaccination and sampling, 
breakthroughs versus FIV-uninfected cases; CT value from FIV RealPCR testing, 
breakthroughs versus controls). When data was not normally distributed, medians were 
reported and Mann-Whitney U-tests used (age, cases versus controls). Fisher’s exact tests 
(two-tailed) were used to investigate whether there was a significant difference in 
recruitment criteria (sex, breed, outdoor access and number of suspected cat fights) or FIV 
prevalence rate between the FIV-vaccinated and FIV-unvaccinated groups. Protective rate 
(PR; effectiveness) of the FIV vaccine was calculated using the formula, where OR is the 
odds ratio: 
PR = (1 – OR) x 100 
 
(Orenstein et al., 1985; Weinberg and Szilagyi, 2010; Marcus et al., 2015). 
                                                 
50
 IDEXX Laboratories, Westbrook, ME, USA. 
51
 Zoetis Animal Health, Lyon, France. 
52
 BioNote, Gyeonggi-do, Korea. 
53
 IDEXX Laboratories, East Brisbane, Queensland, Australia. 
54
 Yamamoto Laboratory, The University of Florida, Gainesville, FL, USA. 
55
 Veterinary Diagnostic Services, The University of Glasgow, Scotland, UK. 
56
 www.blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE_TYPE=BlastSearch 
57
 Minitab 16
th
 Edition for Windows, State College, PA, USA. 
58
 GenStat 16
th
 Edition for Windows, VSN International, Hemel Hempstead, United Kingdom. 
59
 Microsoft Excel 2010 for Windows, Microsoft, Redmond, WA, USA. 
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6.4 RESULTS 
6.4.1 Sample population 
Blood samples were obtained from 440 client-owned cats recruited from 13 clinics 
distributed over five jurisdictions within Australia (NSW, VIC, QLD, SA and ACT) 
(Tables 6.2.1 and 6.2.2). There were 139 FIV-vaccinated cats (cases) and 301 FIV-
unvaccinated cats (controls). 139 cats were excluded from further analysis for various 
reasons (Table 6.3). All cats recruited from VIC and QLD (n = 92) were excluded because 
FIV infection was not detected in any cats, removing the presumption of meaningful FIV 
exposure. 301 cats remained for final analysis (89 FIV-vaccinated, 212 FIV-vaccinated; 
case: control ratio of 1:2.4). 
6.4.1.1 Cases (n = 89) 
The 89 FIV-vaccinated cats recruited ranged from 3 to 18 years (median 8 years; IQR 5–11 
years). These cats comprised 46 castrated males and 43 spayed females. Most had been 
antibody-tested prior to vaccination (60/89; 67%), and a summary of the number of annual 
FIV vaccines administered to cases is provided in Table 6.4. All cats had been vaccinated 
against FIV within the previous 15 months (range 2 to 443 days; mean 224 days; IQR 141–
307 days). Most cats were described by their owner as having mainly day-time outdoor 
access (70/89; 79%), with fewer described as having unlimited outdoor access (17/89; 
19%) or mainly night-time outdoor access (2/89; 2%). The majority of cases were 
suspected of having been in at least one cat fight (64/89; 72%), with 36/89 (40%) involved 
in more than three fights (Table 6.5). 
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6.4.1.2 Controls (n = 212) 
The 212 FIV-unvaccinated cats ranged from 3 to 20 years (median 7 years; IQR 6–11 
years). The cats comprised 102 castrated males and 110 spayed females. 120 cats had 
mainly day-time outdoor access (120/212; 57%), 90 cats had unlimited outdoor access 
(90/212; 42%) and one cat had mainly night-time outdoor access (1/212; 0.5%). The 
majority of controls were suspected of having been in at least one fight (144/212; 68%), 
with 78/212 (37%) involved in more than three fights. 
Controls matched cases when age (P = 0.83), sex (P = 0.61), breed (P = 1.00) and number 
of fights (P = 0.58 for at least one fight) were compared between groups (Table 6.5). The 
only statistical difference between groups was in relation to outdoor access; cases were 
more likely than controls to have day-time only outdoor access, while controls were more 
likely to have unlimited outdoor access (P < 0.001). 
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Table 6.2.1 List of eight recruited veterinary clinics including clinic address and number of cats tested. 
Name of clinic Clinic details FIV-vaccinated cats recruited FIV-unvaccinated cats 
recruited Great Western 
Animal Hospital 
469 Great Western Hwy, Pendle Hill NSW 
2145 
(02) 9631 9322 
19 75 
Elizabeth Drive 
Animal Hospital 
Cnr Elizabeth Drive and Woodlands Rd, 
Liverpool NSW 2170 
(02) 9602 7018 
19 23 
Campbelltown 
Animal Hospital 
15 Chamberlain St, Campbelltown NSW 2560 
(02) 4626 4222 
13 20 
Inner South 
Veterinary Hospital 
47 Jerrabomberra Ave, Narrabundah ACT 2604 
(02) 6295 0770 
12 15 
Bankstown 
Veterinary Hospital 
14 Marshall St, Bankstown NSW 2200 
(02) 9790 1101 
11 27 
Fulham Gardens 
Veterinary Surgery 
441 Tapleys Hill Rd, Fulham Gardens SA 5024 
(07) 8355 5475 
10 26 
Casula Veterinary 
Hospital 
674 Hume Hwy, Casula NSW 2170 
(02) 9602 9863 
5 12 
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Mt Annan 
Veterinary Hospital 
17/2-4 Main St, Mt Annan NSW 2567 
(02) 4647 7722 
0 (used to recruit controls for 
Campbelltown Animal 
Hospital) 
14 
TOTAL:  89 212 
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Table 6.2.2 List of five veterinary clinics excluded owing to an absence of FIV infection in controls (first three clinics) or an inability to 
appropriately match cases to controls (last two clinics), including clinic address and number of cats tested. 
Name of clinic Clinic details Number of cats excluded 
Newtown Veterinary Clinic 121 West Fyans St, Newtown VIC 3220 
(03) 5221 5333 
48 
The Cat Clinic 189 Creek Road, Mt Gravatt, QLD 4122 
(07) 3349 0811 
38 
Kardinia Veterinary Clinic 355 Moorabool St, Geelong VIC 3220 
(03) 5221 5122 
6 
Sydney Animal Hospital 
(Inner West) 
1A Northumberland Ave, Stanmore NSW 2048  
(02) 9516 1466 
3 
Sylvania Veterinary Hospital 335 Princes Hwy, Sylvania NSW 2224 
(02) 9522 7088 
1 
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Table 6.3 Summary of reasons for excluding 139 cats from the final analysis.  
Reason for exclusion Total no. of cats (n = 139) 
 FIV-vaccinated  
(n = 49) 
FIV-unvaccinated  
(n = 90) 
FIV not found in vaccinates or controls (VIC) 14  
 
40 
FIV not found in vaccinates or controls (QLD) 12  
 
26 
No outdoor access 6 5 
FIV vaccinations not given according to 
current manufacturer guidelines 
10 NA 
Unable to match control to vaccinate (either 
neutering status or postcode) 
NA 8
a
 
 
More than two cats sampled from same 
household 
3 4 
Too young 1 6 
FIV PCR testing performed instead of FIV 
antibody testing prior to vaccination 
3
b
  
 
NA 
Questionnaire not completed and unable to 
contact owner 
0 1 
NA = not applicable. 
a
including one FIV-infected, entire male cat. 
b
including one FIV-infected cat # 19; see Table 6.7 for a more detailed explanation. 
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Table 6.4 Summary of number of annual FIV vaccinations received by FIV-vaccinated 
cats (cases) recruited for the study and included in the final analysis (n = 89). The FIV-
vaccinated/FIV-infected cats (vaccine breakthroughs) are identified in brackets.  
Years vaccinated/potentially 
exposed to FIV 
Total no. of FIV-
vaccinated cats          
(n = 89) 
No. of FIV-infected cats 
(vaccine breakthroughs;  
n = 5) 
3 15 1 (# 415) 
4 28 1 (# 106) 
5 24 0 
6 9 2 (# 1, # 404) 
7 12 1 (# 152) 
8 1 0 
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Table 6.5: Summary of criteria used to match controls to cases. All cats recruited had been 
neutered. All control cats sampled lived in the same or an adjacent postcode to the 
matching cases. Only level of outdoor access was statistically significant between groups; 
cases were more likely than controls to have day-time only outdoor access, while controls 
were more likely to have unlimited outdoor access (P < 0.001)
a
. Number of suspected cat 
fights was estimated using a combination of medical records and owner recollection.  
Category FIV-vaccinated  
(Cases) (n = 89) 
FIV-unvaccinated 
(Controls) (n = 212) 
Total age range (years) 3–18 3–20 
Age IQR (years) 5–11 6–11 
Male : female ratio 52 : 48  48 : 52 
Proportion of domestic crossbred 
cats (%) 
88 88 
Outdoor access ‘mainly day-time’ 
(%) 
a
 
79 57 
Outdoor access ‘mainly night-time’ 
(%) 
2 0.5 
Outdoor access ‘unlimited’ (%) a 19  42 
‘0’ cat fights (%) 28 32 
‘1’ cat fight (%) 16 16 
‘2’ cat fights (%) 11 9 
’3’ cat fights (%) 4 6 
‘More than 3’ cat fights (%) 40 37 
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6.4.2 FIV testing 
6.4.2.1 Cases (n = 89) 
The prevalence of FIV infection in the FIV-vaccinated cohort was 6% (5/89). The five 
FIV-vaccinated/FIV-infected cats were 6 to 8 years-of-age, comprising four castrated 
males and one spayed female. Of these vaccine breakthroughs, 4/5 had received their first 
vaccination when they were older than six months-of-age, and thus had been FIV antibody-
tested before vaccination commenced; the fifth cat (# 404) was 16 weeks-of-age when first 
vaccinated and antibody-testing had therefore not been performed. A summary of cat fight 
incidents requiring veterinary intervention, in relation to timing of FIV vaccination, is 
provided in Table 6.6. 
Subtyping results from both VI and FIV RealPCR testing for the five vaccine 
breakthroughs are presented in Table 6.7. FIV subtype A infection was identified in all 
cases. None of the five cats were co-infected with other clades of FIV. The mean CT value 
from FIV RealPCR testing for vaccine breakthroughs was 31.1. 
Two additional cats that were possible vaccine breakthroughs were excluded from further 
analysis because they did not meet the strict inclusion criteria. Information for these two 
cats is provided below, and subtyping results from virus isolation and FIV RealPCR testing 
is provided in Table 6.8. 
(i) Cat (case) # 10 tested FIV-negative during the study and was re-tested 2.5 years later at 
the request of the attending veterinarian and owner following a chronic history of weight 
loss, lethargy and diarrhoea. On this second occasion of FIV testing this cat tested FIV-
positive with all three point-of-care antibody test kits, FIV-negative with PCR testing and 
FIV-positive with VI. The annual FIV vaccine had not been administered in the year 
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following initial recruitment for the study and only recommenced four months prior to 
testing FIV-positive with VI (26 months interval between last annual FIV vaccination and 
recommencing primary course of FIV vaccinations). No FIV testing was performed before 
FIV vaccination was recommenced. The cat was ultimately euthanased due to suspected 
disseminated intestinal lymphoma that was non-responsive to chemotherapy. 
(ii) Cat (case) #19 was excluded from the study since it had received an incomplete 
primary course of FIV vaccinations; FIV PCR testing was performed approximately 12 
months later (negative result), and then FIV vaccinations recommenced. Five annual FIV 
vaccines were given before this cat was sampled for the present study. One month 
following the first annual FIV vaccine this cat presented with spinal pain, mild pyrexia 
(39.3
0
C) and hyperaesthesia due to suspected bacterial meningitis which responded to 
treatment with clindamycin. 
6.4.2.2 Controls (n = 212) 
The FIV prevalence rate in the FIV-unvaccinated cohort was 12% (25/212). The 25 FIV-
unvaccinated/FIV-infected cats ranged from 3 to 16 years-of-age (median 7 years; IQR 5–
10 years), comprising 18 castrated males and 7 spayed females. FIV RealPCR testing 
identified two subtypes (i.e. co-infection) in over half of FIV-infected controls (13/25; 
52%). FIV subtype A infection was most common (20/25 cats; 80%), followed by subtype 
F (5/20 cats; 25%) and subtype D (4/25 cats; 16%) (Table 6.9). The mean CT value from 
FIV RealPCR testing for FIV-infected controls was 31.0 (using the lower CT value when 
two subtypes were identified simultaneously in the same cat). 
There was no significant difference in age or CT value from FIV RealPCR testing when 
FIV-infected cases and controls were compared (P = 0.54 and 0.89, respectively). 
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6.4.3 Vaccine effectiveness (protective rate) 
A summary of results by clinic and group (FIV-vaccinated versus FIV-unvaccinated) is 
provided in Table 6.10. The overall protective rate for Fel-O-Vax FIV
®
 was 56% (95% CI 
-20 to 84). The difference in FIV prevalence rates between the two groups (i.e. 5/89; 6% 
versus 25/212; 12%) failed to reach significance (P = 0.14). 
A post hoc power analysis identified that the higher than predicted rate of FIV infection in 
cases and lower rate of FIV infection in controls reduced the power to detect a significant 
difference between groups to 40%. Had the intended 1:3 vaccinate (case) to control ratio 
been achieved, the power to detect a significant difference between groups would have 
only increased to 43%. When the entire data set (n = 440) was analysed (i.e. including the 
cats excluded as not meeting the stringent criteria), the protective rate was 52% (95% CI 0 
to 81), and there was no appreciable impact on the difference in FIV prevalence between 
groups (6/139; 4.3% v 26/301; 8.6%; P = 0.12). Given the prevalence rates reported in the 
current study, to have achieved a statistically significant effect of the vaccine (assuming 
one exists) with power of 80% and 1:3 case to control ratio would have required 207 FIV-
vaccinated cats and 621 matching FIV-unvaccinated controls. 
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Table 6.6 FIV vaccination and suspected cat fight history (based on retrieved medical records only) of the five vaccine breakthroughs. Ab = 
FIV antibody test, Y = yes, N = no, P = primary vaccine, A = annual vaccine, d = days since last vaccination, m = months since last 
vaccination. P1 (first primary FIV vaccine) is taken as time = 0. Fight history (requiring veterinary intervention and verified using clinic 
medical records) is displayed as the time elapsed since the previous vaccination when the fight occurred. A negative symbol (cat # 415) 
indicates the fights occurred before FIV vaccinations had commenced. Cat # 106 did not have any fight history
a
. As per the manufacturer’s 
guidelines, antibody-testing was not performed prior to commencing FIV vaccination in kittens less than six months-of-age at the time of the 
first vaccination (cat # 404). 
Cat (case) 
no. 
 Ab P1 P2 P3  A1  A2  A3  A4  A5  A6 A7 
# 1 
FIGHT 
HISTORY 
 Y 0d 21d 21d  12m  
9m 
11m  11m  
8m 
14m  12m  
5m 
13m - 
# 106 
FIGHT 
HISTORY
a
 
 Y 0d 14d 14d  12m  8m  14m  12m   
- 
  
- 
 
- 
# 152 
FIGHT 
HISTORY  
 Y 0d 12d 18d  11m  11m  11m  
7m 
11m  
11m 
12m  12m 12m 
 
# 404 
  
N 
 
0d 
 
14d 
 
21d 
 
 
 
11m 
  
12m 
  
12m 
  
13m 
  
12m 
  
12m 
 
- 
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FIGHT 
HISTORY 
3m 
# 415 
FIGHT 
HISTORY 
 
-48d, 
-156d 
Y 0d 27d 29d  15m  
9m 
12m  
7m 
12m   
- 
  
- 
  
- 
 
- 
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Table 6.7 FIV env sequencing results following virus isolation and subtyping results from 
FIV RealPCR testing for the five vaccine breakthroughs. 
Cat (case) no. Subtyping results (VI) Subtyping results  
(FIV RealPCR), CT 
# 1 (FIV-vaccinated) FIV-Dixon (A) FIV-A, 31.7 
# 106 (FIV-vaccinated) FIV-Sendai 1 (A) FIV-A, 32.0 
# 152 (FIV-vaccinated) FIV-Dixon (A) FIV-A, 29.7 
# 404 (FIV-vaccinated) FIV-UK8 (A) FIV-A, 31.5 
# 415 (FIV-vaccinated) FIV-Dixon (A) FIV-A, 30.5 
Env sequences were compared to stored sequences in GenBank to determine subtype. The FIV RealPCR 
assay includes primer pairs for FIV subtypes –A, -B, -D and –F. 
 
Table 6.8 Subtyping results for two possible additional vaccine breakthroughs. 
Cat (case) no. Subtyping results (VI) Subtyping results  
(FIV RealPCR), CT 
# 10 (excluded) FIV-FD Sydney (A) Negative 
# 19 (excluded) FIV-Sendai 1 (A) FIV-A, 32.2 
Env sequences were compared to stored sequences in GenBank to determine subtype. The FIV RealPCR 
assay includes primer pairs for FIV subtypes –A, -B, -D and -F. 
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Table 6.9 Subtyping results from FIV RealPCR testing for 25 FIV-unvaccinated cats 
(controls). 
FIV subtype Frequency 
FIV A only 11/25 = 44% 
FIV B only 0 
FIV D only 0 
FIV F only 1/25 = 4% 
FIV A/F 9/25 = 36% 
FIV D/F 4/25 = 16% 
Primers pairs for FIV subtypes -A, -B, -D and -F were included in the PCR reaction. VI was not performed 
for FIV-infected controls. 
 
Table 6.10 FIV prevalence by veterinary clinic (n = 301). In total, 89 FIV-vaccinated cats 
and 212 FIV-unvaccinated cats were recruited. GWAH = Great Western Animal Hospital, 
EDAH = Elizabeth Drive Animal Hospital, CAH = Campbelltown Animal Hospital, 
MAVH = Mt Annan Veterinary Hospital, ISVH = Inner South Veterinary Hospital, BVH = 
Bankstown Veterinary Hospital, FGVS = Fulham Gardens Veterinary Surgery, CVH = 
Casula Veterinary Hospital. CAH and MAVH were pooled together as they are located in 
adjacent suburbs and cats recruited were from the same area. Cats excluded from final 
analysis (n = 139) are not shown. The difference in FIV prevalence rates between groups 
did not reach statistical significance using a Fisher’s exact test (P = 0.14). 
Veterinary Clinic FIV prevalence                         
(FIV-vaccinated cats) 
FIV prevalence                  
(FIV-unvaccinated cats) 
GWAH (NSW) 1/19 = 5% 8/75 = 11% 
EDAH (NSW) 1/19 = 5% 2/23 = 9% 
CAH/MAVH (NSW) 0/13 = 0% 4/34 = 12% 
ISVH (ACT) 1/12 = 8% 1/15 = 7% 
BVH (NSW) 2/11 = 18% 5/27 = 19% 
FGVS (SA) 0/10 = 0% 3/26 = 12% 
CVH (NSW) 0/5 = 0% 2/12 = 17% 
TOTAL 5/89 = 6% 25/212 = 12% 
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6.5 DISCUSSION 
The nominal protective rate for Fel-O-Vax FIV
®
 in this study, the first field trial conducted 
for this vaccine anywhere in the world, was 56%. Five confirmed vaccine breakthroughs 
were detected, as well as two additional cases which became FIV-infected but where there 
were lapses in timing of vaccine administration. The FIV vaccine was shown not to 
significantly reduce the risk of client-owned cats becoming infected with FIV, although 
there was a trend for some protection. Owners wanting to prevent their cat acquiring FIV 
infection should consider measures in addition to vaccination, such as cat curfews, 
‘modular pet parks’ or keeping their cat(s) exclusively indoors. Cats vaccinated against 
FIV should undergo annual testing prior to booster FIV vaccination, e.g. using a Witness 
FeLV/FIV or Anigen Rapid FIV/FeLV antibody test kit (Chapter 3), to check infection has 
not occurred in the preceding year. 
The benefit of field studies is that they involve natural challenge in terms of dose, route, 
and type (i.e. a selection of genetically different viruses, with a range of pathogenicities 
and env sequences). There are, however, some disadvantages to field studies compared to 
experimental studies for evaluating vaccine effectiveness. The frequency and extent of 
viral challenge cannot be predicted, since challenge relies on bite(s) from FIV-infected 
cat(s) (hence use of the terms ‘vaccine protective rate’ and ‘effectiveness’ for the current 
study, instead of ‘preventable fraction’ and ‘efficacy’). It is possible (based on the FIV 
prevalence rate in controls) that many of the FIV-uninfected cats in the study were never 
exposed to FIV, although the retrospective quantification of cat fight incidents documents 
at least possible exposure for many cats. The need to exclude cats recruited from VIC and 
QLD due to an absence of FIV infection in controls was surprising considering previous 
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studies, including a large recent serosurvey from Australia documenting FIV prevalence 
rates of 10-16% in healthy client-owned cats in these states (Chang-Fung-Martel et al., 
2013; Chapter 2). Differences in housing conditions and lifestyles between groups was 
unavoidable (e.g. amount of time spent outdoors). Thus despite our best efforts to match 
controls to cases on the basis of age, sex and postcode it is possible there was some 
mismatch in relation to level of exposure to FIV between groups. Since this was a 
retrospective field study, there were no housing restrictions to eliminate the risk of 
exposure to FIV during the primary course of FIV vaccination. Furthermore, it was 
impossible to determine when cats became FIV-infected (cases or controls), and it was also 
impossible to ensure controls were FIV-negative at the start of the study period with 
antibody-testing (as was done for vaccinates). This may have introduced a slight bias 
towards the FIV vaccine showing a protective effect, although this seems unlikely, given 
the comparable FIV seroprevalence in the control group to previous Australian studies 
(Malik et al., 1997; Norris et al., 2007; Chapter 2).  
Medical records of the five FIV-vaccinated/FIV-infected cats suspected of representing 
vaccine breakthroughs were scrutinized to investigate the prospect that some vaccine 
breakthroughs occurred before the primary course of FIV vaccination had been completed. 
No cats had received veterinary treatment for possible cat fight wounds during the primary 
course of FIV vaccination (Table 6.6). Cat # 415, when one year-of-age, was in a 
suspected cat fight 48 days prior to FIV antibody testing (SNAP FIV/FeLV Combo) and 
commencement of the primary course of FIV vaccination. Most cats produce detectable 
antibodies to FIV within four weeks of experimental inoculation (O'Connor et al., 1989; 
Fevereiro et al., 1991), although in rare cases this response may be delayed (Yamamoto et 
al., 1988). Consequently, current recommendations are to retest cats with possible recent 
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retrovirus exposure after 56 or 60 days (Barr, 1996; Levy et al., 2008a). It is therefore 
possible this cat was already infected before FIV vaccination commenced. In retrospect, it 
would have been helpful to have retested this cat (antibody and/or PCR testing) (Chapter 3) 
at the end of the primary course of FIV vaccination to investigate this possibility. Given 
the short duration of time in relation to the overall study period (12 weeks versus minimum 
156 weeks) and the ages of these five cats when first vaccinated (all one year-of-age or 
younger) we think it unlikely that vaccine breakthroughs occurred during the primary 
course of FIV vaccination. This is because young cats lack confidence and are thus less 
inclined to fight than older cats; they are therefore much less likely to be FIV-infected than 
a mature, territorial cat older than three years (Chapter 2). In addition, we contend that 
owners are less likely to allow prolonged periods of outdoor access to kittens (< 6 months-
of-age), reducing further the possibility of FIV exposure in the one breakthrough cat that 
was vaccinated as a kitten (# 404). 
The exact mechanism(s) by which the FIV vaccine provides sterilizing immunity against 
certain subtypes is still unclear. In experimental studies, protection appeared to rely on 
both cell-mediated and antibody-mediated immunity (Uhl et al., 2002; Coleman et al., 
2014). Humoral immunity, specifically the production of antibodies directed against the 
hypervariable V5 region of the FIV envelope, is important for homologous challenge (Uhl 
et al., 2002; Yamamoto et al., 2007; Hosie et al., 2011). Passive-transfer studies (using 
pooled serum from FIV-vaccinated cats) have consistently conferred good protection 
against homologous (FIVPet) challenge, but not heterologous (FIVFC1) challenge 
(Yamamoto et al., 2010; Coleman et al., 2014). In contrast, CMI is important for both 
homologous and heterologous challenge (Uhl et al., 2002; Yamamoto et al., 2007; Hosie et 
al., 2011). T-cell responses likely important in CMI include T-helper 1 activity mediated 
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by specific cytokines (IL-2 and IFNɣ), as well as cytotoxic lymphocyte activity, in 
particular the increased production of the cytotoxic-effector molecule perforin (Omori et 
al., 2004). Adoptive-transfer studies (using B-cell depleted, T-cell enriched preparations 
from MHC-matched FIV-vaccinated donor cats) have demonstrated good protection 
against both homologous (FIVPet) and heterologous (FIVFC1 and FIVNZ1) challenge. 
Accordingly, it is believed that CMI is more critical for protection against FIV than 
humoral immunity (Yamamoto et al., 2007; Yamamoto et al., 2010; Coleman et al., 2014). 
The importance of CMI in providing protection against FIV was shown again recently in 
adoptive-transfer studies which found increased cytokine, cytolysin (perforin) and cytoxin 
production in donor cats that conferred protection, with the researchers concluding that 
efforts should be focused on developing a T-cell based FIV (and HIV) vaccine (Aranyos et 
al., 2016). The failure of the FIV vaccine to protect against multiple strains of subtype A in 
the current study (as well as in other studies involving homologous challenge with FIVUK8 
(Dunham, 2006a; Dunham et al., 2006b), but possible protection against subtypes D and F, 
supports the notion that any sterilizing protection induced by the FIV vaccine is reliant 
predominantly on CMI rather than antibody-based immunity. 
The release of the FIV vaccine in 2002 was the culmination of ten years of collaborative 
work and heralded as a triumph of veterinary vaccinology. Many approaches to FIV 
vaccine design were tried, including IWC, IWV, recombinant (e.g. p24), gene-deletion, 
vector-based and DNA-based vaccines, formulated with a range of adjuvants and 
administered in different prime and boost protocols (Uhl et al., 2002; Yamamoto et al., 
2007; Yamamoto et al., 2010; Bienzle, 2014). Vaccinating cats against FIV using an IWC 
vaccine was found to induce higher VNA levels than a IWV vaccine, although the duration 
of protection following IWC vaccination may be shorter (Uhl et al., 2002). The prototype 
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FIV vaccine, which contained only IWV (no IWC), outperformed the commercial FIV 
vaccine in several studies (Pu et al., 2001; Yamamoto et al., 2010; Coleman et al., 2014). 
Ultimately, the lower production cost of IWC over IWV led to the compromise of the 
combined IWC/IWV formulation in Fel-O-Vax FIV
®
 (Yamamoto et al., 2010).  
The identification of five vaccine breakthroughs, and a further two equivocal cases, casts 
doubt over the ability to induce solid protection against an immunodeficiency virus 
through vaccination and is a setback in the quest to develop a uniformly effective HIV-1 
vaccine. Research is already underway towards the development of a FIV epitope vaccine 
targeting T-cell immunity (Yamamoto et al., 2010). It is possible that for both FIV and 
HIV-1, sterilizing immunity is unattainable. A more realistic aim might be a vaccine that 
reduces viral load to a level that delays or prevents the onset of clinical signs (Hosie and 
Beatty, 2007). If the aim of FIV vaccine development shifts from sterilizing to protective 
immunity, like the core vaccines against feline calicivirus and feline rhinotracheitis, then 
future research will need to focus on reduction of FIV-associated disease in vaccinated 
individuals rather than the prevention of infection. 
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6.6 CONCLUSION 
A field study into the effectiveness of a commercial FIV vaccine determined a protective 
rate of 56% in client-owned Australian cats and documented the first convincing in-field 
vaccine breakthroughs. FIV infection rate was not significantly different between FIV-
vaccinated and FIV-unvaccinated cats, although there was a trend for some protection. The 
result is disappointing for veterinarians wanting to use the vaccine in high risk situations, 
as well as for researchers working on developing a HIV-1 vaccine, but is a reminder of the 
difficulties associated with vaccinating against any Lentivirus. Recently, the World Small 
Animal Veterinary Association upgraded the FIV vaccine classification from ‘Not 
Recommended’ to ‘Non-Core’, a change which may encourage more veterinarians to 
administer this vaccine 
(www.wsava.org/sites/default/files/WSAVA%20Vaccination%20Guidelines%202015%20
Full%20Version.pdf). We recommend FIV-vaccinated cats should undergo annual testing 
to ascertain whether they are still FIV-uninfected before administering the booster FIV 
vaccine, with testing commencing at the end of the primary course of FIV vaccination, to 
check infection has not already occurred. Complete protection from FIV infection is only 
possible by eliminating FIV exposure through the use of ‘modular pet parks’ or keeping cat 
exclusively indoors. Further research needs to be conducted where the FIV vaccine is 
available, FIV prevalence is high and other FIV subtypes are present (e.g. Taiwan, Japan) 
to establish the protective rate of Fel-O-Vax FIV
®
 against the full range of FIV subtypes. 
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CHAPTER 7.  DIAGNOSIS OF FeLV INFECTION IN THE 
DOMESTIC CAT USING BLOOD AND SALIVA 
7.1 ABSTRACT 
FeLV can be a challenging infection to diagnose due to a complex feline host-pathogen 
relationship and occasionally unreliable test results. This study compared the accuracy of 
three point-of-care FeLV antigen test kits commonly used in Australia and available 
commercially worldwide (SNAP FIV/FeLV Combo, Witness FeLV/FIV and Anigen Rapid 
FIV/FeLV), using detection of FeLV provirus by an in-house qPCR assay as the diagnostic 
gold standard. Blood (n = 563) and saliva (n = 419) specimens were collected from a 
population of cats determined to include 491 FeLV-uninfected and 72 FeLV-infected 
individuals (45 progressive infections, 27 regressive infections). Sensitivity and specificity 
using whole blood was 63% and 94% for SNAP FIV/FeLV Combo, 57% and 98% for 
Witness FeLV/FIV, and 57% and 98% for Anigen Rapid FIV/FeLV, respectively. SNAP 
FIV/FeLV Combo had a significantly lower specificity using blood compared to the other 
two kits (P = 0.004 compared to Witness FeLV/FIV, P = 0.007 compared to Anigen 
Rapid). False-positive test results occurred with all three kits using blood, and although 
using any two kits in parallel increased specificity, no combination of test kits completely 
eliminated the occurrence of false-positive results. We therefore recommend FeLV 
provirus PCR testing for any cats testing positive with a point-of-care FeLV antigen test 
kit, as well as for any cat that has been potentially exposed to FeLV but tests negative with 
a FeLV antigen kit, before final assignment of FeLV status can be made with confidence. 
For saliva testing, sensitivity and specificity was 52% and 100%, respectively, for all three 
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test kits. The reduced sensitivity of saliva testing compared to blood testing suggests saliva 
testing is unsuitable for screening large populations of cats, such as in shelters. 
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7.2 INTRODUCTION 
Antigen testing (including ELISA, IC and IFA methodologies) has been used for over 40 
years to detect cats with progressive FeLV infections using whole blood, plasma or serum 
as the diagnostic specimen. As qPCR has become the new gold standard for FeLV 
diagnosis, replacing VI (which was never available to veterinarians in the field) and IFA 
(Lutz et al., 2009), a contemporary investigation of the most commonly used rapid FeLV 
antigen test kits using whole blood (the preferred specimen for patient-side testing) and 
considering the current complexity of FeLV infection categories, is overdue. Furthermore, 
to the author’s knowledge, none of the latest generation of rapid FeLV antigen kits have 
been evaluated using saliva. 
The aim of this study was to compare the performance of the three most commonly used 
rapid FeLV test kits in Australia to diagnose FeLV infection, using qPCR testing on blood 
to detect FeLV provirus as the gold standard, using both whole blood and saliva as 
diagnostic specimens. 
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7.3 MATERIALS AND METHODS 
7.3.1 Sample population 
A total of 563 cats were recruited, comprised of three distinct groups: (i) Group 1 (n = 
440) consisted of healthy client-owned cats that were part of a case-control study into the 
effectiveness of a commercially available FIV vaccine, and contained both FIV-vaccinated 
and FIV-unvaccinated cats (Chapter 6); ii) Group 2 (n = 72) consisted of cats that had 
blood sent to our laboratory
60
 for FeLV testing to either confirm a positive in-clinic or 
laboratory microwell
61
 FeLV antigen result (n = 53), to further investigate haematologic 
abnormalities (most commonly non-regenerative anaemia), sent either directly by the 
attending clinician or referred by a commercial New South Wales veterinary laboratory
62
 
(n = 13) or to test cats that had been in-contact with a progressively FeLV-infected cat 
during the previous 12 months (n = 6); and (iii) Group 3 (n = 51) consisted of semi-feral 
cats housed at a rescue facility in western Sydney that were tested in response to recent 
unexplained deaths. The age of some cats in group 3 was undeterminable. 
Recruited cats across all three groups ranged from 3 months to 20 years-of-age (median 7 
years; IQR 5-10 years; age data available for 522 cats). These cats comprised 289 (51%) 
castrated males, 262 (47%) spayed females, 8 (1%) entire males and 4 (0.7%) entire 
females. Most were domestic crossbred cats (485/563; 86%), the remainder comprised a 
range of pedigree breeds.  
7.3.2 Blood collection, DNA extraction and real-time PCR (qPCR) testing 
Blood was collected by jugular or cephalic venipuncture from conscious cats, as described 
in Chapter 3. DNA was extracted from whole EDTA blood using a kit (QIAamp DNA 
Mini Kit)
63, as per manufacturer’s instructions. The concentration and quality of extracted 
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DNA was measured using a spectrophotometer (Nanodrop 1000)
64
. DNA was stored at -
80
o
C. 
PCR testing for FeLV provirus was chosen as the gold standard for the current study. PCR 
testing was performed according to a published protocol, using primers designed to 
amplify a 131 bp section of the unique region (U3) of the LTR of all three subtypes of 
FeLV (-A, -B and -C), but not endogenous retroviral sequences (Tandon et al., 2005). Each 
25 µL PCR reaction was composed of 0.125 µL Taq DNA polymerase
63
, 2.5 µL 10x PCR 
Buffer
63
, 0.5 µL 10 mM dNTP mix, a final concentration of 480 nM of each primer
65
, 160 
nM of a dual-labelled fluorogenic probe (labelled at the 5’ end with the fluorescent reporter 
dye FAM [6-carboxyfluorescein] and at the 3’ end with the fluorescent quencher dye Black 
Hole Quencher-1
TM
)
65
, 3 µL of DNA (approximately 100 ng), and nuclease-free water. 
Following 15 min of denaturation at 95
o
C, 45 cycles of 95
o
C for 15 s and 60
o
C for 60 s 
were carried out. PCR reactions were performed using a Bio-Rad CFX96
TM
 Real-Time 
System Thermocycler PCR machine
66
, and fluorescence was detected during each 
annealing step (60
o
C) at 515-530 nm. All samples were run in duplicate. Known positive 
and negative FeLV samples were included as internal controls in each run, as well as a ‘no 
template’ control. Any sample with two CT values less than 45 was recorded as a positive 
result. Any sample with two CT values greater than 45 was recorded as a negative result. 
Samples with mixed CT values (i.e. one CT < 45 and one CT > 45) were re-run in 
quadruplicate, with a positive result assigned if a sample recorded two or more CT values 
less than 45 in the second run, and a negative result assigned if a sample recorded three or 
four CT values greater than 45. Nine samples declared PCR positive following sample 
testing in quadruplicate had amplicons sequenced and BLAST searches performed in 
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Genbank
®
 to confirm they were genuine FeLV sequences (93–99% alignment with FeLV 
strain Glasgow-1 accession number KP728112.1). 
Construction and production of a FeLV DNA standard for absolute quantitation of the PCR 
assay (precision and sensitivity) was done by molecular cloning. Firstly, PCR 
amplification using DNA from a known progressively FeLV-infected cat (i.e. positive 
control) and the aforementioned cycling conditions was performed, the product run on a 
2% agarose gel for 60 min at 100 V and the product cut out with a scalpel and purified 
(Qiaquick Gel Extraction Kit)
63
. The purified product was cloned into a vector (pCR2.1-
TOPO
®
, 3931 bp)
64
 and grown in E. coli cells (Rapid One Shot
®
)
64
, the transformed cells 
plated onto kanamycin infused SBA plates and the plates incubated overnight at 37
o
C. The 
following day, PCR testing was performed on a selection of colonies using FeLV primers 
and M13 primers, the latter that amplify a section of the plasmid containing the inserted 
PCR product. The products were run on a 2% agarose gel for 60 min at 100 V to confirm 
the presence of the expected amplicons (131 bp for the FeLV primers, 375 bp for the M13 
primers) and the colonies representing the most intensely staining bands subcultured onto 
new kanamycin infused SBA plates and incubated overnight at 37
o
C. The following day, 
PCR testing using both sets of primers and gel electrophoresis were repeated, the six 
colonies representing the most intensely staining bands used to inoculate kanamycin 
infused liquid LB and the cultures placed in a shaking incubator overnight at 37
o
C. DNA 
was then extracted by performing plasmid extraction on each culture (Plasmid Spin 
Miniprep Kit)
63
, spectrophotometer readings were taken to assess DNA quality and 
quantity, and PCR analysis using both sets of primers and gel electrophoresis were 
repeated. Finally, amplicon sequencing and BLAST searches in Genbank
®
 were performed 
to ensure the extracted plasmid contained the same FeLV sequence as the initial PCR 
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product (99% alignment with FeLV strain Glasgow-1 accession number KP728112.1). The 
six DNA standards were stored at -20
o
C. 
Within-run and between-run precision of the FeLV qPCR assay were assessed using three 
dilutions of the DNA standard (10
3
, 10
5
 and 10
7
 molecules per reaction, as determined by 
the average of four spectrophotometer readings (Nanodrop 1000)
64
 and standard 
calculation involving Avogadro’s constant (see below). Within-run precision was 
evaluated with 10 replicates of each dilution, and between-run precision was evaluated 
using 10 replicates of each dilution in three separate experiments. For both, mean CT value 
and standard deviation (SD) were used to calculate coefficients of variation (CV) for the 
CT values (CV = SD / mean CT). Diagnostic sensitivity for the PCR assay was determined 
by 10-fold serial dilutions of the DNA standard. Mean within-run and between-run 
precisions (CV) were both 0.66% (within-run 0.54–0.8%, between-run 0.45–0.85%), while 
the lower limit of detection for the assay was 100 copies of DNA standard per 25 µL 
reaction (10 out of 10 reactions positive). For the next lower dilutions (90, 80, 70, 60, 50 
and 40 copies per 25 µL reaction), 9/10, 7/10, 4/10, 5/10, 4/10 and 5/10 reactions were 
positive, respectively. 
Number of copies (molecules) = A x (6.0221 x 10
23
 molecules/mole)  
                  _____________________________ 
         B x 660g/mole x (1 x 10
9
 ng/g) 
A = amount of plasmid per reaction (64.95 ng, based on the average of four 
spectrophotometer readings)  
B = length of dsDNA plasmid (i.e. number of nucleotides; 4062 including the inserted 131 
bp FeLV amplicon) 
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660g/mole = average mass of 1 bp dsDNA 
 
PCR testing for genomic mammalian DNA was also performed using a published protocol 
to ensure the quality of the thawed DNA (Helps et al., 2005; Pinches et al., 2007b). This 
protocol uses primers designed to amplify a region of the feline 28S rDNA gene. Each 25 
µL PCR reaction was composed of 0.125 µL Taq DNA polymerase
63
, 2.5 µL 10x PCR 
Buffer
63
, 0.5 µL 10mM dNTP mix, 200 nM of each primer
65
, 200 nM of a dual-labelled 
fluorogenic probe (labelled at the 5’ end with the fluorescent reporter dye CAL Fluor 
Orange 560
 TM
 and at the 3’ end with the fluorescent quencher dye Black Hole Quencher-
1
TM
)
65
, 3 µL of 25 mM MgCl2, 3 µL of DNA (approximately 100 ng), and nuclease-free 
water. The same cycling conditions and PCR machine were used as for FeLV proviral 
testing, except fluorescence was detected during each annealing step (60
o
C) at 560–580 
nm. Samples were run singularly. Known positive samples and a no template control were 
included in each run. Samples with a CT value of less than 45 recorded a positive result. 
7.3.3 Blood collection and FeLV antigen testing 
FeLV antigen testing using whole blood was performed as per manufacturers’ instructions 
within 24 hours of sampling (Groups 1 and 3) or within 24 hours of receiving the blood 
sample (Group 2) using whole EDTA blood. Thirteen samples not able to be tested within 
this time period were stored at -20
o
C, either as whole EDTA blood (n = 10) or plasma (n = 
3), then thawed and tested at a later date. Three FeLV antigen test kits were used in parallel 
to detect viral capsid protein p27 in whole blood. SNAP FIV/FeLV Combo is a lateral flow 
ELISA kit, while Witness FeLV/FIV and Anigen Rapid FIV/FeLV use IC methodology. 
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7.3.4 Categories of FeLV infection 
The following outcomes were described: (i) FeLV-uninfected (PCR negative), either due to 
an abortive-infection or non-exposure to FeLV; (ii) FeLV-infected with progressive-
infection (PCR positive and at least one positive p27 test using blood); and (iii) FeLV-
infected with regressive-infection (PCR positive but three negative p27 tests using blood). 
Atypical-infections were unable to be diagnosed in this study owing to testing only being 
performed at a single time point (serial testing was not possible). 
FeLV provirus PCR testing determined 72 cats to be FeLV-infected and 491 cats to be 
FeLV-uninfected. Of 72 FeLV-infected cats, 45 were suspected of being progressively-
infected and 27 regressively-infected. FeLV CT values for progressively FeLV-infected 
cats (median 22, range 14–37, IQR 20–25) were significantly lower (i.e. higher proviral 
load) compared with regressively FeLV-infected cats (median 35, range 29–40, IQR 34–
37) (P < 0.001; Figure 7.1), with 40/45 progressive infections recording a CT value < 30. 
Progressively FeLV-infected cats were younger (median age 3.4 years) than regressively 
FeLV-infected cats (median age 7.6 years; P = 0.007). 
The median CT value for feline 28S testing was 29 (range 27–36, IQR 28-30). The median 
28S CT value for progressively and regressively FeLV-infected cats was not significantly 
different (P = 0.58).  
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Figure 7.1 Scatter plot of CT values (y axis) from FeLV provirus PCR testing of 563 cats. 
Progressively FeLV-infected cats (n = 45) recorded a significantly lower median CT value 
(i.e. higher proviral load) compared with regressively FeLV-infected cats (n = 27) (x axis). 
 
7.3.5 Saliva collection and FeLV antigen testing 
Of 563 cats recruited for blood testing, 419 were available for saliva sampling at the time 
blood was collected. This included 26 FeLV-infected cats (17 progressively-infected, 9 
regressively-infected) and 393 FeLV-uninfected cats. Saliva was collected immediately 
following blood collection, as described in Chapter 4. Briefly, a sterile individually cased 
cotton swab mounted on a plastic rod
67
 was rubbed against the buccal mucosa on each side 
of the mouth, with the cheek pressed gently against the upper dental arcade while slowly 
twisting the swab, for approximately 10 s per side. The plastic rod was cut approximately 2 
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cm from the cotton tip, the tip transferred to a sterile microcentrifuge tube
68
 (plastic rod at 
the bottom of the tube), 450 µL of sterile phosphate buffered saline (PBS) added and the 
tube shaken vigorously by hand for 10 s. The tube, still containing the cut cotton swab, was 
then centrifuged for 30 s at 10,000 g
69
. The swab was then removed from the tube using 
forceps and the supernatant tested using the same three FeLV antigen test kits as used for 
testing with whole blood. FeLV p27 testing was performed as per manufacturers’ 
instructions except that an equivalent volume of saliva-containing supernatant was 
substituted for blood in the test protocol. None of the manufacturers endorses using saliva 
as a diagnostic specimen for their FeLV test kits. The primary author performed FeLV 
antigen testing using saliva immediately following FeLV antigen testing using blood, 
meaning samples were not blinded for saliva testing. 
The average weight of ten swabs after saliva sampling was determined using a Precision 
Plus electronic balance
70
 and compared to the average weight of ten unused swabs. The 
median weight of saliva collected per swab was 70 mg (IQR 30–110 mg).  
At the conclusion of the study a subset of cats with progressive FeLV-infection (n = 15) 
was resampled using three new swabs and the aforementioned technique. However, instead 
of using PBS and centrifugation to extract a supernatant sample, a single cotton swab was 
used exclusively for each FeLV antigen test kit (randomly ordered), using a simpler 
method. For each FeLV antigen test kit, the saliva swab was directly applied to the sample 
well spot, then the cotton tip was soaked with twice the volume of buffer recommended in 
the manufacturers’ instructions, rolling the cotton tip on the sample spot for 10 s while 
buffer was added. The result was read 10 min later. This revised ‘direct’ technique for 
FeLV antigen testing using saliva was investigated to determine the accuracy of a quicker, 
simpler method for patient-side use (Chapter 4). 
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7.3.6 Statistical analysis 
Numerical analyses were performed using statistical software (Genstat 16
th
 Edition)
71
. 
Statistical significance was considered at P < 0.05 and 95% CIs were calculated for test kit 
performance based on a normal approximation and the Wald method using Microsoft 
Excel
72
. A Shapiro-Wilk test was used to assess data for normality; since age and CT value 
(for both FeLV and feline 28S assays) were not normally distributed, median was reported 
for each and a Mann-Whitney U-test used for any age or CT comparisons. PPV and NPV 
were calculated using the standard formulas (PPV = ‘number of true positives’ / (‘number 
of true positives’ + ‘number of false positives’); NPV = ‘number of true negatives’ / 
(‘number of true negatives’ + ‘number of false negatives’)). Overall test accuracy was 
determined by the formula ((‘number of true positives’ + ‘number of true negatives’) / total 
number of cats sampled). Binomial logistic regression with a logit link function was 
conducted on the test results to compare sensitivity and specificity between test kits and 
between blood and saliva results for the same test kit. Cohen’s Kappa Index Value (κ) was 
calculated to assess agreement between blood and saliva results for each test kit using the 
standard formula (κ = 1 – (1 – Po) / (1 – Pe)), where Po was the observed agreement and Pe 
was the expected agreement (0.5). 
                                                 
60
 Veterinary Pathology Diagnostic Services (VPDS), The University of Sydney, Sydney, NSW, Australia. 
61
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62
 Vetnostics, 60 Waterloo Road, North Ryde, NSW 2113 AUSTRALIA. 
63
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64
 Thermo Fisher Scientific, Waltham, MA, USA. 
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 Bio-Rad, Hercules, CA, USA. 
67
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68
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69
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70
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71
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 Edition for Windows, VSN International, Hemel Hempstead, United Kingdom. 
72
 Microsoft Excel 2010 for Windows, Microsoft, Redmond, WA, USA. 
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7.4 RESULTS 
7.4.1 FeLV point-of-care testing using blood (n = 563) 
The performance of the three point-of-care FeLV antigen kits, compared to qPCR for 
FeLV provirus, using blood as the diagnostic specimen is shown in Table 7.1. SNAP 
FIV/FeLV Combo produced more false-positive FeLV results than either Witness 
FeLV/FIV or Anigen Rapid FIV/FeLV, resulting in significantly lower specificity (94% 
versus 98%, P = 0.004 and 0.007, respectively). SNAP FIV/FeLV Combo recorded less 
false-negatives than the other two kits, although its sensitivity was not significantly higher 
(63% versus 57%, P = 0.50 for both). The specificity and sensitivity of Witness FeLV/FIV 
and Anigen Rapid FIV/FeLV were comparable to each other (P = 0.83 and 1.00, 
respectively). A summary of FeLV p27 results grouped by FeLV CT value is provided in 
Table 7.2 to highlight the decreasing sensitivity of all three test kits as CT rose (i.e. as the 
amount of FeLV provirus present decreased). True-positive p27 results (i.e. progressive-
infections) were more common in younger animals (median age 3.4 years) with lower CT 
values, while false-positive p27 results occurred more commonly in older animals (median 
age 7.5 years) (P < 0.001). 
When two different p27 test kits were used in parallel this increased PPV (highest was 
91% using Witness FeLV/FIV and Anigen Rapid FIV/FeLV), but did not completely 
eliminate the occurrence of false-positive FeLV results (Table 7.3). Of the 35 cats that 
recorded a false-positive p27 result with at least one of the test kits, false-positive FeLV 
results were obtained with more than one test kit in 10/35 instances (6 instances where 2/3 
kits were positive and 4 instances where 3/3 kits were positive, despite a negative FeLV 
qPCR result; median age 6 years, range 11 months to 12 years, IQR 4–10 years). Seven of 
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these 10 cases where multiple false-positive p27 results were obtained were in cats 
displaying clinical signs consistent with FeLV disease, while three were in clinically well 
cats. Testing in parallel was able to identify all cats with progressive FeLV infections, so 
long as SNAP FIV/FeLV Combo was one of the test kits used and provirus testing was 
pursued when results were discordant (i.e. one positive p27 result, one negative p27 result). 
If Witness FeLV/FIV and Anigen Rapid FIV/FeLV were used in combination, three cats 
progressively infected with FeLV were not identified (i.e. both kits tested p27 negative). 
We wrestled with whether or not to include suspected regressive-infections in the final 
analyses of test kit performance (sensitivity, specificity, PPV and NPV). Ultimately we 
decided to retain regressive infections in all analyses and consider FeLV provirus PCR 
testing as a true gold standard for diagnosis of FeLV infection. However, we appreciate 
that it could be considered unfair to declare a false-negative p27 result for an antigen test 
kit if there was actually no antigen present to detect. Analyses with the exclusion of likely 
regressive-infections are therefore also provided below in Table 7.4. 
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Table 7.1 Results of testing using three point-of-care FeLV antigen test kits using blood (n 
= 563), comprising 45 FeLV-infected cats with progressive-infections, 27 FeLV-infected 
cats with regressive-infections and 491 FeLV-uninfected cats. 
FeLV test kit SNAP Combo Witness Anigen Rapid 
True positive 45 41 41 
False negative 27 31 31 
True negative 463 481 480 
False positive 28 10 11 
Sensitivity (%) 45/72 = 63  
(51–74) 
41/72 = 57  
(46–68) 
41/72 = 57  
(46–68) 
Specificity (%) 463/491 = 94  
(92–96) 
481/491 = 98  
(97–99) 
480/491 = 98  
(96–99) 
PPV (%) 45/73 = 62  
(50–73) 
41/51 = 80  
(69–91) 
41/52 = 79  
(68–90) 
NPV (%) 463/490 = 94  
(92–97) 
481/512 = 94  
(92–96) 
480/511 = 94  
(92–96) 
Overall accuracy 
(%) 
508/563 = 90 522/563 = 93 521/563 = 93 
CIs (95%) are given in brackets. 
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Table 7.2 Results of testing using three point-of-care FeLV antigen test kits using blood, 
arranged by CT values from FeLV proviral PCR testing using blood. FeLV-infected cats (n 
= 72) with both progressive (n = 45) and regressive (n = 27) infections are included. 
CT values Type of infection SNAP Combo Witness Anigen Rapid 
 Progressive Regressive    
< 20 14 0 14 14 14 
(n = 14)      
20 – 24.99 
(n = 20) 
20 0 2 19 20 
25 – 29.99 
(n = 7) 
6 1 6 6 5 
30 – 34.99 
(n = 11) 
2 9 2 2 2 
> 35 
(n = 20) 
3 17 3 0 0 
TOTAL  
(n = 72) 
45 27 45/72 41/72 41/72 
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Table 7.3 Results of the point-of-care FeLV antigen test kits using blood when considered 
in parallel. If both kits tested p27 positive, the cat was assigned FeLV-positive; conversely, 
if both kits tested p27 negative, the cat was assigned FeLV-negative. When the kits had 
differing results (i.e. one positive and once negative), a discordant result was assigned. 
Considering the results of two kits in combination increased the specificity and positive 
predictive value of p27 testing to identify cats with progressive FeLV infections, although 
no combination completely eliminated the occurrence of false-positive or false-negative 
results. Therefore provirus PCR testing, rather than a second antigen test, should always be 
pursued for FeLV confirmatory testing where possible. 
FeLV test kit SNAP Combo / 
Witness 
SNAP Combo / 
Anigen Rapid 
Witness / Anigen 
Rapid 
True positive 41 41 40 
False negative 27 27 30 
True negative 461 457 476 
False positive 8 5 4 
Discordant results 26 33 13 
Sensitivity (%) 41/68 = 60 
(49–72) 
41/68 = 60 
(49–72) 
40/70 = 57 
(46–69) 
Specificity (%) 461/469 = 98 
(97–99) 
457/462 = 99 
(98–100) 
476/480 = 99 
(98–100) 
PPV (%) 41/49 = 84 
(73–94) 
41/46 = 89 
80–98) 
40/44 = 91 
(82–99) 
NPV (%) 461/488 = 94 
(92–96) 
457/484 = 94 
(92–96) 
476/506 = 94 
(92–96) 
Overall accuracy 
(%) 
502/537 = 93 498/530 = 94 516/550 = 94 
CIs (95%) are given in brackets. 
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Table 7.4 Results of testing using three point-of-care FeLV antigen test kits using blood (n 
= 536, comprising 45 FeLV-infected cats with progressive-infections and 491 FeLV-
uninfected cats). FeLV-infected cats with regressive-infections (n = 27) were excluded 
from final analysis. 
FeLV test kit SNAP Combo Witness Anigen Rapid 
True positive 45 41 41 
False negative 0 4  4  
True negative 463 481 480 
False positive 28 10 11 
Sensitivity (%) 45/45 = 100  
 
41/45 = 91  
(83–99) 
41/45 = 91  
(83–99) 
Specificity (%) 463/491 = 94 
(92–96) 
481/491 = 98  
(97–99) 
480/491 = 98  
(96–99) 
PPV (%) 45/73 = 62  
(50–73) 
41/51 = 80 
(69–91) 
41/52 = 79  
(68–90) 
NPV (%) 463/463 = 100  
 
481/485 = 99  
(98–100) 
480/484 = 99  
(98–100) 
Overall accuracy 
(%) 
508/536 = 95 522/536 = 97 521/536 = 97 
CIs (95%) are given in brackets. 
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7.4.2 FeLV point-of-care testing using saliva (n = 419) 
Table 7.5 shows the comparative performance of the three point-of-care FeLV antigen kits 
using saliva as the diagnostic specimen. The sensitivity (54%) and specificity (100%) of 
each of the three test kits was identical when saliva was used, although there was not 
complete agreement with test results between kits for two cats. Each kit recorded three 
false-negative FeLV results; two progressively FeLV-infected cats tested p27 negative 
with all three kits using saliva, while another two had discordant results with saliva (one 
was p27 positive with SNAP FIV/FeLV and Anigen Rapid FIV/FeLV only, the other was 
p27 positive with Witness FeLV/FIV only). No false-positive FeLV results were recorded 
with any of the kits using saliva. 
FeLV test kit performance using saliva, with the exclusion of suspected regressive-
infections from final analyses, is provided in Table 7.6. 
7.4.3 Repeat FeLV saliva testing using revised ‘direct’ technique (n = 15) 
Table 7.7 shows the results from re-testing 15 progressively FeLV-infected cats using the 
simpler patient-side technique described above. Despite SNAP FIV/FeLV recording three 
more false-negative results than both Witness FeLV/FIV and Anigen Rapid FIV/FeLV, 
owing to the small sample size there was no significant difference in sensitivity (67% 
versus 87%) between the three FeLV test kits using saliva and the direct technique (P = 
0.21). 
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Table 7.5 Results of testing using three point-of-care FeLV antigen test kits using saliva 
and a centrifugation method (n = 419), comprising 17 FeLV-infected cats with 
progressive-infections, 9 FeLV-infected cats with regressive-infections and 393 FeLV-
uninfected cats. 
FeLV test kit SNAP Combo Witness Anigen Rapid 
True positive 14 14 14 
False negative 12 12 12 
True negative 393 393 393 
False positive 0 0 0 
Sensitivity (%) 14/26 = 54  
(35–73) 
14/26 = 54  
(35–73) 
14/26 = 54  
(35–73) 
Specificity (%) 393/393 = 100 393/393 = 100 393/393 = 100 
PPV (%) 14/14 = 100 14/14 = 100 14/14 = 100 
NPV (%) 393/405 = 97  
(95–99) 
393/405 = 97  
(95–99) 
393/405 = 97  
(95–99) 
Overall accuracy 
(%) 
407/419 = 97 407/419 = 97 407/419 = 97 
CIs (95%) are given in brackets. 
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Table 7.6 Results of testing using three point-of-care FeLV antigen test kits using saliva 
and a centrifugation method (n = 410, comprising 17 FeLV-infected cats with progressive-
infections and 393 FeLV-uninfected cats). FeLV-infected cats with regressive-infections (n 
= 9) were excluded from final analysis. 
FeLV test kit SNAP Combo Witness Anigen Rapid 
True positive 14 14 14 
False negative 3 3 3 
True negative 393 393 393 
False positive 0 0 0 
Sensitivity (%) 14/17 = 82 
(64–100) 
14/17 = 82 
(64–100) 
14/17 = 82 
(64–100) 
Specificity (%) 393/393 = 100 393/393 = 100 393/393 = 100 
PPV (%) 14/14 = 100 14/14 = 100 14/14 = 100 
NPV (%) 393/396 = 99 
(98–100) 
393/396 = 99 
(98–100) 
393/396 = 99 
(98–100) 
Overall accuracy 
(%) 
407/410 = 99 407/410 = 99 407/410 = 99 
 
CIs (95%) are given in brackets. 
 
Table 7.7 Results of testing using three point-of-care FeLV antigen test kits using saliva 
and a revised ‘direct’ testing technique (n = 15, comprising 15 FeLV-infected cats with 
progressive-infections). Only sensitivity was able to be calculated since no FeLV-
uninfected cats were tested with the direct technique. 
Test kit SNAP Combo Witness Anigen Rapid 
True positive 10 13 13 
False negative 5 2 2 
Sensitivity (%) 10/15 = 67  
(43–91) 
13/15 = 87 
(69–100) 
13/15 = 87 
(69–100) 
CIs (95%) are given in brackets. 
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7.4.4 Comparing FeLV point-of-care testing for blood and saliva (n = 419) 
Table 7.8 compares the sensitivity and specificity of blood and saliva testing for each 
FeLV antigen test kit. All comparisons were statistically similar. Cohen’s Kappa Index 
Value (κ) confirmed excellent concordance between blood and saliva test results per 
individual: SNAP FIV/FeLV Combo κ = 0.95, Witness FeLV/FIV κ = 0.98, Anigen Rapid 
FIV/FeLV κ = 0.97. 
 
Table 7.8 Comparison of overall sensitivity and specificity for three point-of-care FeLV 
antigen test kits using whole blood and saliva (n = 563 for blood, n = 419 for saliva). There 
were no significant differences between blood and saliva testing for any of the test kits (P 
values shown). 
          SNAP Combo    Witness    Anigen Rapid 
 BLOOD SALIVA BLOOD SALIVA BLOOD SALIVA 
 
Sensitivity 
 
 
63 
(51 – 74)  
 
 
54  
(35 – 73) 
 
57  
(46 – 68) 
 
54  
(35 – 73) 
 
57  
(46 – 68) 
 
54  
(35 – 73) 
 
 
(P = 0.39) (P = 0.78) (P = 0.57) 
 
Specificity 
 
 
 
94  
(92 – 96) 
 
100 
 
98  
(97 – 99) 
 
100 
 
98  
(97 – 99) 
 
100 
 (P = 0.70) (P = 0.73) (P = 0.71) 
CIs (95%) are given in brackets. 
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7.5 DISCUSSION 
The performance of three point-of-care FeLV antigen kits was found to be similar when 
compared with proviral qPCR testing, irrespective of whether whole EDTA blood or saliva 
was tested, except for more false-positive FeLV results occurring with SNAP FIV/FeLV 
Combo compared with the other two kits using blood. Since whole blood is currently the 
recommended specimen for patient-side FeLV testing, these results provide an important 
reminder that PCR detection of DNA provirus remains the gold standard confirmatory test 
to definitely diagnose FeLV infection. Thus, PCR testing should be pursued to confirm any 
positive p27 antigen test result. Furthermore, veterinarians should consider CT value from 
FeLV qPCR testing as a possible predictor of cats more likely to become regressively-
infected; cats with progressive FeLV infections had lower CT values (i.e. higher proviral 
load), with 40/45 progressively-infected cats recording a CT of < 30. 
The rationale of screening for FeLV infection using p27 testing of blood, followed by 
confirmatory PCR testing (Lutz et al., 2009), is to identify cats progressively infected with 
FeLV and avoid unnecessary euthanasia due to false-positive p27 results. False-positives 
become more common as prevalence diminishes (Hawkins, 1991; Beatty et al., 2011; 
Möstl et al., 2013), such as in Australia where the prevalence of progressive FeLV 
infection is likely less than 1% (Chapters 2 and 8). False-positive FeLV results are said to 
occur as a result of anti-mouse IgG antibodies present in a small proportion (estimated ≤ 
0.5%) of the cat population (as well as in people and other domestic animals). The reason 
why anti-mouse IgG is present in cat sera is not well understood, but might relate to 
predation of mice and subsequent ingestion. Whatever the mechanism of their generation, 
anti-mouse IgG bind to murine-derived monoclonal antibodies in FeLV test kits that 
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capture p27 (Lopez and Jacobson, 1989a). It is possible that some false-positive p27 results 
occurred in truly infected cats with different LTR sequences to the primers chosen. Future 
studies could consider repeating provirus PCR testing at another facility with a 
methodologically distinct assay, or performing VI or IFA in these cases.  
Using two different p27 kits in parallel, as some authors have recommended (Hartmann et 
al., 2007), increased PPV and should be considered in cases where an urgent diagnosis is 
necessary or where PCR testing is unavailable. Parallel testing, however, did not 
completely eliminate the occurrence of false-positive p27 results in between four and eight 
FeLV-uninfected cats (depending on the combination of test kits employed). Thus, 
confirmatory PCR testing is still recommended for any cat (healthy or sick) that tests p27 
positive with multiple rapid kits, as decisions regarding treatment or euthanasia will be 
much better informed by the PCR result. 
Several studies have reported populations of regressively FeLV-infected cats, including 5-
10% of cats tested in Switzerland (24/445 and 6/597, respectively), 10% in UK (45/465), 
3% (2/75) in Australia and 1% in Germany (6/495) (Hofmann-Lehmann et al., 2001; 
Gomes-Keller et al., 2006; Pinches et al., 2007b; Beatty et al., 2011; Englert et al., 2012). 
Regressively FeLV-infected cats eliminate the viraemia within 2-16 weeks of exposure, 
and a limitation of our study was that some of the cats defined as progressively-infected 
may have been in the process of clearing the viraemia, thereby becoming regressively-
infected. This limitation could be overcome in the future by serial p27 testing. For this 
reason, and until the role of regressive-infections in disease is explored further, we do not 
recommend solely using qPCR testing for FeLV diagnosis or FeLV screening (including 
blood donors). Instead, a combination of p27 antigen and provirus PCR testing should be 
undertaken in all cases. 
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FeLV provirus PCR testing was chosen as the gold standard as it can detect very low levels 
of nucleic acid from progressive, regressive and, to a variable degree, atypical infections 
(Gomes-Keller et al., 2006; Sand et al., 2010). PCR testing is not without its challenges. 
Since it is able to detect as little as 1 to 10 copies of provirus in a given sample extreme 
care must be taken in the laboratory to avoid DNA contamination and false-positive results 
(Crawford and Levy, 2007), while primer design must allow detection of FeLV-A, -B and -
C sequences to ensure FeLV-infected cats do not test provirus PCR-negative (Tandon et 
al., 2005; Pinches et al., 2007b). It could be argued that it was unreasonable for this study 
to record a false-negative p27 result using proviral PCR as the benchmark, thereby 
lowering test kit sensitivity, when by definition there was no FeLV antigen present to 
detect (i.e. that it was unfair to include regressive infections in the analysis). We contend 
that the purpose of FeLV point-of-care test kits is to screen for FeLV infection, and 
therefore the sensitivities reported (Tables 7.1 and 7.5) highlight the inability of test kits to 
identify a potentially important subcategory of FeLV infection. A recent study using a 
similar methodology also reported comparable (low) sensitivity for SNAP FIV/FeLV 
Combo and Anigen Rapid FIV/FeLV (53% and 40%, respectively) to the current study 
(Sand et al., 2010). The development of molecular techniques such as RT-PCR have 
demonstrated that some cats defined as being regressively-infected are actually 
transcriptionally active and still shed low levels of virus. One group found 5/14 cats, that 
would have traditionally been classified as regressively-infected (p27 negative, qPCR 
positive), tested RT-PCR positive and were thus ‘regressive infections with transient 
antigenaemias’ (Hofmann-Lehmann et al., 2007). 
The performance of all three FeLV test kits using saliva as the diagnostic specimen was 
comparable to testing with blood, in disagreement with the 2008 AAFP guidelines (Levy et 
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al., 2008a). When venipuncture is not possible without skilled physical restraint or 
sedation, collecting and testing saliva for the presence of FeLV p27 antigen should be 
considered. In one previous study, saliva testing was actually considered to have identified 
seven FeLV-infected cats with FeLV-related disease that tested FeLV-negative with 
serum; although definitive FeLV diagnosis was not pursued in these cats, it was proposed 
that the cats were truly infected and the discordant test results were due to viral replication 
being higher in salivary glands than other tissues such as blood (Lutz and Jarrett, 1987). 
This potential added benefit of saliva testing was replicated in one cat using a Witness 
FeLV/FIV test kit in the current study, using both methods of saliva testing. No false-
positive results were recorded with any of the FeLV test kits using saliva, but of concern 
were 3/17 (18%) false-negative FeLV results occurring in progressively-infected cats with 
each test kit. 
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7.6 CONCLUSION 
FeLV antigen testing using whole blood remains justifiable since it is inexpensive and 
produces rapid results which facilitate clinical decision making while waiting for definitive 
confirmatory testing at a PCR facility. Where PCR testing is unavailable, or rapid 
confirmation of a positive p27 result is required, repeat p27 testing with a different rapid 
kit reduces (but doesn’t completely eliminate) the occurrence of false-positive results. 
Consideration of the patient’s age may help direct clinical judgment (progressive FeLV 
infection more common in younger cats, false-positive p27 results more common in older 
cats), while requesting the proviral qPCR CT value may provide another indication as to 
whether the infection is progressive (CT < 30) or regressive (CT > 30). In addition to 
confirming a positive p27 result, PCR testing for FeLV provirus should also be undertaken 
to investigate animals with signs consistent with FeLV-related disease that test p27 
negative, in case a regressive-infection is present and contributing to the clinical picture. 
All blood donor cats should be screened by qPCR for FeLV provirus. Although saliva 
testing with point-of-care kits shows promise, more research is needed before it can be 
recommended as a reliable screening tool for detecting FeLV infection. 
Dr. Mark Edward Westman Faculty of Veterinary Science 
Thesis 2016 The University of Sydney 
197 
 
CHAPTER 8.  EPIDEMIOLOGY OF FeLV INFECTION IN 
THE DOMESTIC CAT IN AUSTRLIA 
8.1 ABSTRACT 
A field study was undertaken to explore the outcomes of natural FeLV exposure in three 
well defined cohorts of cats in Australia (n = 529). Group 1 (n = 440) consisted of healthy 
client-owned cats with outdoor access recruited as part of a FIV vaccine effectiveness 
study (Chapter 6), while Groups 2 (n = 38) and 3 (n = 51) consisted of a mixture of 
apparently healthy and sick cats being group-housed in two separate rescue facilities on the 
outskirts of Sydney (35km apart). Cats in Group 1 were prospectively recruited using 
clinical medical records, while cats in Groups 2 and 3 were tested in response to recent 
outbreaks of illness and sudden death in individual cats sourced from these facilities. 
Diagnostic testing for FeLV infection included antigen (p27) testing using three different 
point-of-care FeLV/FIV kits, qPCR testing for the detection of proviral DNA and qPCR 
testing for the detection of viral RNA following a reverse transcription step (qRT-PCR). In 
total, FeLV-infection was identified in 52/529 cats (21 progressively-infected, 31 
regressively-infected). This was comprised of 11/440 Group 1 cats (2 progressively-
infected [0.5%], 9 regressively-infected [2%]), 14/38 Group 2 cats (7 progressively-
infected [18%], 7 regressively-infected [18%]) and 27/51 Group 3 cats (12 progressively-
infected [24%], 15 regressively-infected [29%]). Progressively-infected cats had 
significantly lower qPCR CT values (i.e. higher levels of proviral DNA) compared to 
regressively-infected cats (P < 0.001). Viral RNA was detected in 16/21 cats with 
progressive FeLV-infections and in 1/31 cats with regressive-infections. Cats with 
progressive-infections tended to be younger than those with regressive-infections (median 
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age 5 versus 10 years; P = 0.064). Five cats were FeLV/FIV co-infected. FeLV infection 
remains a risk for Australian cats, although in the general population it would appear the 
majority of infections are regressive. FeLV infection was widespread among the two 
different rescue populations tested, a reminder of the importance of retroviral testing 
(FeLV and FIV) on entry prior to co-habitation with other cats and the need to reduce 
group-size to facilitate improved infectious disease threat minimization. It is advisable to 
test and vaccinate any young cat in Australia with outdoor access against FeLV to reduce 
the risk of infection.  
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8.2 INTRODUCTION 
Development of molecular methods for FeLV diagnosis such as qPCR to detect proviral 
DNA and qRT-PCR to detect vRNA in blood has enhanced our ability to appreciate the 
complexity of FeLV infection. Consequently, contemporary investigations of FeLV 
prevalence should utilize these techniques to adequately appraise FeLV infection. In places 
such as Australia where the overall prevalence of FeLV in the general cat population is 
low, the resulting low positive predictive value of point-of-care antigen testing creates an 
added challenge, despite generally excellent sensitivity and specificity of the current 
generation of kits (Hartmann et al., 2007; Adam and Dandrieux, 2011; Beatty et al., 2011). 
Without confirmatory provirus PCR testing, estimates of FeLV prevalence are likely to be 
unreliable, prone to error and certain to underestimate the extent of subclinical infection 
(Chapter 7). 
Recent studies utilizing molecular diagnostic techniques have begun to report the full 
gamut of possible outcomes following FeLV exposure (Table 8.1). To date, only one such 
study has been conducted in Australia, although vRNA testing (to detect transcriptional 
activity) was not performed, and cats were only recruited from one city in Australia 
(Sydney), thereby limiting the scope of the report (Beatty et al., 2011). 
The aim of the current study was to report the range of possible outcomes following 
natural FeLV exposure in one widespread group of client-owned cats living predominantly 
in eastern Australia and two groups of rescue cats, also living in eastern Australia (Sydney, 
NSW), using a combination of antigen (p27) and nucleic acid (qPCR and qRT-PCR) 
testing. Unfortunately, considering the higher prevalence of FeLV infection in WA client-
owned cats reported in Chapter 2, samples were only available from eastern Australia.   
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Table 8.1 Summary of previous FeLV studies where categories of FeLV infection were investigated using nucleic acid amplification (proviral 
qPCR +/- vRNA qRT-PCR testing). Where FeLV-antibody testing was not performed, not exposed/abortive-infections are grouped together. 
Where qRT-PCR testing to detect vRNA was not performed, regressive-infections with or without detectable vRNA are grouped together. 
Focal-infections are not represented as none of the studies shown performed the necessary testing for detection. 
  ----------Outcome of FeLV exposure------------ 
Author 
(chronological 
order)/country 
Recruitment 
criteria 
Not 
exposed 
Abortive 
infection 
Regressive 
infection 
(without 
detectable 
vRNA) 
Regressive 
infection (with 
detectable 
vRNA) 
Progressive 
infection 
Ratio 
progressive: 
regressive infections 
Hofmann-
Lehmann et al. 
(2001) 
Switzerland 
Not specified 495/597 (83%) 61/597 (10%) 41/597 (7%) 0.7 
Gomes-Keller 
et al. (2006)  
Switzerland 
Mainly multi-cat 
households (not 
representative of 
the general cat 
population) 
367/445 (82%) 23/445 (5%) 1/445 (0.2%)
a
 54/445 (12%) 2.3 
Pinches et al. 
(2007b)  
UK 
Samples sent to 
a diagnostic 
laboratory 
(presumably 
364/465 (78%) 45/465 (10%) 56/465 (12%) 1.2 
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from sick cats) 
Beatty et al. 
(2011)  
Sydney, 
Australia 
Mixed 
population 
comprising sick 
cats presenting 
to a university 
veterinary 
hospital, FeLV 
in-contact cats 
and juvenile (< 
12 months) 
healthy cats 
243/248 (98%) 3/248 (1%) 2/248 (1%) 0.7 
Englert et al. 
(2012) 
Germany 
Mixture of 
randomly 
selected cats 
presenting to a 
university 
veterinary 
hospital and 
healthy shelter 
cats 
458/49
5 
(93%) 
22/495 (4%) 6/495 (1%) 0/495 (0%)
b
 9/495 (2%) 1.5 
a
evaluated by testing both blood and saliva with RT-PCR assay. 
b
evaluated by testing saliva only with RT-PCR assay. 
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8.3 MATERIALS AND METHODS 
8.3.1 Sample population 
Three groups of cats were recruited in Australia: (i) Group 1 (n = 440) consisted of 
healthy client-owned cats that were part of a case-control study into the effectiveness of a 
commercially available FIV vaccine
73
 (Chapter 6). Both FIV-vaccinated cats (cases) and 
FIV-unvaccinated cats (controls) were recruited using medical records from participating 
veterinary clinics located in four states and one territory; (ii) Group 2 (n = 38) consisted of 
a mixture of healthy and sick rescue cats group-housed in a facility on the outskirts of 
Sydney, NSW; and (iii) Group 3 (n = 51) comprised a mixture of healthy and sick rescue 
cats group-housed in a different facility on the outskirts of Sydney, NSW (35km from 
Group 2; no transfer of cats between two facilities) (Figure 8.1). Cats in Group 2 and 3 
were sampled and tested at the request of each facility manager in response to recent 
unexplained illnesses and deaths in the cat populations. Approval was granted by the 
University of Sydney Animal Ethics Committee (Approval number N00/1-2013/3/5920). 
Recruited cats from Group 1 (n = 440) ranged from two to 20 years-of-age (median 7 
years; IQR 5–10 years), comprising 229 (52%) castrated males, 207 (47%) spayed females 
and four (1%) entire males. Most were domestic crossbred cats (371/440; 84%), the 
remainder comprising a range of pedigree breeds. Most cats were described by their owner 
as having some level of outdoor access (429/440; 98%). 
Recruited cats from Group 2 (n = 38) ranged from one to 14 years-of-age (median 4 years; 
IQR 3–10 years), comprising 15 (39%) castrated males and 23 (61%) spayed females. Most 
were domestic crossbred cats (36/38; 95%). The age of one cat in group 2 was unknown. 
Recruited cats from Group 3 (n = 51) ranged in age from three months to five years 
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(median 1 year; IQR 0.4–2 years), although the age of only 10 cats in group 3 was known 
(the other 41 were adult cats > 6 months). This comprised 23 (45%) castrated males, 27 
(53%) spayed females and one entire female (2%). Most were domestic crossbred cats 
(49/51; 96%). Cats in groups 2 and 3 were predominantly free-roaming, with some group-
housing of the more tractable cats exercised at night (Figure 8.2 provides images of the 
first rescue facility (Group 2) to illustrate the free-roaming, group-housing conditions). 
A complete vaccination history was available for cats in Group 1 only: 146/440 (33%) had 
been vaccinated against FeLV with an IWV vaccine
74
, of which 108/146 (74%) had been 
vaccinated within the past 12 months and 38/146 (26%) were overdue for FeLV 
vaccination (more than 12 months since last vaccination; median time 3.5 years, range 1–
11 years, IQR 2–6 years). 
8.3.2 FeLV/FIV point-of-care testing 
Three commercially available dual FeLV-antigen/FIV-antibody kits were used to test 
whole blood (EDTA anti-coagulated). All three kits (SNAP FIV/FeLV Combo
75
,
 
Witness 
FeLV/FIV
76
 and Anigen Rapid FIV/FeLV
77
) detect FeLV viral capsid protein p27 in whole 
blood, plasma, serum and saliva (Chapter 7). 
8.3.3 FeLV qPCR testing 
DNA extraction from white cells within whole blood and the qPCR assay used for 
detection of FeLV proviral DNA is described in detail in section 7.3.2. 
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8.3.4 FeLV qRT-PCR testing 
Plasma was thawed from -80
o
C and RNA extracted using a standard kit (Qiagen RNeasy)
78
 
as per manufacturer’s instructions. A standard RT protocol was used to create 
complementary DNA (cDNA; RevertAid)
79
, the resulting cDNA being measured using a 
spectrophotometer (Nanodrop 1000)
79
. The FeLV qPCR assay described in section 7.3.2 
was run to detect vRNA, using cDNA as the template (instead of genomic DNA), with a 
slightly altered primer/probe concentration as recommended by the original authors (900 
nM of forward primer, 300 nM of reverse primer and 200 nM of probe (Tandon et al., 
2005). 
8.3.5 Determination of FeLV status 
Table 8.2 describes the possible outcomes to FeLV exposure that were considered (Englert 
et al., 2012). Cats that tested (i) p27 with at least one point-of-care kit and qPCR positive 
were classified as progressively-infected; (ii) p27 negative with all three kits and qPCR 
positive were classified as regressively-infected, with the qRT-PCR result dividing 
regressive-infections further into with or without detectable vRNA; and (iii) p27 negative 
and PCR negative were classified as FeLV-uninfected (which may have included non-
exposure to FeLV and abortive-infections). Focal- infections have variable p27 and qPCR 
results and therefore, if present, may have been classified as progressive-infections, 
regressive-infections or FeLV-uninfected (FeLV PCR testing of tissue samples would have 
been required to determine) (Hartmann, 2012). Due to an absence of sequential testing, it is 
possible that cats that were viraemic as a result of recent exposure to FeLV may have 
cleared the viraemia if retested 2–16 weeks later, and therefore might have been incorrectly 
categorized as progressive rather than regressive-infections. 
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8.3.6 Determination of FIV status 
Since all three FeLV antigen kits used simultaneously tested for the presence of FIV 
antibodies, the presence of dual retroviral infections was investigated. Defining FIV 
positivity in Group 1 was complicated by 139 cats having received at least one FIV-
vaccination previously, meaning some false-positive FIV antibody test results were 
encountered (Uhl et al., 2002). The algorithm used to overcome this issue and determine 
FIV infection status was described in Chapter 3 and involved both FIV PCR testing (using 
a commercially available assay) as well as VI in rare discrepant cases. Diagnosis of FIV 
infection in Groups 2 and 3 was not complicated by recent FIV vaccination and a positive 
FIV status was assigned when all three test kits tested positive for FIV antibodies. No 
discordant FIV results from Groups 2 and 3 were recorded (i.e. the three FIV antibody tests 
were always in agreement, either all positive or all negative). 
8.3.7 Statistical analysis 
Numerical analyses were performed using statistical software (Genstat 16
th
 Edition)
80
. 
Statistical significance was considered at P < 0.05. A Shapiro-Wilk test was used to assess 
data for normality; where data was normally distributed REML testing was performed 
(comparing age between groups), and where data was not normally distributed Mann-
Whitney U-tests were used (comparing age between progressive and regressive-infections, 
CT values between progressive and regressive-infections, and CT values between groups). 
Two-sample binomial tests were used to compare sex and breed proportions between 
groups, FeLV outcome between groups and the likelihood of a single retroviral infection 
(FeLV or FIV) versus co-infection (FeLV and FIV). Two-tailed Fisher’s exact tests were 
used to investigate the relationship between sex and pedigree status on the prevalence of 
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FeLV and FIV infection. Potential geographic ‘hot spots’ of FeLV infection in Group 1 
based on postcode were investigated using the scan statistic (SaTScan version 7). A 
Bernoulli model (case-control) was used and both circular and elliptical scanning windows 
of up to 50% of the study area size were investigated. 
                                                 
73
 Fel-O-Vax
®
 FIV, Boehringer Ingelheim, Fort Dodge, IA, USA. 
74
 All cats in this study vaccinated against FeLV had been given Fel-O-Vax LvK (Boehringer Ingelheim, Fort 
Dodge, IA, USA). 
75
 IDEXX Laboratories, Westbrook, ME, USA. 
76
 Zoetis Animal Health, Lyon, France. 
77
 BioNote, Gyeonggi-do, Korea. 
78
 Qiagen, Valencia, CA, USA. 
79
 Thermo Fisher Scientific, Waltham, MA, USA. 
80
 GenStat 16
th
 Edition for Windows, VSN International, Hemel Hempstead, United Kingdom. 
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Figure 8.1 Map of Australia, showing the location of 13 veterinary clinics used to recruit cats for Group 1 (blue dots) and the location of the 
two rescue facilities that formed Groups 2 and 3 (red dots). An enlargement of Sydney, NSW is shown in the breakout box. The grey shading 
in the breakout box represents the ‘Built Up Areas’ of Sydney (as defined by Geosciences Australia, 
www.ga.gov.au/mapspecs/250k100k/appendixA_files/Habitation.html#Habitation Built Up Area Polygon) and is included to show the semi-
rural location of the two rescue facilities and one veterinary clinic on the outskirts of Sydney. 
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Figure 8.2 Images of the first rescue facility to illustrate the free-roaming, group-housing conditions of cats in Group 2 (n = 38). Images of 
cats in Group 3 (n = 51) were unavailable. 
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Table 8.2 Outcomes following FeLV exposure categorized by observed test results. In the current study abortive-infections could not be 
diagnosed as FeLV-antibody testing was not performed and focal-infections could not be determined as FeLV PCR of tissue samples was not 
performed.  
 
Test 
performed 
                                     -------------------------------------------------------------Outcome of FeLV exposure---------------------------
--- 
FeLV-
uninfected 
Regressive infection (without detectable 
vRNA) 
Regressive infection (with detectable 
vRNA) 
Progressive 
infection 
p27 antigen - - - + 
qPCR (DNA) - + + + 
qRT-PCR 
(vRNA) 
NP - + + 
NP = not performed. 
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8.4 RESULTS 
8.4.1 Sample population 
The median age of each group was significantly different (Group 1 [median = 7 years] > 
Group 2 [median = 4 years] > Group 3 [median = 1 year], P < 0.001). The proportion of 
males and females in each group was similar (P = 0.11). Group 1 contained proportionally 
more pure-bred cats compared to Group 3 (P = 0.02) but not Group 2 (P = 0.08). Groups 2 
and 3 contained a similar proportion of pure-bred cats (P = 0.76). 
8.4.2 FeLV status 
A summary of outcomes by group is presented in Table 8.3. Of the 529 cats tested, 52 
FeLV-infected cats were identified (21 progressively-infected, 31 regressively-infected). 
Of the 52 FeLV-infected cats, 11 were from Group 1 (2 progressively-infected, 9 
regressively-infected from a total of 440 cats), 14 were from Group 2 (7 progressively-
infected, 7 regressively-infected from a total of 38) and 27 were from Group 3 (12 
progressively-infected, 15 regressively-infected from a total of 51). 
CT values from qPCR testing of progressively-infected cats ranged from 17 to 37 (median 
21, IQR 18–29). CT values from qPCR testing of regressively-infected cats ranged from 28 
to 40 (median 35, IQR 33–37). Progressively-infected cats had significantly lower qPCR 
CT values (i.e. higher levels of proviral DNA) than regressively-infected cats (P < 0.001). 
When analysed by cohort, Group 1 cats had significantly higher qPCR CT values (i.e. 
lower levels of proviral DNA; median 36) compared to cats in Group 2 (median 25) and 
Group 3 (median 33) (P = 0.008 and 0.03, respectively), but qPCR CT values for Groups 2 
and 3 were not significantly different (P = 0.15) (Figure 8.3). 
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With regards to qRT-PCR testing, 16/21 progressively-infected cats and 1/29 regressively-
infected cats tested positive for vRNA (plasma not available from two regressively-
infected cats). The qRT-PCR CT values from the 16 progressively-infected cats ranged 
from 25 to 42 (median 34, IQR 26–38). The five progressive-infections that tested qRT-
PCR negative for vRNA recorded the five highest qPCR CT values (i.e. lowest levels of 
proviral DNA) of the progressively-infected cats. The qRT-PCR CT value for the one 
regressively-infected cat that tested positive was 38. 
A summary of the signalments of FeLV-infected cats is presented in Table 8.4. 
Progressively-infected cats were younger than regressively-infected cats (median age 5 
versus 10 years), although this difference did not reach statistical significance (P = 0.064). 
There was no sex predilection for either progressive or regressive-infections (P = 0.38 and 
P = 0.71, respectively). When FeLV-infected cats were analysed by breed (domestic cross-
bred versus pure-bred), there was no significant difference in proportion compared to 
FeLV-uninfected cats for either progressive or regressive-infections (P = 0.10 and P = 
1.00, respectively). Cats in Groups 2 and 3 were significantly more likely to be FeLV-
infected than cats in group 1 (P < 0.001). There was no significant difference in likelihood 
of FeLV-infection between Groups 2 and 3 (P = 0.13), irrespective of whether progressive 
(P = 0.56) or regressive-infections (P = 0.23) were analysed separately. The age of only 
three FeLV-infected cats in Group 3 was known. 
Using a circular scanning window, two potential geographical ‘hot spots’ of FeLV 
infection in group 1 were identified, one in NSW (postcode 2145; 4 cases reported, 1.63 
expected) and one in VIC (postcodes 3218, 3219 and 3220; 3 cases reported, 0.58 
expected). Using an elliptical scanning window, two similar potential geographical ‘hot 
spots’ of FeLV infection were identified in NSW (postcodes 2145 and 2168; 7 cases 
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reported, 3.43 expected) and in VIC (postcodes 3218, 3219 and 3220; 3 cases reported, 
0.58 expected). However, none of these ‘hot spots’ were statistically significant (P ≥ 0.60). 
One cat with a progressive FeLV infection (1/21; cat # 62) had been vaccinated against 
FeLV with an IWV vaccine
b
 (two primary vaccinations given one month apart, 16 months 
before sampling, with a single annual booster administered four months before sampling). 
FeLV testing, however, had not been performed in this cat to ensure it was FeLV-
uninfected prior to vaccination. Of the regressively FeLV-infected cats, three (3/31) had 
been vaccinated against FeLV (two cats within the past 12 months, one cat 11 years 
previously) but none had been FeLV tested prior to vaccination. There was no significant 
difference in qPCR CT values between FeLV-vaccinated and FeLV-unvaccinated 
regressive-infections (P = 0.11). 
8.4.3 FIV status 
In total, 39/529 (7%) cats were FIV-infected, comprising 32/440 (7%) in Group 1, 3/38 
(8%) of Group 2 and 4/51 (8%) of Group 3. FIV-infected cats ranged from three to 16 
years-of-age (median 7 years; IQR 5–9 years), comprised 27 (79%) castrated males, 11 
(28%) spayed females and one (4%) entire male. Most were domestic crossbred cats 
(35/39; 90%). Male cats were significantly more likely to be FIV-infected than female cats 
(P = 0.008, odds ratio 2.6). The age of only one FIV-infected cat in group 3 was known. 
8.4.4 FeLV/FIV co-infection 
Five cats (5/529; 1%) were FIV/FeLV co-infected (3 progressively FeLV-infected, 2 
regressively FeLV-infected) (Table 8.5). One co-infection was identified in Group 1 
(progressively FeLV-infected; cat # 62; FIV-unvaccinated), one in Group 2 (progressively 
FeLV-infected) and the remaining three were from Group 3 (one progressively FeLV-
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infected, two regressively FeLV-infected). All three FIV-infected/progressively FeLV-
infected cats have died since their diagnosis (survival time from testing 5 months, 5 
months and 13 months). There was no statistical difference in CT values for FeLV PCR 
testing between FIV/FeLV co-infected and FeLV-infected/FIV-uninfected cats, 
irrespective of whether regressive FeLV infections were included (P = 0.24) or excluded 
(P = 0.60). Cats in all three groups were more likely to be infected with one retrovirus 
(either FeLV or FIV) than be co-infected with both (P < 0.001). 
8.4.5 Follow up of rescue cats (Groups 2 and 3) 
All p27 negative cats in Groups 2 and 3 were vaccinated against FeLV using either an 
IWV vaccine or a recombinant p45 vaccine
81
 (two primary vaccinations given one month 
apart)
82
. Cats in Group 2 were closely followed; serial testing of progressively-infected 
cats (tested up to six times over two years) confirmed all seven remained strongly 
antigenaemic with p27 testing. A summary of outcomes for progressively-infected cats in 
Group 2 is provided in Table 8.6. Husbandry advice and assistance with FIV/FeLV testing 
of new animals was provided to both rescue facilities in an effort to reduce the incidence of 
retroviral disease in the cat populations. 
                                                 
81
 Fel-O-Vax LvK (Boehringer Ingelheim, Fort Dodge, IA, USA) or Leucogen (Virbac Animal Health, 
Carros, France). 
82
 Both FeLV-uninfected and regressively FeLV-infected cats in Group 2 were vaccinated against FeLV after 
PCR testing. Although data is lacking and more research needs to be done in this area, we hypothesized 
vaccinating regressively-infected cats might ‘prime’ the immune system to help prevent them reverting to a 
progressive state and becoming viraemic. p27 negative cats in Group 3 were vaccinated against FeLV 
immediately after testing (i.e. before PCR results were known), in order to protect these cats from becoming 
progressively-infected as quickly as possible. Consequently, both FeLV-uninfected and regressively FeLV-
infected cats in Group 3 were also vaccinated against FeLV. 
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Table 8.3 FeLV infection status in each group from the current study (n = 529). Abortive-infections could not be diagnosed as FeLV-antibody 
testing was not performed and focal-infections could not be determined as FeLV PCR of tissue samples was not performed. 
  Outcome of FeLV exposure 
Group Description FeLV-
uninfected 
Regressive infection 
(without detectable 
vRNA) 
Regressive 
infection (with 
detectable vRNA) 
Progressive infection 
Group 1 (n = 
440) 
Case-control in-field 
study of a FIV vaccine 
429/440 
(98%) 
9/440 (2%) 0/440 (0%) 2/440 (0.5%) 
Group 2 (n = 
38) 
Rescue facility with 
group-housing  
24/38 (63%) 7/38 (18%) 0/38 (0%) 7/38 (18%) 
Group 3 (n = 
51) 
Rescue facility with 
group-housing 
24/51 (47%) 14/51 (27%) 1/51 (2%) 12/51 (24%) 
 
 
 
 
Dr. Mark Edward Westman Faculty of Veterinary Science 
Thesis 2016 The University of Sydney 
215 
 
Figure 8.3 Scatter plot of CT values (y axis) from FeLV provirus PCR testing of whole 
blood in 529 cats. Progressively FeLV-infected cats (n = 21) recorded a significantly lower 
median CT value (i.e. higher proviral load, P < 0.001) compared with regressively FeLV-
infected cats (n = 31) (x axis). CT values for Group 1 were significantly higher (i.e. lower 
proviral load) than Group 2 (P = 0.008) and Group 3 (P = 0.03), but CT values for Groups 
2 and 3 were not significantly different (P = 0.15). 
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Table 8.4 Age, sex and breed of FeLV-infected cats identified in the study (n = 52, including 21 progressive and 31 regressive infections). 
Category Age (years) Sex Breed 
Progressively FeLV-infected    
Group 1 (n = 2) 
Group 2 (n = 7) 
Group 3 (n = 12) 
OVERALL (n = 21) 
Regressively FeLV-infected 
Group 1 (n = 9) 
Group 2 (n = 7) 
Group 3 (n = 15) 
OVERALL (n = 31) 
3, 6 
2–11 (median 8) 
0.4, 5
a
 
0.4–11 (median 5)b 
 
2–16 (median 10) 
3–14 (median 10) 
4
a
 
2–16 (median 10)b 
1 MN, 1 FS 
5 MN, 2 FS 
7 MN, 5 FS 
13 MN, 8 FS
c
 
 
7 MN, 2 FS 
3 MN, 4 FS 
7 MN, 8 FS 
17 MN, 14 FS
c
 
2 DCB 
7 DCB 
12 DCB 
21 DCB
d
 
 
7 DCB, 2 PB 
6 DCB, 1 PB 
14 DCB, 1 PB 
27 DCB, 4 PB
d
 
MN = neutered (castrated), FS = female spayed, DCB = domestic cross-bred, PB = pure-bred. 
a
The age of only three FeLV-infected cats in group 3 was known. 
b
Progressively-infected cats were younger than regressively-infected cats, although this difference did not reach statistical significance (P = 0.064). 
c
There was no sex predilection for either progressive or regressive-infections (P = 0.38 and P = 0.71, respectively). 
d
When FeLV-infected cats were analysed by breed, there was no significant difference in proportion compared to FeLV-uninfected cats for either progressive or 
regressive-infections (P = 0.10 and P = 1.00, respectively). 
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Table 8.5 Summary of FIV antibody testing, stratified by FeLV infection status. A total of 39 cats (39/529; 7%) were FIV-infected, including 
five (5/529; 1%) FeLV/FIV co-infected cats. Group 1 consisted of cats recruited as part of a study into FIV vaccine effectiveness, while 
Groups 2 and 3 consisted of rescue cats being group-housed in different locations on the outskirts of Sydney (35km apart). Cats in all three 
groups were more likely to be infected with one retrovirus (either FeLV or FIV) than be co-infected with both (P < 0.001). 
Category Group 1 Group 2 Group 3 
FIV-infected/FeLV-uninfected (n = 34) 
 
31 2 1 
FIV-infected/progressively FeLV-infected (n = 3)
a
 
 
1  
(CT = 17) 
1 
(CT = 23) 
1 
(CT = 21) 
FIV-infected/regressively FeLV-infected (n = 2)
a
 
 
0 0 2 
(CT = 31, 37) 
TOTAL (n = 39) 
 
32/440 (7%) 3/38 (11%) 4/51 (8%) 
a
CT = cycle threshold value from FeLV proviral PCR testing using blood. 
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Table 8.6 Outcomes known at the time of writing for progressively FeLV-infected cats in Group 2 (n = 7). All cats were domestic cross-bred.  
Cat Age at time of diagnosis 
(years) 
Sex Outcome 
SP-5 11 FS Euthanased 24 months after diagnosis due to mass in abdomen, post-mortem not 
performed 
SP-7 11 FS Alive and healthy 
SP-14 4 MN Euthanased one month after diagnosed with feline sarcoma virus (FeSV) infection, 
multiple skin masses all over body, index case for group 2 
SP-20 8 MN Euthanased 38 months after diagnosis due to nasal cavity tumour, awaiting 
histopathology 
SP-21 9 MN Euthanased 13 months after diagnosis due to breathing difficulties, cardiac disease 
suspected due to severe heart murmur, post-mortem not performed, co-infected with 
FIV 
SP-30 
 
2 MN Euthanased 22 months after diagnosis due to breathing difficulties, post-mortem 
revealed mediastinal lymphoma 
SP-31 2 MN Euthanased 6 months after diagnosis, severe non-regenerative anaemia and icterus, 
post-mortem revealed hepatomegaly, splenomegaly, pericardial effusion and pleural 
effusion 
MN = male neutered (castrated), FS = female spayed. 
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8.5 DISCUSSION 
This study reports for the first time a comprehensive analysis of outcomes following 
natural FeLV exposure in cats domiciled in Australia. The data suggests FeLV-infection 
has not decreased in prevalence over the past 20 years, and that most infections are 
subclinical regressive-infections, whose long term effects are not completely understood. 
In a cohort representative of cats with some level of outdoor access (Group 1), FeLV 
prevalence was 2.5% (11/440), including 9 regressively-infected cats identified with 
proviral qPCR testing. Investigation of closed populations with ‘FeLV outbreaks’ (Groups 
2 and 3) revealed that FeLV was common among in-contact cats. 
Previous FeLV prevalence studies in Australia have reported variable rates of infection in 
‘healthy’ populations of cats, ranging from 0% to 7% (Chapter 2). One Australian study 
from 26 years ago reported FeLV seroprevalence of 7% (5/72) in a small population of 
healthy cats recruited by random selection of households from the electoral roll (Robertson 
et al., 1990b). This relatively high rate of progressive-infections compared to the current 
study (2/440 in Group 1; 0.5%) was probably a reflection of limited sample size, location 
sampled (Perth, Western Australia has since been shown to have a higher rate of FeLV-
infected cats compared to the rest of the country (Chapter 2) and an era when FeLV 
infection was more prevalent worldwide than it is today (Lutz et al., 2009). More recent 
studies in Australia (1997, 2007 and 2011) have reported lower FeLV prevalence rates in 
healthy client-owned cats of 0–2% (Malik et al., 1997; Norris et al., 2007; Beatty et al., 
2011) (Chapter 2). Only one previous study of healthy Australian cats employed proviral 
PCR testing to confirm any p27 positive result (Beatty et al., 2011); thus, earlier estimates 
of FeLV prevalence may have been falsely elevated due to the reduced positive predictive 
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value of point-of-care test kits associated with testing a low prevalence population (Möstl 
et al., 2013). Beatty et al. (2011) did not identify any progressive or regressive FeLV 
infections in a population (n = 169) comprising healthy young cats (all < 1 year), mostly 
re-homed from rescue organisations where single-housing was carried out (except for 
kittens) (Beatty et al., 2011). The current study has fulfilled the need for a comprehensive 
contemporary investigation of the prevalence of progressive and regressive FeLV 
infections in the general cat population in Australia. 
Several studies have reported mixed populations of progressively and regressively FeLV-
infected cats (Table 8.1) (Hofmann-Lehmann et al., 2001; Gomes-Keller et al., 2006; 
Pinches et al., 2007b; Beatty et al., 2011; Englert et al., 2012). The current study found 
0.5% (2/440) and 2% (9/440) of the general cat population (Group 1) were progressively 
and regressively FeLV-infected, respectively. Despite vaccination regressive-infections 
can still occur, irrespective of which FeLV vaccine is administered (Torres et al., 2005; 
Hofmann-Lehmann et al., 2007), and indeed three regressively-infected cats in Group 1 
had been given an IWV FeLV vaccine (Fel-O-Vax LvK). 
Studies using highly sensitive qRT-PCR assays capable of detecting extremely low 
concentrations of vRNA in plasma have demonstrated that most regressively FeLV-
infected cats are transcriptionally active, despite testing antigen (p27) and VI negative 
(Hofmann-Lehmann et al., 2007; Torres et al., 2010). Based on studies documenting 
transmission of FeLV to uninfected cats transfused with blood taken from regressively-
infected cats, the low level vRNA detected in p27 negative/provirus positive cats likely 
represents infectious viral particles (Nesina et al., 2015). Hofmann-Lehmann and 
colleagues also suggested that vRNA-positive regressively FeLV-infected cats are at 
higher risk for reactivation of active infection than vRNA-negative regressively FeLV-
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infected cats (Hofmann-Lehmann et al., 2008). We identified only one cat in this category; 
the remainder (28/29) of regressively FeLV-infected cats tested negative with the qRT-
PCR assay. In the current study, qPCR testing for proviral DNA and qRT-PCR testing for 
vRNA demonstrated good agreement in progressive-infections (16/21), but consistent with 
other reports, five progressive-infections tested negative for vRNA with RT-PCR (Tandon 
et al. 2005 reported agreement between DNA and vRNA testing in 104/120 samples, while 
Torres et al. 2008 reported agreement in 240/264 samples) (Tandon et al., 2005; Torres et 
al., 2008). This discrepancy is probably a consequence of the RT-PCR assay (which 
detects RNA) being less sensitive than the PCR assay (which detects DNA). This notion is 
consistent with the five progressive-infections that tested negative for vRNA having the 
lowest levels of proviral DNA. Other possible explanations include RNA degradation that 
may have occurred during plasma harvesting and storage and difficulties with RNA 
extraction due to a small amount of RNA actually present in the sample. For these reasons, 
it is conceivable that the qRT-PCR assay was unable to detect very low levels of viral 
RNA in some regressively-infected cats (< 2250 viral copies per mL plasma) (Tandon et 
al., 2005). Additionally, serial qRT-PCR testing was required by Hofmann-Lehmann’s 
group to identify transcriptional activity in 11/14 cats. It is therefore possible that with 
repeated testing, some of the regressively FeLV-infected cats in the current study may have 
demonstrated transcriptional activity (Hofmann-Lehmann et al., 2007). It is more likely, 
however, that the high rate of transcriptionally active regressive-infections reported by the 
Swiss group (14/14; 100%) was an experimental phenomenon, since other studies in the 
field have found low levels or absent vRNA in regressively FeLV-infected cats (Gomes-
Keller et al., 2006; Englert et al., 2012). The risk of FeLV transmission from regressively-
infected cats to in-contact cats, therefore, appears low in Australia, although the effect of 
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low level virus transmission via cat bites (akin to blood transmission experiments) remains 
to be assessed. 
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8.6 CONCLUSION 
Despite a reduction in FeLV prevalence in pet cats, the threat of FeLV infection remains 
present. Veterinarians should consider vaccinating any cat with outdoor access against 
FeLV to reduce the risk of infection, especially in the first few years of a cat’s life, and 
testing for FeLV prior to vaccination. Rescue facilities that allow group-housing need to be 
especially vigilant about screening new arrivals for FeLV during an initial quarantine 
period before mixing of animals is permitted. The role of regressive-infections in FeLV-
associated disease and contagion, particularly those in which detectable vRNA is present in 
blood, needs further investigation. Specifically, the contribution of regressive FeLV-
infections to the development of lymphoma must be addressed. 
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CHAPTER 9.  CONCLUSIONS AND FUTURE DIRECTIONS 
The chapters in this thesis have been ordered in the way considered to be most logical:  
(i) Background prevalence of both FIV and FeLV in domestic cats in Australia;  
(ii) FIV research (diagnosis of FIV infection, duration of antibody response following FIV 
vaccination and protective rate of the FIV vaccine), and;  
(iii) FeLV research (diagnosis of FeLV infection and epidemiological considerations of 
FeLV in domestic cats in Australia). 
As discussed in section 1.14, however, this was not the chronological order of our 
investigations. The discussion below recounts some of the major highlights of our research 
with a ‘real-world’ chronological approach, in order to give a truer feel as to how this 
research effort evolved over time, and suggests some of the future research projects that 
might be performed as a continuation of our lines of enquiry. 
This entire body of work was born out of the aim to report, for the first time, a field 
protective rate of the FIV vaccine (Fel-O-Vax FIV) in Australia. Chapter 6 described the 
first five unequivocal FIV vaccine breakthroughs in the field (as well as two additional 
possible vaccine breakthroughs) and determined a protective rate (effectiveness) of 56%, 
with no significant difference in FIV prevalence found between the FIV-vaccinated cats 
(cases) and FIV-unvaccinated cats (controls). Unfortunately, for a variety of reasons 
discussed previously, the power of the study was ultimately 40% instead of 80% as 
projected in the study design. It is possible with greater study numbers that a significant 
effect of the vaccine would have been found (if one indeed exists). Based on our 
experiences, however, there is no doubt it is very difficult to recruit cases using the 
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retrospective approach described due to vaccine protocol compliance issues. We also found 
it difficult to recruit matching control (FIV-unvaccinated) cats, since most cats from the 13 
participating clinics with outdoor access were vaccinated against FIV. It could be that a 
poor attitude to accepting a recommendation of FIV vaccination might reflect a less 
attentive state of mind on the part of the client (owner), which might introduce bias into the 
study inadvertently if they are likewise inattentive observers of curfews and border security 
issues. 
To address some of the flaws of the retrospective study design raised in section 6.5 a 
prospective study would be ideal, but would take longer to generate meaningful data, 
probably with a timeframe of 8 to 10 years. A prospective study design would enable FIV 
testing of both vaccinates and controls on day 0, thereby circumventing any potential bias 
from recruitment of control cats already FIV-infected at the beginning of the study period. 
Furthermore, strict indoor housing restrictions for cats could be enforced during the 12 
weeks prior to recruitment and commencement of FIV vaccination, to ensure FIV infection 
does not occur before vaccine-related immunity is achieved (alternatively, appropriate FIV 
testing could be performed after the course of primary FIV vaccination has been completed 
to ensure infection has not occurred during this ‘window of opportunity’). Finally, a 
prospective study with sequential testing (prior to annual booster FIV vaccination) could 
be pursued to establish if and when cats become FIV-infected. This type of study design 
would require a considerably larger sample population to account for the inevitable losses 
that occur in a longitudinal study of the required duration, and would be significantly more 
expensive. A faster and less expensive option for future studies would be to encourage 
veterinarians to routinely test for FIV infection at the time of annual FIV vaccination, 
using Witness or Anigen Rapid. If this recommendation were embraced by a few large 
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veterinary clinics that routinely use the FIV vaccine, and FIV-unvaccinated controls in the 
area were recruited at the same time, within a few years a large database of cases and 
controls could be compiled to further refine the protective rate of 56% reported in Chapter 
6. 
In addition to further research into the overall effectiveness of the FIV vaccine in the field, 
both in Australia and elsewhere, the issue of cross-protection against various FIV subtypes 
needs to be addressed in response to results from Chapter 6. Despite 5/25 FIV-infected 
controls in the current study being infected with subtypes D and F, only subtype A was 
identified in the five vaccine breakthroughs (and both additional ‘possible breakthroughs’), 
suggesting that the vaccine may provide superior immunity against these other subtypes, 
which is counterintuitive. To further investigate this prospect, a larger Australian field 
study needs to be conducted to increase the number of vaccinates potentially exposed to 
other FIV subtypes, as well as to conduct such field studies in countries where non-A 
subtypes are more common (e.g. Taiwan and Japan), where subtypes C and D, 
respectively, are more prevalent (Kakinuma et al., 1995; Uema et al., 1999; Yamamoto et 
al., 2007). The diverse subtyping results in the FIV-infected controls (with presence of 
clades A, D and F) compared to previous Australian studies (which found a marked 
preponderance of subtype A, with rare subtype B isolates) (Kann et al., 2006; Iwata and 
Holloway, 2008) was surprising and therefore needs further attention. For subtyping results 
from the FIV-infected controls to be considered valid, sequencing of the env gene of FIV 
isolates from all FIV-infected cats (not just vaccinates) needs to be performed in the future 
to confirm the accuracy of the PCR subtyping results. 
It was during this investigation into the effectiveness of the FIV vaccine that a most 
unexpected and novel result was obtained – the observation that two point-of-care antibody 
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test kits (Witness and Anigen Rapid) could generally diagnose FIV infection, irrespective 
of FIV vaccination status (Chapter 3). It must be remembered that at the start of our 
research (2012) it was universally considered that FIV vaccination rendered all FIV 
antibody test kits ‘useless’ in a discriminatory sense (e.g. 
(www.wsava.org/sites/default/files/VaccinationGuidelines2010.pdf; Levy et al., 2008; 
Hosie et al., 2009). The ability of these inexpensive test kits (current price wholesale 
approximately $11 AUD) to quickly and easily differentiate FIV-vaccinated and FIV-
infected cats will significantly change the approach veterinarians use to screen for FIV 
infection, especially in pounds and shelters, and the referencing of our study in the most 
recent World Small Animal Veterinary Association Vaccination Guidelines (2015) 
evidences the impact of this finding. Our study has also recently been replicated in field 
studies in Florida, USA, with almost identical results reported (Crawford, 2016). In a 
shelter environment, where resources are limited and vaccination histories are commonly 
unavailable, the testing algorithm we proposed (Figure 3.4) would result in a substantial 
cost saving and could influence whether shelters can routinely afford to test for FIV, as 
well as reduce the number of cats euthanased due to testing FIV false-positive with SNAP 
Combo (Crawford and Levy, 2007; Levy et al., 2008a). 
Chapter 4 expanded on the findings in Chapter 3 by reporting that the discriminant ability 
of the two IC test kits (Witness and Anigen Rapid) also applied when saliva was used as 
the diagnostic specimen (both kits demonstrated better than 99% accuracy). This finding 
has the potential to facilitate rapid and accurate determination of FIV infection status in 
certain scenarios, e.g. when a veterinarian or veterinary technician is unavailable for 
venipuncture, where cats are too fractious for safe venipuncture without chemical restraint, 
in shelters where large numbers of cats need to be assessed for FIV infection prior to 
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rehoming and where vaccination history is often unknown and for cat breeders screening 
new cats on entry to a cattery, or prior to mating. This will, in some circumstances, provide 
a less expensive and less stressful option for owners and carers and thus a superior option 
for their cats. Preliminary results also showed that an excellent outcome could be obtained 
using Anigen Rapid by applying the cotton swab directly to the sample well and flooding 
the cotton tip with buffer solution. It must be stressed, however, that this method should 
not be relied upon for making clinical decisions until further validation is undertaken with 
a larger study. In contrast, the performance of both SNAP Combo and Witness deteriorated 
with the ‘direct application’ technique and consequently this technique should not be used 
for saliva testing with either of these kits. 
The surprise findings from Chapters 3 and 4, and conflicting results from another 
researcher (in a refereed conference abstract) shortly after our results were published 
(Lappin, 2015), led us to design the study in Chapter 5 to attempt to characterise the 
‘antibody cascade’ that occurs following primary FIV vaccination using point-of-care test 
kits. Importantly, the prospective study design showed that some care needs to be taken in 
the six months after a primary course of FIV vaccination has been administered, and 
consequently the recommendation made in Chapter 3 regarding the use of Witness and 
Anigen Rapid kits for FIV screening was modified to highlight this qualification. A similar 
longitudinal study is now required in adult cats prior to and following annual FIV 
vaccination ‘boosters’ to determine whether this period of detectable antibody responses 
with point-of-care test kits also applies to cats receiving their annual FIV vaccination, or 
whether it only applies to young cats being vaccinated against FIV for the first time. In a 
shelter situation, where large scale FIV screening is being undertaken, it is highly unlikely 
cats will have received a primary FIV vaccination series in the preceding six months as 
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FIV vaccination rates are generally low, and cats so vaccinated are generally well cared for 
and less likely to be surrendered to a shelter facility (Salman et al., 1998). Transient 
antibody production for up to six months after primary FIV vaccination is also not relevant 
when testing cats for FIV vaccine breakthrough immediately prior to the next annual FIV 
vaccination booster. To further investigate the role of age and re-vaccination, we plan to 
monitor cats in Study 2 for several years using gp40 ELISA laboratory testing to 
quantitatively determine the gp40 antibody response following booster FIV vaccination, 
particularly to see if there is a diminished antibody response following annual re-
vaccination compared to initial (primary) vaccination. Future research should ideally also 
quantitate the antibody response directed against other epitopes (e.g. p15 and p24) over 
time, using a common methodology for each (e.g. ELISA testing), to further understand 
the breadth, magnitude and duration of the antibody cascade following FIV vaccination. 
As discussed in section 6.5, the exact mechanism(s) by which the FIV vaccine provides 
sterilising immunity (if indeed it does at all) is still unclear. Generally speaking, it is 
thought that humoral immunity plays some role in protection against homologous 
challenge, while CMI is important for protection against both homologous and 
heterologous protection. This distinction is possibly slightly arbitrary, however, since 
nucleotide sequences can vary as much as 15% within a particular subtype (Sodora et al., 
1994). Thus, in reality, a combination of humoral and CMI is probably required for 
protection from challenge. Consequently, investigations into the immune response 
following FIV vaccination need to consider both antibody production and markers of T-
cell immunity, of which this thesis has focused on an understanding of the former. Chapter 
5 showed a decreased level of antibodies to both p24 and gp40 six months after primary 
FIV vaccination as measured with Witness and Anigen Rapid, and Chapter 6 showed all 
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FIV-vaccinated cats (including the five vaccine breakthroughs) had detectable levels of 
antibodies to p15 as measured with SNAP Combo, both of which have diagnostic 
implications as discussed. Further (unpublished) research I have performed in the Hosie 
Laboratory (Centre for Virus Research, The University of Glasgow) utilising an in vitro 
neutralising antibody assay (Bęczkowski et al., 2015b) found that of 114 FIV-
vaccinated/FIV-uninfected cats (sourced from Chapter 3), most (107/114) had strong 
neutralisation potency (81-100% neutralisation) against homologous challenge 
(pseudotype designated KKS, derived from a possible vaccine breakthrough SV1, the 
sequence of which closely resembles that of FIVPet), while none of a subset tested (0/25) 
had strong neutralisation potency against a different homologous challenge (FIVUK8). 
Considering these results in tandem suggests that all FIV-vaccinated cats have some level 
of antibody response following vaccination, although this antibody response wanes over 
time, and antibody-mediated protection is highly variable even amongst different 
homologous challenges. Clearly more work is required to understand the relative 
importance of humoral and CMI, and whether it is possible to predict protection from 
challenge based on the presence of particular antibodies. As a result, we have been 
cautious about extrapolating our antibody results beyond FIV diagnosis to duration of 
vaccine-induced immunity, or to speculate immunologically as to why the five vaccine 
breakthroughs occurred. For example, without further research into the importance of 
antibodies in conferring protection, it would be overreaching to suggest any protection 
provided by the FIV vaccine lasts for less than six months, based on results from Chapter 
5. Future research undertaken by our group will likely include assessing the quality of the 
T-cell immune response in the five vaccine breakthroughs, as well as neutralising antibody 
assay work using FIV pseudotypes derived from the vaccine breakthrough isolates as the 
Dr. Mark Edward Westman Faculty of Veterinary Science 
Thesis 2016 The University of Sydney 
231 
 
challenge, to better understand why the breakthroughs occurred and to assess whether 
other FIV-vaccinated cats in the study would have been susceptible to infection, has they 
been challenged with the same strain of FIV. 
The three FIV antibody detection kits tested in Chapters 3 and 4 also tested for FeLV 
antigen (p27), and therefore it was logical to examine the performance of the three kits 
using blood and saliva in the same cohort of cats (Chapter 7). To further increase study 
numbers, additional samples were sourced from veterinary clinicians around Australia, a 
veterinary laboratory and a rescue facility. One of the kits (SNAP Combo) was determined 
to have a significantly lower specificity than the other two kits tested (Witness and Anigen 
Rapid). All three kits, however, produced a concerning number of false-positive p27 test 
results, even in cats with clinical signs consistent with FeLV-infection, and testing two kits 
in series did not completely eliminate the possibility of an incorrect diagnosis. 
Consequently, our conclusion was that any cat returning a positive p27 result must have 
confirmatory proviral PCR testing performed. Consideration of other pertinent details, 
including lifestyle (e.g. higher FeLV risk in fighting cats, multi-cat households and shelters 
practicing group-housing), age (younger cats more likely to be progressively FeLV-
infected, older cats more likely to return a false-positive p27 result) and clinical signs of 
FeLV-related disease (e.g. macrocytic anaemia, aplastic anaemia, lymphoma) will increase 
a clinician’s index of suspicion for FeLV-infection further, but are not enough to eliminate 
doubt about the validity of a positive p27 test result. Although the lower sensitivity of p27 
saliva testing compared to p27 blood testing was not statistically significant, with a larger 
study the trend for saliva to have increased specificity at the expense of reduced sensitivity 
(compared with blood) may have become further apparent. Further research into the use of 
saliva for FeLV p27 testing needs to be undertaken, including further assessment of the 
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‘direct application’ technique trialled. In the meantime, p27 testing using whole blood as 
the diagnostic specimen (with confirmatory qPCR testing of kit-positive cases) remains the 
recommendation for rapid screening of large numbers of cats, even though the usefulness 
of p27 testing using saliva looks promising. 
It was whilst the research for Chapters 3, 4, 6 and 7 was being conducted that we decided a 
current report into the prevalence of FIV and FeLV infections in domestic cats in Australia 
was needed. Chapter 2 reported a higher prevalence of both FIV and FeLV infections in 
client-owned cats in Western Australia compared to the rest of the country (Cohort 2), a 
finding supported by older Australian studies from this region (Robertson et al., 1990b; 
Thomas et al., 1993b). This disparity based on geographical location might be attributable 
to the significantly higher proportion of entire male cats encountered in WA (23%) 
compared to elsewhere (12%) amongst cats that were sampled, a trend that may actually be 
a true reflection of the entire owned cat population in WA rather than merely a sampling 
bias. Previous studies have reported a lower de-sexing rate of client-owned male cats in 
Perth, WA compared with Sydney, NSW (82% versus 96%) (Robertson et al., 1990a; 
Toribio et al., 2009). This disparity, however, was not supported by results from Cohort 3 
(MUVH); the FIV seroprevalence of WA cats in Cohort 3 (14%) was similar to the 
national FIV seroprevalence of cats in Cohort 2 (15%). A similar percentage of entire male 
cats was sampled in Cohort 3 (10%) compared to Cohort 2 (12%). It is not clear from the 
current data why the high proportion of entire male cats sampled in WA in Cohort 2 was 
not observed in WA cats sampled in Cohort 3 (i.e. 23% versus 10%). This possible 
increased risk of retroviral infection in WA cats should be the subject of future focused 
regional investigations, and may indicate a true difference in risk of exposure to the virus. 
In the interim, it would be prudent for WA veterinarians to conduct a public awareness 
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campaign to highlight the need for early neutering of male and female cats prior to sexual 
maturity and to routinely vaccinate young cats against FeLV. 
In response to the low specificity of the FeLV antigen kits reported in Chapter 7, I decided 
it was important to follow up the FeLV prevalence results reported in Chapter 2 with a 
more detailed investigation of FeLV infection that included confirmatory PCR testing 
(Chapter 8). PCR testing to look for FeLV provirus also enabled us to identify regressive-
infections that cannot be detected using antigen testing alone. The results reported in 
Chapter 8 demonstrate FeLV remains a genuine threat to Australian cats under certain 
circumstances. In light of this finding, young cats in Australia with access to other cats of 
unknown retroviral status should be vaccinated against FeLV, after pre-vaccination testing, 
to reduce the possibility of them becoming progressively-infected (Sparkes, 2003; Lutz et 
al., 2009; Patel et al., 2015). Our finding also serves to reinforce previous 
recommendations for shelters that allow contact between cats, including testing of all 
incoming cats for FeLV antigen and FIV antibody, and minimization of group size when 
co-housing cats to reduce the risk for cross-infection (Möstl et al., 2013).  
The impact of regressive FeLV infections on the health of cats is largely unknown since 
few studies to date have followed a cohort of regressively-infected cats longitudinally 
(under field conditions) to measure outcomes from infection. Future research needs to 
further investigate the impact of regressive-infections on feline health, and such studies 
need to be longer than the usual time-frame for feline research to detect late sequelae of 
infection, including lymphoma and myelodysplasia. Identification of regressively-infected 
cats (such as the 31 cats in Chapter 8) will greatly facilitate longitudinal case-control 
studies of this nature, and we aim to follow all cats recruited for the current study over time 
to investigate the occurrence of FeLV-related disease in both progressive and regressive-
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infections compared to the FeLV-uninfected controls. Potential relationships between 
potential pathogens and the resulting impact on disease severity also needs to be explored, 
particularly FeLV infection (progressive and regressive), FIV infection and feline 
gammaherpesvirus (FcaGHV1) infection. FcaGHV1 infection was first described in 2014 
in a survey of cats from the USA, Singapore and Australia, reporting that infected cats 
were 2.8 times more likely to be sick than uninfected controls (Troyer et al., 2014; Beatty 
et al., 2014). In relation to Australian cats, FcaGHV1 prevalence was 11% and FIV-
infected cats had significantly higher FcaGHV1 loads than FIV-uninfected cats. As a 
result, a similar mechanism to the increased Epstein-Barr virus (another human 
gammaherpesvirus) load encountered in HIV-infected people was hypothesised. FcaGHV1 
infection was also found to be significantly associated with FeLV infection in the 
Singapore group (Beatty et al., 2014). Recently, the complete FcaGHV1 sequence was 
announced, and future research will need to determine if any of the orfs identified are 
indeed oncogenic (Troyer et al., 2015), and whether FcaGHC1 enhances the oncogenic 
ability FIV and FeLV. 
In summary, this thesis has shown that retroviruses have continued importance in domestic 
cats in Australia. FIV infection remains prevalent amongst cats with outdoor access (12-
15%, Chapters 2 and 6), and although progressive FeLV infection is approximately ten 
times less common (0.5-1.6%, Chapters 2 and 8), FeLV-related disease is still an important 
cause of mortality in at-risk cats (particularly group-housed cats). Chapter 6 provided a 
conceptual framework that might be utilised for future retrospective studies investigating 
the effectiveness of the FIV vaccine, both in Australia and elsewhere, and also suggested 
possible study design improvements (most importantly, a prospective study design). 
Similar study designs (i.e. retrospective or prospective) could be utilised to determine the 
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effectiveness of FeLV vaccines in the field, which to the author’s knowledge has not been 
conducted anywhere in the world, although circumstantial evidence testifies to their likely 
efficacy, pushing FeLV ‘back into nature’ in the words of Niels C. Pedersen 
(www.sockfip.info/about-fip/all-articles/67-about-fip). There would be challenges with 
FeLV vaccine trials in an Australian setting, however, including the requirement for higher 
study numbers to show a difference in prevalence rates between cases and controls (due to 
the lower prevalence of FeLV in Australia), and the requirement to do serial testing of any 
infected (p27 positive) cats to establish progressive versus regressive infections (since no 
FeLV vaccine claims to provide sterilising immunity, i.e. protection from regressive-
infections).  
Finally, this work has made a substantial contribution to understanding antibody 
production following FIV vaccination and the resulting impact on the diagnosis of FIV 
infection. Already these results have changed how many shelters and veterinary clinics in 
Australia test for FIV and FeLV infection (RSPCA, Animal Welfare League and Sydney 
Dogs and Cats Home staff, personal communication), with veterinarians now able to 
confidently diagnose FIV infection in cats irrespective of their FIV vaccination status. 
Furthermore, more veterinarians have become aware of the absolute requirement to 
perform FeLV PCR testing following any positive in-clinic p27 result. The importance of 
FIV antibodies as a correlate of protection following vaccination has been questioned, and 
undoubtedly in the future we will see more research attempting to understand the relative 
importance of humoral versus CMI, which in turn will influence FIV (and HIV) vaccine 
development.
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